Neutralizing antibody levels are highly predictive of im SARS-CoV-2 infection

Nature Medicine

27, 1205-1211

DOI: 10.1038/s41591-021-01377-8

Citation Report

#	Article	IF	Citations
1	Antibody titres decline 3-month post-vaccination with BNT162b2. Emerging Microbes and Infections, 2021, 10, 1495-1498.	3.0	141
2	SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-Reactive IgG and Unequal Strain-Specific Neutralizing Antibodies in NaÃ¯ve and Previously Infected Recipients. SSRN Electronic Journal, 0, , .	0.4	0
3	'One Year Later' - SARS-CoV-2-Specific Immunity in Mild Cases of COVID-19. SSRN Electronic Journal, 0, , .	0.4	1
4	Reactogenicity and Immunogenicity of Heterologous ChAdOx1-nCoV19 and BNT162b2 Vaccination: A Systematic Review and Meta-Analysis of the Heterologous COVID-19 Vaccination Outcomes. SSRN Electronic Journal, 0, , .	0.4	1
5	Maintenance of Broad Neutralising Antibodies and Memory B Cells 12 Months Post-Infection Is Predicted by SARS-CoV-2 Specific CD4+ T Cell Responses. SSRN Electronic Journal, 0, , .	0.4	0
6	COVID-19 â€“ One Virus, One World But Different Vaccines and Shots. SSRN Electronic Journal, 0, , .	0.4	0
12	What scientists know about new, fast-spreading coronavirus variants. Nature, 2021, 594, 19-20.	13.7	63
17	Scientists zero in on long-sought marker of COVID-vaccine efficacy. Nature, 2021, , .	13.7	3
24	Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet, The, 2021, 397, 2331-2333.	6.3	490
25	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature, 2021, 596, 417-422.	13.7	549
26	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. Microorganisms, 2021, 9, 1389.	1.6	4
28	Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Cell Reports Medicine, 2021, 2, 100296.	3.3	56
29	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. ACS Nano, 2021, 15, 11180-11191.	7.3	60
37	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Science Immunology, 2021, 6, .	5.6	34
38	SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses, 2021, 13, 1211.	1.5	35
39	Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response. Annals of the Rheumatic Diseases, 2021, 80, 1361-1362.	0.5	21
40	Six months of COVID vaccines: what 1.7 billion doses have taught scientists. Nature, 2021, 594, 164-167.	13.7	61
41	Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. Vaccines, 2021, 9, 615.	2.1	15

#	Article	IF	Citations
42	Antibody response to SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipientsÂand in-centre and satellite centre haemodialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 2127-2128.	1.4	10
44	Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nature Medicine, 2021, 27, 1379-1384.	15.2	296
47	Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid organ transplant recipients. Journal of Clinical Investigation, 2021, 131, .	3.9	17
49	Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assayâ€“Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays. Archives of Pathology and Laboratory Medicine, 2021, 145, 1212-1220.	1.2	38
52	SARS-CoV-2 Antiviral Therapy. Clinical Microbiology Reviews, 2021, 34, e0010921.	5.7	64
55	Animal Coronavirus Diseases: Parallels with COVID-19 in Humans. Viruses, 2021, 13, 1507.	1.5	7
58	Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. Open Forum Infectious Diseases, 2021, 8, ofab393.	0.4	3
64	A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. Current Medical Science, 2021, 41, 1037-1051.	0.7	136
65	Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nature Medicine, 2021, 27, 1530-1535.	15.2	276
66	Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature, 2021, 596, 276-280.	13.7	1,803
70	Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?. Infection, 2022, 50, 11-25.	2.3	50
76	Colloidal gold immunochromatographic assay (GICA) is an effective screening method for identifying detectable anti-SARS-CoV-2 neutralizing antibodies. International Journal of Infectious Diseases, 2021, 108, 483-486.	1.5	14
82	Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual. Open Forum Infectious Diseases, 2021, 8, ofab369.	0.4	2
84	Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality. Nature Medicine, 2021, 27, 1321-1323.	15.2	35
85	The success of SARS-CoV-2 vaccines and challenges ahead. Cell Host and Microbe, 2021, 29, 1111-1123.	5.1	67
86	AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Lancet, The, 2021, 398, 207-209.	6.3	112
88	Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population. Viruses, 2021, 13, 1508.	1.5	12
89	Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial. Chinese Medical Journal, 2021, 134, 1967-1976.	0.9	24

#	Article	IF	Citations
90	SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Eurosurveillance, 2021, 26, .	3.9	31
91	After the pandemic: perspectives on the future trajectory of COVID-19. Nature, 2021, 596, 495-504.	13.7	260
92	A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nature Medicine, 2021, 27, 1147-1148.	15.2	171
93	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nature Communications, 2021, 12, 4598.	5.8	88
94	Scientists identify long-sought marker for COVID vaccine success. Nature, 2021, , .	13.7	3
97	COVIDâ€19 vaccines: what do we know so far?. FEBS Journal, 2021, 288, 4996-5009.	2.2	7
103	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells, 2021, 10, 1942.	1.8	38
104	Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New England Journal of Medicine, 2021, 385, 1474-1484.	13.9	1,162
106	Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nature Microbiology, 2021, 6, 1140-1149.	5.9	254
107	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. Npj Vaccines, 2021, 6, 104.	2.9	241
108	Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people. Immunity and Ageing, 2021, 18, 34.	1.8	60
109	Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer Journal, 2021, 11, 142.	2.8	106
111	Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience. Journal of Heart and Lung Transplantation, 2022, 41, 148-157.	0.3	83
112	COVID-19 Vaccine among Actively-Treated People with Cancer: A Glimpse into the Known Unknowns?. Journal of the National Cancer Institute, 2021, , .	3.0	0
113	Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2021, 80, 1365-1366.	0.5	22
118	Immunity to SARSâ€CoVâ€2 induced by infection or vaccination. Journal of Internal Medicine, 2022, 291, 32-50.	2.7	97
120	Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. EClinicalMedicine, 2021, 38, 100989.	3.2	56
121	Reply to Schulte-Pelkum, J. Comment on â€œFavresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms 2021, 9, 556â€: Microorganisms, 2021, 9, 1849.	1.6	3

#	Article	IF	Citations
122	COVID-19 Vaccination Issues in Solid Organ Transplant Recipients. Vestnik Medicinskogo Instituta REAVIZ ReabilitaciÃ¢, VraÄ•I ZdorovÊ¹e, 2021, 11, 5-14.	0.1	0
127	A Perspective on the Role of Point-of-Care â€œImmuno-Triagingâ€•to Optimize COVID-19 Vaccination Distribution in a Time of Scarcity. Frontiers in Public Health, 2021, 9, 638316.	1.3	3
129	Molecular Level Dissection of Critical Spike Mutations in SARSâ€CoVâ€2 Variants of Concern (VOCs): A Simplified Review. ChemistrySelect, 2021, 6, 7981-7998.	0.7	18
133	A vaccination update for rheumatologistsâ€"SARSâ€CoVâ€2, influenza and herpes zoster. International Journal of Rheumatic Diseases, 2021, 24, 979-983.	0.9	4
135	Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia. Viruses, 2021, 13, 1618.	1.5	3
137	Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers. Vaccines, 2021, 9, 913.	2.1	12
141	Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine. Journal of Infection, 2021, , .	1.7	3
142	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature Reviews Immunology, 2021, 21, 626-636.	10.6	777
143	Poor Humoral Response in Solid Organ Transplant Recipients Following Complete mRNA SARS-CoV-2 Vaccination. Clinical Chemistry, 2021, 68, 251-253.	1.5	7
144	Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses. Viruses, 2021, 13, 1579.	1.5	14
148	Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics. Indian Journal of Medical Microbiology, 2021, 39, 417-422.	0.3	5
150	Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. Immunologic Research, 2021, 69, 576-583.	1.3	34
151	B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. EBioMedicine, 2021, 70, 103539.	2.7	67
152	Antibody and TÂcell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell, 2021, 39, 1034-1036.	7.7	132
155	Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. JAMA - Journal of the American Medical Association, 2021, 326, 1533.	3.8	331
159	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. Exploration of Immunology, 2021, , 199-225.	1.7	5
161	An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines. Journal of Clinical Medicine, 2021, 10, 3817.	1.0	16
162	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner. MBio, 2021, 12, e0100221.	1.8	7

#	Article	IF	Citations
164	Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Nature Communications, 2021, 12, 5135.	5.8	107
166	Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Transplantation, 2021, 105, e280-e281.	0.5	103
167	Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematology,the, 2021, 8, e583-e592.	2.2	211
173	The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review. Vaccines, 2021, 9, 885.	2.1	57
175	Hybrid immunity: the immune response of COVID-19 survivors to vaccination. Revista Bionatura, 2021, 3, 1890-1892.	0.1	0
177	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. Trends in Cardiovascular Medicine, 2022, 32, 1-9.	2.3	31
178	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer Journal, 2021, 11, 138.	2.8	103
181	Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. American Journal of Transplantation, 2021, 21, 3980-3989.	2.6	120
182	To mix or not to mix? A rapid systematic review of heterologous primeâ€“boost covid-19 vaccination. Expert Review of Vaccines, 2021, 20, 1211-1220.	2.0	85
185	Immunity after COVID-19 and vaccination: follow-up study over 1Âyear among medical personnel. Infection, 2022, 50, 439-446.	2.3	27
187	Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine. Journal of Infectious Diseases, 2021, , .	1.9	11
188	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. Cancers, 2021, 13, 4480.	1.7	44
190	Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples. JAMA - Journal of the American Medical Association, 2021, 326, 868.	3.8	83
191	Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. Blood Cancer Discovery, 2021, 2, 577-585.	2.6	44
192	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. Blood Advances, 2021, 5, 4398-4405.	2.5	39
194	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, The, 2021, 398, 856-869.	6.3	430
196	Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave. Clinical Infectious Diseases, 2022, 75, e249-e256.	2.9	29
198	Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Science Immunology, 2021, 6, eabl4509.	5.6	141

#	Article	IF	Citations
199	Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Frontiers in Immunology, 2021, 12, 742914.	2.2	52
200	Advances in understanding the formation and fate of B-cell memory in response to immunization or infection. Oxford Open Immunology, 2021, 2, .	1.2	3
201	IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population. Vaccines, 2021, 9, 999.	2.1	23
202	Should people with chronic liver diseases be vaccinated against COVID-19?. World Journal of Clinical Cases, 2021, 9, 7959-7962.	0.3	2
203	Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. JAMA - Journal of the American Medical Association, 2021, 326, 1400.	3.8	160
205	Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVIDâ€19 infection: Prospective observational study. Journal of Medical Virology, 2022, 94, 279-286.	2.5	20
206	Development and preclinical evaluation of virusâ€like particle vaccine against COVIDâ€19 infection. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 258-270.	2.7	27
207	The temporal course of T- and B-cell-responses to vaccination with BNT162b2 and mRNA-1273. Clinical Microbiology and Infection, 2021, , .	2.8	22
208	Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Regional Health - Europe, The, 2021, 10, 100208.	3.0	446
209	COVID-19 vaccination in kidney transplant recipients. Nature Reviews Nephrology, 2021, 17, 785-787.	4.1	99
212	Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurology, 2021, 78, 1510.	4.5	134
215	COVID vaccine immunity is waning â€" how much does that matter?. Nature, 2021, 597, 606-607.	13.7	105
216	Beta testing the monkey model. Nature Immunology, 2021, 22, 1201-1203.	7.0	0
217	SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients. Clinical Gastroenterology and Hepatology, 2022, 20, 162-172.e9.	2.4	113
218	COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. Cell, 2021, 184, 5077-5081.	13.5	114
221	Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response. Vaccines, 2021, 9, 977.	2.1	12
225	The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. Frontiers in Immunology, 2021, 12, 737083.	2.2	18
226	Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVIDâ€19 with Bâ€cell malignancies. British Journal of Haematology, 2021, 195, 706-709.	1.2	16

#	Article	IF	Citations
227	The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. Nature Medicine, 2021, 27, 1518-1524.	15.2	178
230	Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in NaÃ¯ve and COVID-19-Convalescent Individuals. Open Forum Infectious Diseases, 2021, 8, ofab468.	0.4	10
231	Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science, 2021, 374, eabj9853.	6.0	236
232	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. Vaccines, 2021, 9, 1017.	2.1	10
234	Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis. EBioMedicine, 2021, 71, 103567.	2.7	1
236	Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. Vaccines, 2021, 9, 1092.	2.1	96
237	Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response. Microbiology Spectrum, 2021, 9, e0073321.	1.2	22
238	Expression and Display of Glycoengineered Antibodies and Antibody Fragments with an Engineered Yeast Strain. Antibodies, 2021, 10, 38.	1.2	4
239	Vaccines for COVID-19: Where do we stand in 2021?. Paediatric Respiratory Reviews, 2021, 39, 22-31.	1.2	53
240	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	44
241	Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. New England Journal of Medicine, 2021, 385, 1244-1246.	13.9	456
243	Ronapreve for prophylaxis and treatment of covid-19. BMJ, The, 2021, 374, n2136.	3.0	12
244	Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. JAMA Network Open, 2021, 4, e2123622.	2.8	49
246	Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2022, 79, 137-139.	2.1	12
249	The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773.	7.7	778
250	Acceptance Rates and Beliefs toward COVID-19 Vaccination among the General Population of Pakistan: A Cross-Sectional Survey. American Journal of Tropical Medicine and Hygiene, 2021, 105, 1230-1239.	0.6	20
254	Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discovery, 2021, 2, 568-576.	2.6	62
255	The viral phoenix: enhanced infectivity and immunity evasion of SARS-CoV-2 variants. Environmental Chemistry Letters, 2022, 20, 1539-1544.	8.3	6

#	Article	IF	Citations
256	Vitamin D deficiency and inactivated SARS-CoV-2 vaccines. European Journal of Internal Medicine, 2021, 93, 114.	1.0	1
257	Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe, The, 2021, 2, e423.	3.4	112
258	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	15.2	900
259	Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. New England Journal of Medicine, 2021, 385, 1393-1400.	13.9	979
262	SARSâ€CoVâ€2 neutralizing antibodies decline over one year and patients with severe COVIDâ€19 pneumonia display a unique cytokine profile. International Journal of Infectious Diseases, 2021, 112, 227-234.	1.5	13
263	Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics. Journal of Personalized Medicine, 2021, 11, 886.	1.1	17
264	Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. JCI Insight, 2021, 6, .	2.3	18
267	A government-led effort to identify correlates of protection for COVID-19 vaccines. Nature Medicine, 2021, 27, 1493-1494.	15.2	26
268	Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients. Kidney International, 2021, 100, 698-700.	2.6	8
269	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. Journal of Clinical Investigation, 2021, 131, .	3.9	89
271	Immune imprinting and SARS-CoV-2 vaccine design. Trends in Immunology, 2021, 42, 956-959.	2.9	73
273	Countries with similar COVID-19 vaccination rates yet divergent outcomes: are all vaccines created equal?. International Journal of Infectious Diseases, 2021, 110, 258-260.	1.5	9
276	Persistence of neutralizing antibodies a year after SARSâ€CoVâ€2 infection in humans. European Journal of Immunology, 2021, 51, 3202-3213.	1.6	76
277	Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2. Vaccines, 2021, 9, 1089.	2.1	33
278	Safety and Immunogenicity of a Recombinant Adenovirus Type-5â€“Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged â‰¥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. Clinical Infectious Diseases, 2022, 75, e783-e791.	2.9	71
279	Covid-19 vaccination: evidence of waning immunity is overstated. BMJ, The, 2021, 374, n2320.	3.0	30
280	BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Frontiers in Immunology, 2021, 12, 743422.	2.2	10
283	Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 3208-3220.	3.0	74

#	Article	IF	Citations
284	Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination. Lancet Rheumatology, The, 2021, 3, e753-e754.	2.2	11
287	Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet, The, 2021, 398, 1038-1041.	6.3	73
288	Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infectious Diseases, The, 2022, 22, 56-63.	4.6	117
289	Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination. Vaccine, 2021, 39, 5688-5698.	1.7	10
290	Elucidating causes of COVID-19 infection and related deaths after vaccination. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102212.	1.8	27
292	Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer. Cancer Cell, 2021, 39, 1171-1172.	7.7	45
294	Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nature Medicine, 2021, 27, 2025-2031.	15.2	361
297	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. Zeitschrift Fur Rheumatologie, 2021, 80, 33-48.	0.5	13
298	Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine. Clinical Chemistry and Laboratory Medicine, 2021, 59, 2010-2018.	1.4	41
299	Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1885-1888.	1.4	19
301	Heterologous primeâ€“boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infectious Diseases, The, 2021, 21, 1212-1213.	4.6	111
303	Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nature Medicine, 2021, 27, 2002-2011.	15.2	167
304	Overview of the neutralizing antibody and memory B cell response kinetics in SARS-CoV-2 convalescent and/or mRNA vaccinated individuals.. Systems Biology and Physiology Reports, 2021, 1, 1-5.	0.4	2
305	Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study. Journal of Infection, 2021, , .	1.7	6
306	Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions â€" United States, Marchâ€“August 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1337-1343.	9.0	358
308	Post-SARS-CoV-2 vaccination specific antibody decrease â€" Thresholds for determining seroprevalence and seroneutralization differ. Journal of Infection, 2021, 83, e4-e5.	1.7	20
309	CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infectious Diseases, The, 2021, 21, 1352-1354.	4.6	65
310	Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab. Multiple Sclerosis and Related Disorders, 2021, 55, 103203.	0.9	2

#	Article	IF	Citations
311	Vaccination after prior COVID-19 infection: Implications for dose sparing and booster shots. EBioMedicine, 2021, 72, 103586.	2.7	10
312	Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. EBioMedicine, 2021, 72, 103589.	2.7	16
313	Track-etched membrane microplate and smartphone immunosensing for SARS-CoV-2 neutralizing antibody. Biosensors and Bioelectronics, 2021, 192, 113550.	5.3	14
314	Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103251.	0.9	36
315	Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. International Journal of Infectious Diseases, 2021, 112, 40-44.	1.5	31
316	An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinicalMedicine, 2021, 41, 101143.	3.2	78
317	An update of anti-viral treatment of COVID-19. Turkish Journal of Medical Sciences, 2021, 51, 3372-3390.	0.4	55
321	Poor Antibody Responses to SARS-CoV-2 Infection or Vaccination Are Associated With High Re-Infection Rates in Haemodialysis and Renal Transplant Patients. SSRN Electronic Journal, 0, , .	0.4	0
322	Immunology of SARS-CoV-2 infections and vaccines. Advances in Immunology, 2021, 151, 49-97.	1.1	12
323	COVID-19 mRNA Based Vaccine Immune-Response Assessment for Public Health Decision. SSRN Electronic Journal, 0, , .	0.4	1
324	Cancer Therapy and Immunogenicity of COVID Vaccine â€“ CANINE Study. SSRN Electronic Journal, 0, , .	0.4	0
325	Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination. Viruses, 2021, 13, 1972.	1.5	22
326	When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak. Frontiers in Immunology, 2021, 12, 692598.	2.2	7
327	BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2022, 81, 575-583.	0.5	61
328	Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19â€"a prospective multicenter cohort study. BMC Medicine, 2021, 19, 270.	2.3	22
329	Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection. Viruses, 2021, 13, 2003.	1.5	16
332	HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. ELife, 2021, 10, .	2.8	28
333	SARS-CoV-2 Infection in Fully Vaccinated Individuals of Old Age Strongly Boosts the Humoral Immune Response. Frontiers in Medicine, 2021, 8, 746644.	1.2	8

#	Article	IF	Citations
334	Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. Annual Review of Medicine, 2022, 73, 55-64.	5.0	55
335	Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose. CKJ: Clinical Kidney Journal, 2022, 15, 226-234.	1.4	30
337	Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. Science Immunology, 2021, 6, eabl5842.	5.6	33
338	mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science, 2021, 374, abm0829.	6.0	609
339	Longitudinal SARSâ€CoVâ€2 seroprevalence in Portugal and antibody maintenance 12 months after infection. European Journal of Immunology, 2022, 52, 149-160.	1.6	15
340	Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. IScience, 2021, 24, 103341.	1.9	47
341	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection, 2022, 28, 202-221.	2.8	569
342	Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers. Vaccines, 2021, 9, 1223.	2.1	48
343	T cell immunity to SARS-CoV-2. Seminars in Immunology, 2021, 55, 101505.	2.7	55
345	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2021, 32, 3027-3033.	3.0	82
346	COVID-19 vaccination in patients receiving dialysis. Nature Reviews Nephrology, 2021, 17, 788-789.	4.1	13
347	Inactivated vaccines may not provide adequate protection in immunosuppressed patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 295-296.	0.5	11
349	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nature Microbiology, 2021, 6, 1433-1442.	5.9	94
351	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 2021, 600, 517-522.	13.7	239
353	<scp>COVID</scp>â€19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology, 2022, 91, 89-100.	2.8	119
354	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. Life, 2021, 11, 1077.	1.1	25
355	COVID-19: State of the Vaccination. Drugs and Therapy Perspectives, 2021, 37, 508-518.	0.3	5
356	Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children. Frontiers in Pediatrics, 2021, 9, 678937.	0.9	10

#	Article	IF	Citations
361	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. Lancet Respiratory Medicine,the, 2021, 9, 1450-1466.	5.2	110
363	Generation and persistence of S1ÂIgG and neutralizing antibodies in post-COVID-19 patients. Infection, 2021, 50, 447.	2.3	5
365	The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2. Vaccines, 2021, 9, 1163.	2.1	28
366	SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques. Nature Communications, 2021, 12, 5877.	5.8	21
367	A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications, 2021, 12, 6197.	5.8	61
368	Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43. Viruses, 2021, 13, 2075.	1.5	1
369	Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern. Emerging Microbes and Infections, 2021, 10, 1-9.	3.0	25
370	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineâ€“boosted nonhuman primates. Science, 2021, 374, 1343-1353.	6.0	83
371	Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respiratory Medicine,the, 2021, 9, 1396-1406.	5.2	105
372	SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study). American Journal of Transplantation, 2022, 22, 813-822.	2.6	27
373	Receptor binding domainâ€IgG levels correlate with protection in residents facing SARSâ€CoVâ€2 B.1.1.7 outbreaks. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1885-1894.	2.7	13
374	Polymersomes as Stable Nanocarriers for a Highly Immunogenic and Durable SARS-CoV-2 Spike Protein Subunit Vaccine. ACS Nano, 2021, 15, 15754-15770.	7.3	18
375	SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Science Immunology, 2021, 6, eabl9105.	5.6	147
376	Hydrogelâ€Based Slow Release of a Receptorâ€Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARSâ€CoVâ€2. Advanced Materials, 2021, 33, e2104362.	11.1	48
381	Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, 2022, 61, 3351-3361.	0.9	13
382	The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe, The, 2021, 2, e666-e675.	3.4	147
383	SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma. Microbiology Spectrum, 2021, 9, e0129821.	1.2	15
385	Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet, The, 2021, 398, 1407-1416.	6.3	978

#	Article	IF	Citations
386	Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation. Cell Reports, 2021, 37, 109942.	2.9	9
388	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 2022, 14, eabj1996.	5.8	18
390	Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trial. Lancet Respiratory Medicine,the, 2021, 9, 1344-1345.	5.2	0
391	Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection. Diagnostics, 2021, 11, 1915.	1.3	1
393	Humoral response to SARS-CoV-2 vaccines in people living with HIV. Infection, 2022, 50, 617-623.	2.3	37
397	Inhibition of receptorâ€binding domainâ€”ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARSâ€CoVâ€2 vaccines. Journal of Medical Virology, 2021, , .	2.5	5
398	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. Science Advances, 2021, 7, eabj3107.	4.7	23
400	Robust SARS-CoV-2 Antibody Responses in Asian COVID-NaÃ¯ve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine. Vaccines, 2021, 9, 1241.	2.1	12
402	Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naÃ¯ve CD8 T cells of unexposed individuals. EBioMedicine, 2021, 72, 103610.	2.7	24
403	SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection. Signal Transduction and Targeted Therapy, 2021, 6, 368.	7.1	38
405	Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. New England Journal of Medicine, 2021, 385, e84.	13.9	1,394
407	Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patients. Lancet Regional Health - Europe, The, 2021, 10, 100237.	3.0	8
408	SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy. EBioMedicine, 2021, 73, 103635.	2.7	5
409	Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patientsâ€”AuthorsÂ´ Reply. Lancet Regional Health - Europe, The, 2021, 10, 100244.	3.0	3
410	Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. EBioMedicine, 2021, 73, 103626.	2.7	43
411	Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors. Clinical Immunology, 2021, 232, 108871.	1.4	11
412	A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era. Journal of Clinical Virology Plus, 2021, 1, 100044.	0.4	2
413	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nature Communications, 2021, 12, 6250.	5.8	88

#	Article	IF	Citations
414	Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men. Emerging Microbes and Infections, 2021, 10, 2141-2150.	3.0	20
415	IgG antibodies against SARS-CoV-2 decay but persist 4Âmonths after vaccination in a cohort of healthcare workers. Clinica Chimica Acta, 2021, 523, 476-482.	0.5	31
416	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	5.7	66
417	IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19. Lancet Rheumatology, The, 2021, 3, e829-e831.	2.2	13
418	Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2. Journal of the American Society of Nephrology: JASN, 2021, 32, 2725-2727.	3.0	15
419	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	5.7	123
421	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. Npj Vaccines, 2021, 6, 128.	2.9	102
425	SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays. Clinica Chimica Acta, 2021, 523, 446-453.	0.5	19
427	COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries. Vaccine, 2021, 39, 7128-7130.	1.7	4
428	The COVID-19 pandemic and ANCA-associated vasculitis â€“ reports from the EUVAS meeting and EUVAS education forum. Autoimmunity Reviews, 2021, 20, 102986.	2.5	25
430	Seroconversion rate after vaccination against COVID-19 in patients with cancerâ€”a systematic review. Annals of Oncology, 2022, 33, 158-168.	0.6	59
431	Waning Immunity after the BNT162b2 Vaccine in Israel. New England Journal of Medicine, 2021, 385, e85.	13.9	860
433	Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA - Journal of the American Medical Association, 2021, 326, 2524.	3.8	88
434	Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses. Frontiers in Immunology, 2021, 12, 750448.	2.2	9
436	Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response. EBioMedicine, 2021, 73, 103656.	2.7	31
437	Vaccine protection and how we measure it. Transplant Infectious Disease, 2021, 23, e13748.	0.7	1
438	Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. EClinicalMedicine, 2021, 41, 101174.	3.2	57
439	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. JAMA - Journal of the American Medical Association, 2021, 326, 1930.	3.8	140

#	Article	IF	Citations
440	The study of COVID-19 infection following vaccination in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103363.	0.9	7
441	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. Medicinski Podmladak, 2021, 72, 20-29.	0.2	3
442	SARS-CoV-2 Vaccination Elicits Unconventional IgM Specific Responses in NaÃ¯ve and Previously COVID19-Infected Individuals. SSRN Electronic Journal, 0, , .	0.4	0
444	Decisive conditions for strategic vaccination against SARS-CoV-2. Chaos, 2021, 31, 101105.	1.0	4
447	Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Frontiers in Immunology, 2021, 12, 747830.	2.2	69
448	Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines. EBioMedicine, 2021, 73, 103677.	2.7	6
450	The way of SARS-CoV-2 vaccine development: success and challenges. Signal Transduction and Targeted Therapy, 2021, 6, 387.	7.1	42
451	Myeloid dysregulation and therapeutic intervention in COVID-19. Seminars in Immunology, 2021, 55, 101524.	2.7	9
452	Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19. Journal of Infection, 2022, 84, 418-467.	1.7	7
453	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nature Medicine, 2021, 27, 2136-2143.	15.2	346
454	Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract. Viruses, 2021, 13, 2202.	1.5	9
455	BNT162b2 vaccination induces durable SARS-CoV-2â€“specific T cells with a stem cell memory phenotype. Science Immunology, 2021, 6, eabl5344.	5.6	166
456	T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination. Journal of Leukocyte Biology, 2022, 111, 355-365.	1.5	25
457	Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5Âmonths after vaccination. Clinical and Experimental Medicine, 2022, 22, 477-485.	1.9	18
458	Clinical and Immunological Effects of p53-Targeting Vaccines. Frontiers in Cell and Developmental Biology, 2021, 9, 762796.	1.8	12
459	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science, 2021, 374, eabl9551.	6.0	111
460	Evaluation of a Novel Multiplex Platform for Simultaneous Detection of IgG Antibodies Against the 4 Main SARS-CoV-2 Antigens. journal of applied laboratory medicine, The, 2022, 7, 698-710.	0.6	3
462	Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age. Vaccines, 2021, 9, 1277.	2.1	1

#	Article	IF	Citations
463	An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine â€œSputnik Lightâ€•for prevention of coronavirus infection in healthy adults. Lancet Regional Health - Europe, The, 2021, 11, 100241.	3.0	50
465	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. Pathogens and Immunity, 2021, 6, 27-49.	1.4	10
466	Factors associated with COVID-19 vaccine hesitancy amongst refugees in Australia. HÃ¶gre Utbildning, 2021, 12, 1997173.	1.4	31
467	Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines. Journal of Infectious Diseases, 2022, 225, 327-331.	1.9	12
468	Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2â€“Naive Residents of Nursing Homes. Clinical Infectious Diseases, 2022, 75, e695-e704.	2.9	23
469	Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters. Clinical Immunology, 2022, 234, 108897.	1.4	20
470	Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2. Clinica Chimica Acta, 2022, 524, 11-17.	0.5	16
471	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. Pathogens and Immunity, 2021, 6, 27-49.	1.4	46
472	Mt10-CVB3 Vaccine Virus Protects against CVB4 Infection by Inducing Cross-Reactive, Antigen-Specific Immune Responses. Microorganisms, 2021, 9, 2323.	1.6	6
473	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. Npj Vaccines, 2021, 6, 143.	2.9	47
474	Application of SARS-CoV-2 Serology to Address Public Health Priorities. Frontiers in Public Health, 2021, 9, 744535.	1.3	4
475	Antibody Response to BNT162b2 Vaccine in Immune Modifiersâ€“Treated Psoriatic Patients. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 24-28.	0.3	1
476	Impact of Distinct Therapies on Antibody Response to <scp>SARSâ€CoV</scp>â€2 Vaccine in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 562-571.	1.5	25
481	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. Emerging Microbes and Infections, 2022, 11, 18-29.	3.0	25
482	Kinetics of <scp>antiâ€SARSâ€CoV</scp>â€2 neutralizing antibodies development after <scp>BNT162b2</scp> vaccination in patients with amyloidosis and the impact of therapy. American Journal of Hematology, 2022, 97, E27.	2.0	5
483	A call for caution in the immunocompromised: COVID-19 associated with mortality in a vaccinated lung transplant recipient. Open Forum Infectious Diseases, 2021, 8, ofab557.	0.4	2
484	Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine. Annals of Internal Medicine, 2022, 175, 226-233.	2.0	46
485	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Vaccines, 2021, 9, 1345.	2.1	22

#	Article	IF	Citations
486	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2022, 10, 167-179.	5.2	89
487	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe, The, 2022, 3, e52-e61.	3.4	436
489	Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell Host and Microbe, 2021, 29, 1738-1743.e4.	5.1	61
491	Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	1.0	1
492	RBD206-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern. Signal Transduction and Targeted Therapy, 2021, 6, 390.	7.1	5
494	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. Journal of Clinical Oncology, 2022, 40, 12-23.	0.8	75
495	Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. Journal of Virology, 2022, 96, JVI0197321.	1.5	35
496	Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay. Microbiology Spectrum, 2021, 9, e0120221.	1.2	25
497	Chinese experience in the management and control of COVID-19 epidemic. Revista Bionatura, 2021, 6, 2144-2148.	0.1	0
498	Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study. Cureus, 2021, 13, e19879.	0.2	22
499	Role of maternal COVIDâ€19 vaccination in providing immunological protection to the newborn. Pharmacotherapy, 2022, 42, 58-70.	1.2	23
500	Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. Journal of Thoracic Oncology, 2022, 17, 239-251.	0.5	51
501	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nature Communications, 2021, 12, 6871.	5.8	147
505	mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease. Neuromuscular Disorders, 2022, 32, 33-35.	0.3	6
506	Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches. PLoS ONE, 2021, 16, e0259731.	1.1	8
507	Immune response against SARS-CoV-2 variants: the role of neutralization assays. Npj Vaccines, 2021, 6, 142.	2.9	26
509	COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e321-e326.	0.2	9
510	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. Journal of Thoracic Oncology, 2022, 17, 214-227.	0.5	26

#	Article	IF	Citations
511	The glycosylation in SARS-CoV-2 and its receptor ACE2. Signal Transduction and Targeted Therapy, 2021, 6, 396.	7.1	111
512	Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma. Journal of Clinical Medicine, 2021, 10, 5499.	1.0	7
513	Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines, 2021, 9, 1376.	2.1	37
514	Modeling SARS-CoV-2 propagation using rat coronavirus-associated shedding and transmission. PLoS ONE, 2021, 16, e0260038.	1.1	4
515	SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. BioDrugs, 2022, 36, 41-53.	2.2	26
516	Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ, The, 2021, 375, e067873.	3.0	110
517	Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiotherapy and Oncology, 2021, 166, 88-91.	0.3	8
519	Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine. Vaccines, 2021, 9, 1379.	2.1	12
520	Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection. Viruses, 2021, 13, 2313.	1.5	13
521	Increased B Cell Selection Stringency In Germinal Centers Can Explain Improved COVID-19 Vaccine Efficacies With Low Dose Prime or Delayed Boost. Frontiers in Immunology, 2021, 12, 776933.	2.2	24
522	Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience. Journal of Infectious Diseases, 2022, 225, 785-792.	1.9	38
523	Boosting immunity to COVID-19 vaccines. Nature Medicine, 2021, 27, 1874-1875.	15.2	56
524	Descriptive evaluation of antibody responses to severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in plasma and gingival crevicular fluid in a nursing home cohortâ€"Arkansas, Juneâ€"August 2020. Infection Control and Hospital Epidemiology, 2022, 43, 1610-1617.	1.0	3
525	Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. Cells, 2021, 10, 3367.	1.8	42
528	mRNA vaccines against COVIDâ€19: a showcase for the importance of microbial biotechnology. Microbial Biotechnology, 2022, 15, 135-148.	2.0	9
529	The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplantation, 2022, 106, 821-834.	0.5	127
532	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-Î± inhibitors. Med, 2021, 2, 1327-1341.e4.	2.2	31
533	Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies. Diagnostics, 2021, 11, 2193.	1.3	4

#	Article	IF	Citations
534	Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay. Journal of Infection and Chemotherapy, 2022, 28, 273-278.	0.8	19
535	Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study. Viruses, 2021, 13, 2270.	1.5	5
538	Comparison of long-term antibody response to mRNA SARS-CoV-2 vaccine among peritoneal dialysis and hemodialysis patients. Nephrology Dialysis Transplantation, 2022, 37, 602-604.	0.4	5
540	Comparison of the immunogenicity of <scp>BNT162b2</scp> and <scp>CoronaVac COVID</scp>â€19 vaccines in Hong Kong. Respirology, 2022, 27, 301-310.	1.3	127
541	Possibility of exosomeâ€'based coronavirus disease 2019 vaccine (Review). Molecular Medicine Reports, 2021, 25, .	1.1	18
545	COVID-19 vaccines in the age of the delta variant. Lancet Infectious Diseases, The, 2022, 22, 429-430.	4.6	6
546	Sensitivity of SARS-CoV-2 variant Delta to serum neutralization in BNT162b2 vaccinees and unvaccinated COVID-19 recovered cases. Infection, 2021, , 1.	2.3	1
547	Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects. Viruses, 2021, 13, 2329.	1.5	13
548	Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination. Diagnostic Microbiology and Infectious Disease, 2022, 102, 115597.	0.8	16
549	Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study. Journal of Clinical Medicine, 2021, 10, 5362.	1.0	18
550	Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population. Vaccines, 2021, 9, 1375.	2.1	37
551	12-month SARS-CoV-2 antibody persistency in aÂTyrolean COVID-19 cohort. Wiener Klinische Wochenschrift, 2021, 133, 1265-1271.	1.0	2
552	Antibody Response 3 Months after 2 Doses of BNT162b2 mRNA COVID-19 Vaccine in Residents of Long-Term Care Facilities. Gerontology, 2021, , 1-7.	1.4	7
554	A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies. Communications Medicine, 2021, 1, .	1.9	23
555	Interaction between Spike Protein of SARS-CoV-2 and Human Virus Receptor ACE2 Using Two-Color Fluorescence Cross-Correlation Spectroscopy. Applied Sciences (Switzerland), 2021, 11, 10697.	1.3	2
556	Molecular and Serological Characterization of the SARS-CoV-2 Delta Variant in Bangladesh in 2021. Viruses, 2021, 13, 2310.	1.5	9
558	CoronaVac efficacy data from Turkey. Lancet, The, 2021, 398, 1873-1874.	6.3	9
559	Placebo control group in COVID-19 vaccine trials: context and timing matters. European Journal of Clinical Pharmacology, 2022, 78, 523-526.	0.8	2

#	Article	IF	Citations
561	Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis. EBioMedicine, 2021, 73, 103651.	2.7	25
562	Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants. Microbiology Spectrum, 2021, 9, e0056021.	1.2	20
563	Previous COVID-19 Infection and Antibody Levels After Vaccination. Frontiers in Public Health, 2021, 9, 778243.	1.3	69
564	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1681-1691.	5.1	118
565	The influence of interval between doses on response to vaccines. Vaccine, 2021, 39, 7123-7127.	1.7	9
566	Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood, 2022, 139, 678-685.	0.6	96
568	The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. Biochemical Society Transactions, 2021, 49, 2879-2890.	1.6	16
569	Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics, 2022, 19, 325-333.	2.1	32
570	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell, 2022, 185, 113-130.e15.	13.5	64
571	Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine. Infectious Diseases and Therapy, 2022, 11, 351-365.	1.8	10
572	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. Human Vaccines and Immunotherapeutics, 2024, 17, 4714-4740.	1.4	16
573	Current and future nanoparticle vaccines for COVID-19. EBioMedicine, 2021, 74, 103699.	2.7	57
574	Longevity of anti-spike and anti-nucleocapsid antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent controls. American Journal of Transplantation, 2022, 22, 1245-1252.	2.6	13
576	Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Advances, 2022, 6, 2014-2034.	2.5	57
577	Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet Rheumatology, The, 2022, 4, e113-e124.	2.2	24
578	Pharmacokinetics of high-titer antiâ€“SARS-CoV-2 human convalescent plasma in high-risk children. JCI Insight, 2022, 7, .	2.3	12
579	Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 2021, 17, e1010022.	2.1	139
580	Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. The Lancet Healthy Longevity, 2021, 2, e811-e819.	2.0	54

#	Article	IF	Citations
581	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 2021, 74, 103729.	2.7	29
582	The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. Journal of Functional Foods, 2021, 87, 104850.	1.6	23
583	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. RSC Drug Discovery Series, 2021, , 45-60.	0.2	0
584	Tear antibodies to SARSâ€CoVâ€2: implications for transmission. Clinical and Translational Immunology, 2021, 10, e1354.	1.7	15
585	Point-of-care diagnostics: recent developments in a pandemic age. Lab on A Chip, 2021, 21, 4517-4548.	3.1	34
586	Six-Month Follow-Up of a Booster Dose of CoronaVac: Two Single-Centre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trials. SSRN Electronic Journal, 0, , .	0.4	1
587	Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine. Journal of Korean Medical Science, 2021, 36, e311.	1.1	33
588	SARS-CoV-2 Infection Generates Long-Lived Memory B Cells Against the Receptor Binding Domain of the Spike Protein. SSRN Electronic Journal, 0, , .	0.4	0
589	The Immunogenicity and Safety of Different COVID-19 Booster Vaccination Following CoronaVac or ChAdOx1 nCoV-19 Primary Series. SSRN Electronic Journal, 0, , .	0.4	1
590	Anti-SARS-CoV-2 IgG Antibody Levels Among Thai Healthcare Providers Receiving Homologous and Heterologous COVID-19 Vaccination Regimens. SSRN Electronic Journal, 0, , .	0.4	1
591	Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial. SSRN Electronic Journal, 0, , .	0.4	1
592	Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination. Clinical Infectious Diseases, 2022, 75, e884-e887.	2.9	31
593	Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression. SSRN Electronic Journal, 0, , .	0.4	34
594	Comprehensive Analysis of CD4+ T Cell Response Cross-Reactive to SARS-CoV-2 Antigens at the Single Allele Level of HLA Class II. Frontiers in Immunology, 2021, 12, 774491.	2.2	6
595	Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G. Internal Medicine, 2022, 61, 811-819.	0.3	6
596	Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers. American Journal of Tropical Medicine and Hygiene, 2022, 106, 556-561.	0.6	12
597	Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2022, 58, 103486.	0.9	19
598	Humoral immune response to <scp>COVIDâ€19</scp> vaccination in diabetes is ageâ€dependent but independent of type of diabetes and glycaemic control: The prospective <scp>COVACâ€DM</scp> cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 849-858.	2.2	45

#	Article	IF	Citations
602	Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 1609-1612.e1.	2.4	18
603	Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell, 2022, 40, 103-108.e2.	7.7	30
604	Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. Journal of Autoimmunity, 2022, 127, 102792.	3.0	96
605	Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel. Emerging Infectious Diseases, 2022, 28, 338-346.	2.0	25
606	Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. European Journal of Cancer, 2022, 162, 182-193.	1.3	40
607	Standardization of two SARS-CoV-2 serology assays to the WHO 20/136 human standard reference material. Journal of Virological Methods, 2022, 300, 114430.	1.0	13
608	Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody. Biosensors and Bioelectronics, 2022, 199, 113883.	5.3	21
609	Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases. Brain, Behavior, and Immunity, 2022, 101, 49-56.	2.0	18
610	Phase I Interim Results of a Phase I/II Study of the IgG-Fc Fusion COVID-19 Subunit Vaccine, AKS-452. SSRN Electronic Journal, 0, , .	0.4	1
611	Long-Term Comparison of 7 SARS-CoV-2 Antibody Assays in the North Zealand Covid-19 Cohort. journal of applied laboratory medicine, The, 2022, 7, 711-726.	0.6	5
612	Comparative analysis of existing platforms for the development of vaccines against dangerous and extremely dangerous viral infections with pandemic potential. BIOpreparations Prevention Diagnosis Treatment, 2021, 21, 225-233.	0.2	0
613	Primer of COVID-19 Vaccines for the Perioperative Physician. Journal of Neurosurgical Anesthesiology, 2022, 34, 101-106.	0.6	0
614	Delta variant of SARS-CoV-2: characteristics and implications for public health in Colombia. Revista Facultad De Medicina, 2021, 70, e97460.	0.0	1
617	Physiciansâ€™ Experience with COVID-19 Vaccination: A Survey Study. Healthcare (Switzerland), 2021, 9, 1746.	1.0	7
618	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Research, 2022, 32, 269-287.	5.7	54
619	Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nature Medicine, 2022, 28, 496-503.	15.2	215
620	Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers. American Journal of Transplantation, 2022, 22, 1459-1466.	2.6	9
621	Homologous and Heterologous Covid-19 Booster Vaccinations. New England Journal of Medicine, 2022, 386, 1046-1057.	13.9	418

#	Article	IF	Citations
622	Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ TÂcell responses. Cell Reports, 2022, 38, 110345.	2.9	30
624	Quantitative measurement of IgG to SARSâ€CoVâ€2 antigens using monoclonal antibodyâ€based enzymeâ€linked immunosorbent assays. Clinical and Translational Immunology, 2022, 11, e1369.	1.7	8
625	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. Med, 2022, 3, 28-41.e8.	2.2	19
626	Great Expectations of COVID-19 Herd Immunity. MBio, 2022, 13, e0349521.	1.8	9
627	Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain. Cell Reports Medicine, 2022, 3, 100527.	3.3	47
629	A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. Cell Reports Medicine, 2022, 3, 100486.	3.3	16
631	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Science Translational Medicine, 2022, 14, eabl8124.	5.8	143
632	Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS) Tj ETQq1 1 0.784314 rgBT /O Lancet Infectious Diseases, The, 2022, 22, 636-648.	4.6	52
633	An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. Journal of Medical Virology, 2022, 94, 2212-2221.	2.5	28
635	Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell, 2022, 185, 1025-1040.e14.	13.5	243
637	Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nature Medicine, 2022, 28, 486-489.	15.2	305
638	Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers. Public Health, 2022, 205, 1-5.	1.4	2
639	Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2. BMC Medicine, 2022, 20, 32.	2.3	7
640	Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe, The, 2022, 3, e193-e202.	3.4	45
641	Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time. MBio, 2022, 13, e0344221.	1.8	19
643	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Science Translational Medicine, 2022, 14, eabm7853.	5.8	71
644	High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals. Cell Reports, 2022, 38, 110237.	2.9	21
645	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2022, 375, 183-192.	6.0	91

#	Article	IF	Citations
646	Innovative vaccine approachesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1511, 59-86.	1.8	5
648	Twelve-Month Follow-up of Early COVID-19 Cases in the United States: Cellular and Humoral Immune Longevity. Open Forum Infectious Diseases, 2022, 9, ofab664.	0.4	0
649	DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model. Frontiers in Immunology, 2021, 12, 785349.	2.2	7
650	<scp>COVID</scp>â€19 vaccine response in patients with hematologic malignancy: A systematic review and metaâ€analysis. American Journal of Hematology, 2022, 97, .	2.0	18
651	Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19. Irish Journal of Medical Science, 2022, 191, 2833-2838.	0.8	1
652	Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNAâ€"mRNA or Vectorâ€"mRNA COVID-19 Vaccines. Vaccines, 2022, 10, 75.	2.1	8
655	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients. Blood Cancer Journal, 2022, 12, 8.	2.8	5
656	CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103448.	0.9	19
657	Immune-Guided Therapy of COVID-19. Cancer Immunology Research, 2022, 10, 384-402.	1.6	20
658	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. Journal of Allergy and Clinical Immunology, 2022, 149, 1242-1252.e12.	1.5	23
659	Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model. Vaccine, 2022, 40, 1289-1298.	1.7	9
660	Using correlates to accelerate vaccinology. Science, 2022, 375, 22-23.	6.0	13
661	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2022, 375, 43-50.	6.0	788
662	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nature Medicine, 2022, 28, 477-480.	15.2	342
663	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9
665	COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. Blood Reviews, 2022, 54, 100931.	2.8	49
666	Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021. Eurosurveillance, 2022, 27, .	3.9	30
667	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell, 2022, 185, 872-880.e3.	13.5	165

#	Article	IF	Citations
668	TNFÎ±-Producing CD4 ⁺ T Cells Dominate the SARS-CoV-2-Specific T Cell Response in COVID-19 Outpatients and Are Associated with Durable Antibodies. SSRN Electronic Journal, 0, , .	0.4	0
669	Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations. Pathogens, 2022, 11, 171.	1.2	4
670	SARS-CoV-2 Variants, Vaccines, and Host Immunity. Frontiers in Immunology, 2021, 12, 809244.	2.2	176
671	Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination. Vaccines, 2022, 10, 154.	2.1	8
672	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. New England Journal of Medicine, 2022, 386, 340-350.	13.9	501
673	SARS-CoV-2 antibody response eight months after vaccination with mRNA vaccines. Influence of prior SARS-CoV-2 exposure. European Journal of Internal Medicine, 2022, 97, 113-115.	1.0	4
675	Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort. Frontiers in Immunology, 2022, 13, 829665.	2.2	19
676	Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar. New England Journal of Medicine, 2022, 386, 799-800.	13.9	58
677	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. Biomedicines, 2022, 10, 204.	1.4	7
678	Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2. Frontiers in Immunology, 2022, 13, 811020.	2.2	11
679	VariaciÃ³n longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2022, 3, 45-50.	0.1	0
680	Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell Host and Microbe, 2022, 30, 69-82.e10.	5.1	42
682	Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group. Frontiers in Immunology, 2021, 12, 766278.	2.2	13
688	Cellular Immune Response after Vaccination in Patients with Cancerâ€"Review on Past and Present Experiences. Vaccines, 2022, 10, 182.	2.1	9
689	Multiplexed Lab-on-a-Chip Bioassays for Testing Antibodies against SARS-CoV-2 and Its Variants in Multiple Individuals. Analytical Chemistry, 2022, 94, 2510-2516.	3.2	7
690	RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. BMC Infectious Diseases, 2022, 22, 87.	1.3	26
691	Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?. Clinical Chemistry and Laboratory Medicine, 2022, 60, 64-65.	1.4	2
692	Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine, 2022, 40, 306-315.	1.7	107

#	Article	IF	Citations
693	Humoral and cellular immune responses to SARS CoV-2 vaccination in People with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments. Multiple Sclerosis and Related Disorders, 2022, 59, 103554.	0.9	11
694	mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell, 2022, 185, 457-466.e4.	13.5	881
696	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. Cell Reports Medicine, 2022, 3, 100528.	3.3	6
699	A report of two cases of myocarditis following mRNA coronavirus disease 2019 vaccination. European Heart Journal - Case Reports, 2022, 6, ytac004.	0.3	7
700	Evaluating Correlates of Protection for Mix-Match Vaccine Against COVID-19 VOCs With Potential of Evading Immunity. SSRN Electronic Journal, 0, , .	0.4	0
701	Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges. Nature Communications, 2022, 13, 140.	5.8	22
702	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nature Communications, 2022, 13, 153.	5.8	45
703	Robust and durable serological response following pediatric SARS-CoV-2 infection. Nature Communications, 2022, 13, 128.	5.8	54
704	A Global Map of COVID-19 Vaccine Acceptance Rates per Country: An Updated Concise Narrative Review. Journal of Multidisciplinary Healthcare, 2022, Volume 15, 21-45.	1.1	157
705	A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination. Emerging Microbes and Infections, 2022, 11, 250-259.	3.0	3
707	Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China. BMC Medicine, 2022, 20, 37.	2.3	10
708	Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition. Frontiers in Immunology, 2022, 13, 830710.	2.2	19
710	Impaired SARS-CoV-2 mRNA Vaccine Antibody Response in Chronic Medical Conditions. Chest, 2022, 161, 1490-1493.	0.4	8
711	A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 844-847.	2.5	36
713	Are convalescent plasma stocks collected during former COVIDâ€19 waves still effective against current <scp>SARSâ€CoV</scp>â€2 variants?. Vox Sanguinis, 2022, 117, 641-646.	0.7	8
714	Evaluating immunity to <scp>SARSâ€CoV</scp>â€2 in nursing home residents using saliva <scp>IgG</scp>. Journal of the American Geriatrics Society, 2022, 70, 659-668.	1.3	7
715	Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial. EBioMedicine, 2022, 75, 103811.	2.7	15
716	Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. EBioMedicine, 2022, 75, 103810.	2.7	17

#	Article	IF	Citations
718	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood, 2022, 139, 1409-1412.	0.6	28
719	Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet, The, 2022, 399, 905-907.	6.3	60
722	Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccineâ€“induced antibody and T cell immunity and function. JCI Insight, 2022, 7, .	2.3	69
723	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. Med, 2022, 3, 137-153.e3.	2.2	19
725	CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity. Blood Cancer Discovery, 2022, 3, 95-102.	2.6	36
726	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host and Microbe, 2022, 30, 154-162.e5.	5.1	153
727	Milder disease with Omicron: is it the virus or the pre-existing immunity?. Nature Reviews Immunology, 2022, 22, 69-71.	10.6	123
728	mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annual Review of Medicine, 2022, 73, 17-39.	5.0	120
729	Lower probability and shorter duration of infections after COVID-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs. PLoS ONE, 2022, 17, e0263014.	1.1	14
730	Boosting of the SARS-CoV-2â€“Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. Journal of Immunology, 2022, 208, 1139-1145.	0.4	10
731	Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021. Eurosurveillance, 2022, 27, .	3.9	6
732	Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies. Nephrology Dialysis Transplantation, 2022, 37, 1132-1139.	0.4	12
734	Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine. Vaccine, 2022, 40, 1098-1107.	1.7	16
736	Six-Month Follow-Up after Vaccination with BNT162b2: SARS-CoV-2 Antigen-Specific Cellular and Humoral Immune Responses in Hemodialysis Patients and Kidney Transplant Recipients. Pathogens, 2022, 11, 67.	1.2	13
737	SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents. JAMA Oncology, 2022, 8, 612.	3.4	35
738	Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine. Life, 2022, 12, 57.	1.1	6
739	Decreased memory B cell frequencies in COVIDâ€19 delta variant vaccine breakthrough infection. EMBO Molecular Medicine, 2022, 14, e15227.	3.3	31
740	Finger stick blood test to assess postvaccination <scp>SARSâ€CoV</scp>â€2 neutralizing antibody response against variants. Bioengineering and Translational Medicine, 2022, 7, .	3.9	7

#	Article	IF	Citations
742	Kinetics and persistence of cellular and humoral immune responses to SARSâ€CoVâ€2 vaccine in healthcare workers with or without prior COVIDâ€19. Journal of Cellular and Molecular Medicine, 2022, 26, 1293-1305.	1.6	28
743	Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma. Blood, 2022, 139, 137-142.	0.6	29
744	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine, 2022, 75, 103761.	2.7	104
745	Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA - Journal of the American Medical Association, 2022, 327, 341.	3.8	76
747	Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease. Lancet Rheumatology, The, 2022, 4, e241-e243.	2.2	22
748	Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in NaÃ¯ve and Previously Infected Individuals: A Comparative Study. Vaccines, 2022, 10, 191.	2.1	2
749	HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development. Current HIV/AIDS Reports, 2022, 19, 86.	1.1	6
750	Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2. Journal of Microbiology, 2022, 60, 335-346.	1.3	18
752	Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy. Lancet Infectious Diseases, The, 2022, 22, 649-656.	4.6	12
753	Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals. JAMA - Journal of the American Medical Association, 2022, 327, 279.	3.8	68
754	Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint. BMC Medicine, 2022, 20, 36.	2.3	17
755	Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety. Journal of Medical Virology, 2022, 94, 2369-2375.	2.5	24
756	Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department. Journal of Clinical Microbiology, 2022, 60, jcm0239021.	1.8	5
757	Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med, 2022, 3, 104-118.e4.	2.2	38
758	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Reports Medicine, 2022, 3, 100523.	3.3	18
759	Imprinted SARS-CoV-2-Specific Memory Lymphocytes Define Hybrid Immunity. SSRN Electronic Journal, 0, , .	0.4	0
760	Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 171.	2.1	17
761	SARS-CoV-2 Antibody Response After ChAdOx1 nCoV-19 Vaccination in Persons With Previous SARS-CoV-1 Infection. JAMA Internal Medicine, 2022, 182, 347.	2.6	3

#	Article	IF	Citations
762	Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection. Journal of Travel Medicine, 2022, 29, .	1.4	3
763	Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. IScience, 2022, 25, 103602.	1.9	6
764	Fast and real-time electrical transistor assay for quantifying SARS-CoV-2 neutralizing antibodies. Communications Materials, 2022, 3, .	2.9	6
765	Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine, 2022, 40, 1253-1260.	1.7	10
766	Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals. Journal of Infection, 2022, 84, 579-613.	1.7	21
768	Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a caseâ€“control study (COVID-19VacRTX). Rheumatology, 2022, , .	0.9	10
769	Zwitterionic Polymer Electroplating Facilitates the Preparation of Electrode Surfaces for Biosensing. Advanced Materials, 2022, 34, e2107892.	11.1	17
770	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nature Medicine, 2022, 28, 490-495.	15.2	577
771	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. New England Journal of Medicine, 2022, 386, 951-963.	13.9	102
772	Three-dose vaccination elicits neutralising antibodies against omicron. Lancet, The, 2022, 399, 715-717.	6.3	82
773	The T cell immune response against SARS-CoV-2. Nature Immunology, 2022, 23, 186-193.	7.0	785
774	SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Cell Reports, 2022, 38, 110336.	2.9	41
775	Neutralizing antibody activity against the B.1.617.2 (delta) variant 8Âmonths after two-dose vaccination with BNT162b2 in health care workers. Clinical Microbiology and Infection, 2022, 28, 1024.e7-1024.e12.	2.8	15
776	Strategies for fighting pandemic virus infections: Integration of virology and drug delivery. Journal of Controlled Release, 2022, 343, 361-378.	4.8	11
777	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). Scientific Reports, 2022, 12, 1727.	1.6	11
778	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell, 2022, 185, 1008-1024.e15.	13.5	101
780	SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 â€“ April 2021. American Journal of Emergency Medicine, 2022, 54, 81-86.	0.7	3
781	Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. Clinical Infectious Diseases, 2022, 75, e878-e879.	2.9	20

#	Article	IF	Citations
782	Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. Cmaj, 2022, 194, E297-E305.	0.9	26
784	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. Biomedicines, 2022, 10, 338.	1.4	21
785	Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovineâ€“Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019. Journal of Infectious Diseases, 2022, 226, 655-663.	1.9	4
786	Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discovery, 2022, 8, 10.	3.1	100
788	Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. Science Translational Medicine, 2022, 14, eabl6141.	5.8	52
789	COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. Nephrology Dialysis Transplantation, 2022, 37, 1357-1365.	0.4	17
790	WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. Lancet Microbe, The, 2022, 3, e81-e82.	3.4	56
791	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. Med, 2022, 3, 188-203.e4.	2.2	11
792	SARS-CoV-2 Vaccine in Dialysis Patients: Time for a Boost?. American Journal of Kidney Diseases, 2022, 79, 162-163.	2.1	5
793	Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2. Molecular Therapy, 2022, 30, 1926-1940.	3.7	16
794	Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infectionâ€"A comparative study from Novi Sad, Serbia. PLoS ONE, 2022, 17, e0263468.	1.1	33
795	Immunity to SARS-CoV-2 up to 15Âmonths after infection. IScience, 2022, 25, 103743.	1.9	56
796	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Advances, 2022, 6, 1537-1546.	2.5	45
797	Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?. The Lancet Gastroenterology and Hepatology, 2022, 7, 280-282.	3.7	8
799	Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model. MSphere, 2022, 7, e0088321.	1.3	10
800	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. JCI Insight, 2022, 7, .	2.3	12
801	Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications â€“ A pilot study. Multiple Sclerosis and Related Disorders, 2022, 59, 103560.	0.9	11
802	Community seroprevalence and risk factors for SARS-CoV-2 infection in different subpopulations in Vellore, India, and their implications for future prevention. International Journal of Infectious Diseases, 2022, 116, 138-146.	1.5	3

#	Article	IF	Citations
803	High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV â€“ but HIV viremia matters?. Aids, 2022, 36, 479-481.	1.0	24
804	IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccination. Diagnostic Microbiology and Infectious Disease, 2022, 102, 115638.	0.8	6
805	The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study. The Lancet Regional Health - Western Pacific, 2022, 21, 100389.	1.3	16
806	Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials. The Lancet Regional Health Americas, 2022, 9, 100196.	1.5	5
807	Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut, 2022, 71, 1106-1116.	6.1	84
808	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nature Microbiology, 2022, 7, 423-433.	5.9	78
810	Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence. Frontiers in Immunology, 2022, 13, 796481.	2.2	7
812	Interdependencies of cellular and humoral immune responses in heterologous and homologous SARSâ€CoVâ€2 vaccination. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2381-2392.	2.7	14
813	Fc effector cross-reactivity: A hidden arsenal against SARS-CoV-2â€™s evasive maneuvering. Cell Reports Medicine, 2022, 3, 100540.	3.3	12
814	Testing fractional doses of COVID-19 vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	20
815	Development of a TÂcell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status. Cell Host and Microbe, 2022, 30, 388-399.e3.	5.1	26
817	Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 710-719.	0.5	16
820	Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up. Viruses, 2022, 14, 312.	1.5	19
821	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell, 2022, 185, 896-915.e19.	13.5	189
822	Immune titers of protection against severe acute respiratory syndrome coronavirus 2: are we there yet?. Exploration of Immunology, 0, , 9-24.	1.7	5
823	Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccineâ€“elicited human sera. Science, 2022, 375, 678-680.	6.0	303
824	Vaccination of <scp>COVID</scp>â€19 convalescent plasma donors increases binding and neutralizing antibodies against <scp>SARSâ€CoV</scp>â€2 variants. Transfusion, 2022, 62, 563-569.	0.8	7
825	SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. PLoS Biology, 2022, 20, e3001531.	2.6	10

#	Article	IF	Citations
827	A Lateral Flow Immunoassay Coupled with a Spectrum-Based Reader for SARS-CoV-2 Neutralizing Antibody Detection. Vaccines, 2022, 10, 271.	2.1	9
829	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. Science Translational Medicine, 2022, 14, .	5.8	77
830	Predictive factors of a viral neutralizing humoral response after a third dose of COVID-19 mRNA vaccine. American Journal of Transplantation, 2022, 22, 1442-1450.	2.6	15
831	Salivary antibodies are detected with a commercial anti-SARS-CoV-2 assay only after two doses of vaccine using serum thresholds. Clinical Biochemistry, 2022, 104, 66-69.	0.8	5
832	Waning humoral immune response to the BNT162b2 vaccine in heart transplant recipients over 6 months. American Journal of Transplantation, 2022, 22, 1931-1932.	2.6	5
833	Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination. Journal of Infectious Diseases, 2022, 226, 23-31.	1.9	17
835	Advanced Materials for SARSâ€CoVâ€2 Vaccines. Advanced Materials, 2022, 34, e2107781.	11.1	25
836	Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. Journal of Hematology and Oncology, 2022, 15, 15.	6.9	21
838	SARS-CoV-2 antibody testing for transplant recipients: A tool to personalize protection versus COVID-19. American Journal of Transplantation, 2022, 22, 1316-1320.	2.6	18
839	Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115659.	0.8	44
840	Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice. Npj Vaccines, 2022, 7, 17.	2.9	19
842	Latex Microsphere-Based Bicolor Immunochromatography for Qualitative Detection of Neutralizing Antibody against SARS-CoV-2. Biosensors, 2022, 12, 103.	2.3	8
843	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS ONE, 2022, 17, e0263328.	1.1	21
846	Evaluation of Two Rapid Lateral Flow Tests and Two Surrogate ELISAs for the Detection of SARS-CoV-2 Specific Neutralizing Antibodies. Frontiers in Medicine, 2022, 9, 820151.	1.2	11
847	Divergent SARS-CoV-2 Omicronâ€"reactive T and B cell responses in COVID-19 vaccine recipients. Science Immunology, 2022, 7, eabo2202.	5.6	337
848	Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform. Molecular Therapy, 2022, 30, 1913-1925.	3.7	21
849	Analytical characterization of the SARS-CoV-2 EURM-017 reference material. Clinical Biochemistry, 2022, 101, 19-25.	0.8	5
850	Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects. Biosensors and Bioelectronics, 2022, 204, 114067.	5.3	9

#	Article	IF	Citations
852	SARS-CoV-2 and COVID-19: revisiting the most important research questions. Cell and Bioscience, 2021, 11, 215.	2.1	0
853	B Cell Numbers Predict Humoral and Cellular Response Upon <scp>SARS</scp>â€“<scp>CoV</scp>â€2 Vaccination Among Patients Treated With Rituximab. Arthritis and Rheumatology, 2022, 74, 934-947.	2.9	55
854	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell, 2022, 40, 114-116.	7.7	50
855	Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex. EBioMedicine, 2021, 74, 103748.	2.7	17
856	Booster doses for inactivated COVID-19 vaccines: if, when, and for whom. Lancet Infectious Diseases, The, 2022, 22, 430-432.	4.6	15
857	Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatology, The, 2022, 4, e177-e187.	2.2	122
858	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, 0, , .	13.7	104
859	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , .	13.7	101
860	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nature Communications, 2021, 12, 7217.	5.8	80
861	The germinal centre B cell response to SARS-CoV-2. Nature Reviews Immunology, 2022, 22, 7-18.	10.6	150
862	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nature Reviews Immunology, 2022, 22, 57-65.	10.6	217
863	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670.	13.7	917
864	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, 2022, 602, 654-656.	13.7	928
865	The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerging Microbes and Infections, 2022, 11, 1-5.	3.0	320
866	Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?. Clinical and Experimental Immunology, 2022, 207, 263-271.	1.1	14
867	Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection. Clinical Infectious Diseases, 2022, 75, e827-e837.	2.9	9
868	Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clinical Infectious Diseases, 2022, 75, e822-e826.	2.9	322
869	Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines. Journal of Infectious Diseases, 2022, 225, 1141-1150.	1.9	102

#	Article	IF	Citations
870	Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naÃ¯ve and previously infected individuals. Journal of Travel Medicine, 2021, 28, .	1.4	20
871	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. HemaSphere, 2022, 6, e677.	1.2	17
872	SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis. Journal of the Chinese Medical Association, 2022, 85, 421-430.	0.6	10
899	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science, 2021, 374, 1621-1626.	6.0	232
900	Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans â€" Five Veterans Affairs Medical Centers, United States, February 1â€"September 30, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1700-1705.	9.0	73
902	SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. Frontiers in Cellular and Infection Microbiology, 2021, 11, 777212.	1.8	29
903	Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. Vaccines, 2022, 10, 64.	2.1	144
904	Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset. Journal of Immunology, 2022, 208, 429-443.	0.4	12
905	SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis. Annals of Internal Medicine, 2022, 175, 371-378.	2.0	55
907	Interim statement on covid-19 vaccine booster doses. Neurosciences, 2021, 26, 403-405.	0.1	2
908	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2021, , eab3435.	6.0	145
909	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2021, , eabm0811.	6.0	10
910	Observed Protection Against SARS-CoV-2 Reinfection Following a Primary Infection: A Danish Cohort Study Using Two Years of Nationwide PCR-Test Data. SSRN Electronic Journal, 0, , .	0.4	5
911	Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults. Clinical and Experimental Vaccine Research, 2022, 11, 116.	1.1	3
912	Kinetics and Factors Associated With 12-Month Persistence of Neutralizing Antibody Induced by Two Inactivated COVID-19 Vaccines. SSRN Electronic Journal, 0, , .	0.4	0
913	ChAdOx1 nCoV-19, BNT162b2 and CoronaVac Vaccines Do Not Induce as Strong Neutralising Antibodies with Broad Variant Protection as Infection and Suggest Vaccines that Induce Broader Sterilising Immunity are Essential to Stop the Pandemic. SSRN Electronic Journal, 0, , .	0.4	0
914	Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic. Journal of Korean Medical Science, 2022, 37, e67.	1.1	3
915	Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults. Journal of Korean Medical Science, 2022, 37, e70.	1.1	10

#	Article	IF	Citations
916	Probabilistic classification of antiâ€šSARSâ€šCoVâ€‚2 antibody responses improves seroprevalence estimates. Clinical and Translational Immunology, 2022, 11, e1379.	1.7	4
917	Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210873.	0.5	4
918	Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III Trial. SSRN Electronic Journal, 0, , .	0.4	0
919	On the way to mandate booster vaccine dose of coronavirus disease 2019 for transplant recipients: A narrative review of literature. Indian Journal of Transplantation, 2022, 16, 17.	0.0	0
920	Vaccine Effectiveness of Two-Dose BNT162b2 Over Time Against COVID-19 Symptomatic Infection and Severe Cases Among Adolescents: Test Negative Design Case Control Studies in Brazil and Scotland. SSRN Electronic Journal, 0, , .	0.4	4
921	Cold atmospheric plasma for preventing infection of viruses that use ACE2 for entry. Theranostics, 2022, 12, 2811-2832.	4.6	8
922	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nature Reviews Rheumatology, 2022, 18, 191-204.	3.5	105
923	Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines. Npj Vaccines, 2022, 7, 22.	2.9	14
924	Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. Cell Discovery, 2022, 8, 17.	3.1	23
925	Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19. Viruses, 2022, 14, 380.	1.5	4
926	Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nature Communications, 2022, 13, 907.	5.8	94
927	Antibody response to COVID-19 vaccination in patients with lymphoma. International Journal of Hematology, 2022, 115, 728-736.	0.7	13
928	SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore. Vaccines, 2022, 10, 331.	2.1	17
929	Convalescent plasma to deliver therapeutic antibodies against COVID-19. Trends in Molecular Medicine, 2022, 28, 435-436.	3.5	3
930	A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. Frontiers in Immunology, 2022, 13, 844837.	2.2	13
931	Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. Frontiers in Immunology, 2022, 13, 828053.	2.2	11
932	SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study. Journal of Infection, 2022, 84, 171-178.	1.7	25
933	Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. International Journal of Molecular Sciences, 2022, 23, 1987.	1.8	48

#	Article	IF	Citations
936	Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. Frontiers in Immunology, 2022, 13, 846753.	2.2	37
938	SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic. Frontiers of Medicine, 2022, 16, 185-195.	1.5	11
939	High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV. Infection, 2022, , 1.	2.3	4
940	Intensity and Dynamics of Anti-SARS-CoV-2 Immune Responses after BNT162b2 mRNA Vaccination: Implications for Public Health Vaccination Strategies. Vaccines, 2022, 10, 316.	2.1	10
941	Immunological Response to ChAdOx1 nCoV-19 Vaccine among Health Care Workers at a Tertiary Care Hospital in Chennai. Journal of Pure and Applied Microbiology, 2022, 16, 578-584.	0.3	0
942	COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. Kidney International, 2022, 101, 883-894.	2.6	82
943	Antiâ€SARSâ€CoVâ€2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVIDâ€19 vaccination regimens. Influenza and Other Respiratory Viruses, 2022, , .	1.5	8
944	An overview of COVID-19 in solid organ transplantation. Clinical Microbiology and Infection, 2022, 28, 779-784.	2.8	10
945	Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizerâ€“BioNTech) in Patients on Hemodialysis. Vaccines, 2022, 10, 327.	2.1	7
946	Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination. Cancer Cell, 2022, 40, 338-339.	7.7	22
947	A Faster, Novel Technique to Detect COVID-19 Neutralizing Antibodies. Medical Science Monitor, 2022, 28, e935812.	0.5	3
948	Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents. Journal of the American Medical Directors Association, 2022, 23, 750-753.	1.2	11
949	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Scientific Reports, 2022, 12, 2628.	1.6	34
950	Evaluation of Simple Lateral Flow Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies. Vaccines, 2022, 10, 347.	2.1	5
951	Patients with Liver Cirrhosis Show High Immunogenicity upon COVID-19 Vaccination but Develop Premature Deterioration of Antibody Titers. Vaccines, 2022, 10, 377.	2.1	30
952	Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Nature Communications, 2022, 13, 864.	5.8	72
954	COVID-19 Vaccines: An Overview of Different Platforms. Bioengineering, 2022, 9, 72.	1.6	32
956	Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. PLoS ONE, 2022, 17, e0261979.	1.1	10

#	Article	IF	Citations
957	Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance. International Journal of Environmental Research and Public Health, 2022, 19, 2263.	1.2	3
959	Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants. Vaccines, 2022, 10, 324.	2.1	9
960	SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. ELife, 2022, 11, .	2.8	26
961	SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot. Vaccines, 2022, 10, 341.	2.1	10
962	Low-entry-barrier point-of-care testing of anti-SARS-CoV-2 IgG in the population of Upper Austria from December 2020 until April 2021â€"a feasible surveillance strategy for post-pandemic monitoring?. Analytical and Bioanalytical Chemistry, 2022, 414, 3291-3299.	1.9	0
963	Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. Frontiers in Microbiology, 2022, 13, 828806.	1.5	17
966	Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern. Signal Transduction and Targeted Therapy, 2022, 7, 61.	7.1	12
967	Comparison of Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2 Vaccines. Archives of Pathology and Laboratory Medicine, 2022, 146, 677-685.	1.2	7
968	An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission. Npj Vaccines, 2022, 7, 24.	2.9	18
969	Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan. Vaccines, 2022, 10, 312.	2.1	3
971	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine, 2022, 28, 1072-1082.	15.2	147
972	A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. Kidney International, 2022, 101, 1073-1076.	2.6	44
973	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. Vaccines, 2022, 10, 285.	2.1	13
975	Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination. JAMA Oncology, 2022, 8, 201.	3.4	17
976	High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens. Microbiology Spectrum, 2022, 10, e0169521.	1.2	8
977	Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls. Frontiers in Immunology, 2022, 13, 832501.	2.2	23
978	Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine. Frontiers in Immunology, 2022, 13, 790212.	2.2	3
981	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. Frontiers in Medicine, 2022, 9, 815389.	1.2	96

#	Article	IF	Citations
982	SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell, 2022, 185, 603-613.e15.	13.5	176
983	Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. Nature Computational Science, 2022, 2, 123-131.	3.8	39
985	The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors. Frontiers in Public Health, 2022, 10, 816848.	1.3	6
986	Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. PLoS ONE, 2022, 17, e0257930.	1.1	12
987	Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clinical Infectious Diseases, 2022, 75, e585-e593.	2.9	26
988	Correlates of protection via modeling. Nature Computational Science, 2022, 2, 140-141.	3.8	1
989	Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients. Journal of Hepatology, 2022, 77, 152-162.	1.8	25
990	Low antispike antibody levels correlate with poor outcomes in COVIDâ€19 breakthrough hospitalizations. Journal of Internal Medicine, 2022, 292, 127-135.	2.7	15
992	Comparison of Seroconversion in Children and Adults With Mild COVID-19. JAMA Network Open, 2022, 5, e221313.	2.8	55
993	Effect of Mycophenolate Mofetil Dosing on Antibody Response to SARS-CoV-2 Vaccination in Heart and Lung Transplant Recipients. Transplantation, 2022, 106, e269-e270.	0.5	16
994	Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ, The, 2022, 376, e068632.	3.0	253
996	Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2. Scientific Reports, 2022, 12, 3549.	1.6	34
998	SARS-CoV-2 Receptor-Binding Domain IgG Response to AstraZeneca (AZD1222) COVID-19 Vaccination, Jamaica. American Journal of Tropical Medicine and Hygiene, 2022, 106, 1511-1514.	0.6	3
1001	Conference proceedings from virtual 24th Bangkok International Symposium on HIV medicine. Future Virology, 0, , .	0.9	0
1002	Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia. Blood, 2022, 139, 2842-2846.	0.6	9
1003	A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. IScience, 2022, 25, 103960.	1.9	16
1004	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell, 2022, 185, 1572-1587.e11.	13.5	71
1005	Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial. Vaccine, 2022, 40, 1761-1767.	1.7	12

#	Article	IF	Citations
1006	Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre. PLoS ONE, 2022, 17, e0265130.	1.1	23
1007	Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. Nature Communications, 2022, 13, 1699.	5.8	34
1008	Count on us: TÂcells in SARS-CoV-2 infection and vaccination. Cell Reports Medicine, 2022, 3, 100562.	3.3	86
1010	Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation. Frontiers in Medical Technology, 2022, 4, 867982.	1.3	11
1011	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature Reviews Clinical Oncology, 2022, 19, 385-401.	12.5	135
1012	Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet, The, 2022, 399, 924-944.	6.3	752
1013	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine, 2022, 386, 1532-1546.	13.9	1,709
1014	Humoral and Cellular Response after mRNA Vaccination in Nursing Homes: Influence of Age and of History of COVID-19. Vaccines, 2022, 10, 383.	2.1	6
1015	SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women. EBioMedicine, 2022, 77, 103940.	2.7	3
1017	Validation of the GSPÂ®/DELFIAÂ® Anti-SARS-CoV-2 IgG Kit Using Dried Blood Samples for High-Throughput Serosurveillance and Standardized Quantitative Measurement of Anti-Spike S1 IgG Antibody Responses Post-Vaccination. Vaccines, 2022, 10, 514.	2.1	4
1018	Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals. Immunity, Inflammation and Disease, 2022, 10, e592.	1.3	6
1019	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Frontiers in Immunology, 2022, 13, 863039.	2.2	10
1020	Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. Frontiers in Immunology, 2022, 13, 861050.	2.2	8
1021	Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2. Frontiers in Immunology, 2022, 13, 845887.	2.2	13
1022	Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity. Frontiers in Immunology, 2022, 13, 830433.	2.2	12
1023	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	13.7	117
1024	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. Frontiers in Drug Discovery, 2022, 2, .	1.1	4
1025	Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. Frontiers in Immunology, 2022, 13, 842912.	2.2	31

#	Article	IF	Citations
1027	Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection. Viruses, 2022, 14, 651.	1.5	17
1028	Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test. Microbiology Spectrum, 2022, 10, e0099321.	1.2	3
1029	Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients. Scientific Reports, 2022, 12, 3587.	1.6	17
1030	MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters. Frontiers in Immunology, 2022, 13, 845969.	2.2	16
1032	Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?. Journal of Clinical Microbiology, 2022, 60, e0048221.	1.8	21
1033	The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. Clinical Chemistry and Laboratory Medicine, 2022, 60, 934-940.	1.4	5
1034	Broad antiâ€“SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination. Science, 2022, 375, 1041-1047.	6.0	59
1036	Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population. Human Vaccines and Immunotherapeutics, 2022, 18, 1-6.	1.4	9
1037	Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic. Clinical Infectious Diseases, 2022, 75, e938-e946.	2.9	44
1038	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of Clinical Oncology, 2022, 40, 3057-3064.	0.8	31
1039	Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Science Translational Medicine, 2022, 14, eabn9243.	5.8	84
1040	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. ACS Infectious Diseases, 2022, 8, 825-840.	1.8	3
1041	Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 445-459.	2.7	17
1042	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine, 2022, 45, 101323.	3.2	26
1043	Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell, 2022, 185, 1588-1601.e14.	13.5	137
1044	Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO). Cancers, 2022, 14, 1544.	1.7	3
1045	SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2022, , ASN.2021121587.	3.0	4
1046	Development of an Adeno-Associated Virus-Vectored SARS-CoV-2 Vaccine and Its Immunogenicity in Mice. Frontiers in Cellular and Infection Microbiology, 2022, 12, 802147.	1.8	3

#	Article	IF	Citations
1047	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. MBio, 2022, 13, e0297921.	1.8	117
1050	Inactivated SARS-CoV-2 vaccine in primary SjÃ¶grenâ€™s syndrome: humoral response, safety, and effects on disease activity. Clinical Rheumatology, 2022, 41, 2079-2089.	1.0	7
1051	SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naÃ¯ve and previously COVID-19-infected individuals. EBioMedicine, 2022, 77, 103888.	2.7	39
1052	Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. Lancet Infectious Diseases, The, 2022, 22, 813-820.	4.6	64
1055	Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose. Frontiers in Public Health, 2022, 10, 847384.	1.3	12
1056	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. Nephrology Dialysis Transplantation, 2022, 37, 1400-1410.	0.4	21
1057	Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients. Kidney International, 2022, 101, 639-642.	2.6	8
1058	SARS-CoV-2 variants, immune escape, and countermeasures. Frontiers of Medicine, 2022, 16, 196-207.	1.5	39
1059	Prevalence and Main Clinical Characteristics of Fully Vaccinated Patients Admitted to Hospital for Delta Variant COVID-19. Frontiers in Medicine, 2022, 9, 809154.	1.2	8
1061	Development of a peptide vaccine against hookworm infection: Immunogenicity, efficacy, and immune correlates of protection. Journal of Allergy and Clinical Immunology, 2022, 150, 157-169.e10.	1.5	5
1062	Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection. Vaccines, 2022, 10, 502.	2.1	12
1063	Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Science Translational Medicine, 2022, 14, eabn8057.	5.8	150
1064	Neutralizing antibodies to SARSâ€CoVâ€2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. European Journal of Immunology, 2022, 52, 816-824.	1.6	31
1067	Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility. Vaccines, 2022, 10, 446.	2.1	7
1068	Population differences in antibody response to SARSâ€CoVâ€2 infection and BNT162b2 vaccination. FASEB Journal, 2022, 36, e22223.	0.2	7
1069	Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. PLoS ONE, 2022, 17, e0261045.	1.1	70
1070	Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies. Frontiers in Immunology, 2022, 13, 797589.	2.2	30
1071	Humoral immune responses against SARSâ€CoVâ€2 in transplantation: Actionable biomarker or misplaced trust?. American Journal of Transplantation, 2022, , .	2.6	1

#	Article	IF	Citations
1072	Long-Term Antibody Response and Vaccination Efficacy in Patients with COVID-19: A Single Center One-Year Prospective Study from the Czech Republic. Viruses, 2022, 14, 526.	1.5	0
1074	Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients. Frontiers in Immunology, 2022, 13, 840136.	2.2	15
1076	Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines. Human Vaccines and Immunotherapeutics, 2022, 18, 1-7.	1.4	12
1077	Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms. Cells, 2022, 11, 1182.	1.8	10
1078	Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory. Nature Immunology, 2022, 23, 768-780.	7.0	41
1079	The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients. Microbiology Spectrum, 2022, 10, e0021122.	1.2	8
1080	Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nature Medicine, 2022, 28, 1042-1049.	15.2	61
1082	The immunology and immunopathology of COVID-19. Science, 2022, 375, 1122-1127.	6.0	434
1083	Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. Frontiers in Immunology, 2022, 13, 827242.	2.2	5
1084	COVID-19 vaccination: The road ahead. Science, 2022, 375, 1127-1132.	6.0	134
1085	COVID-19 mRNA vaccine in patients with lymphoid malignancy or anti-CD20 antibody therapy: a systematic review and meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	7
1086	A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies. Vaccine, 2022, 40, 1958-1967.	1.7	5
1087	Breakthrough SARS-CoV-2 infections after vaccination: a critical review. Human Vaccines and Immunotherapeutics, 2022, 18, 1-5.	1.4	6
1089	The vacciniaâ€based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses. Immunology and Cell Biology, 2022, 100, 250-266.	1.0	1
1093	Advances in the epidemiology, clinical features, diagnosis, clinical management and prevention of coronavirus disease 2019. Current Opinion in Pulmonary Medicine, 2022, 28, 166-173.	1.2	13
1094	Antibody Response to SARS-CoV-2 in Relation to the Contributing Factors in COVID-19 Patients. Viral Immunology, 2022, 35, 142-149.	0.6	3
1095	Waning anti-SARS-CoV-2 neutralizing antibody in CoronaVac-vaccinated individuals in Indonesia. F1000Research, 0, 11, 300.	0.8	1
1096	RapidQ: A reader-free microfluidic platform for the quantitation of antibodies against the SARS-CoV-2 spike protein. Biomicrofluidics, 2022, 16, 024105.	1.2	2

#	Article	IF	Citations
1097	Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 1036-1043.	0.5	30
1099	An Analysis of Serological Response and Infection Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas Transplants. Transplantation, 2022, 106, 1421-1429.	0.5	7
1101	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nature Cancer, 2022, 3, 552-564.	5.7	51
1102	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. Frontiers in Immunology, 2022, 13, 773982.	2.2	10
1103	Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19. Biomedicines, 2022, 10, 630.	1.4	2
1104	A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. Journal of Clinical Investigation, 2022, 132, .	3.9	49
1105	Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. American Journal of Transplantation, 2022, 22, 2089-2093.	2.6	61
1106	Engineering monoclonal antibodies for COVID-19 prophylaxis. Med, 2022, 3, 157-158.	2.2	0
1108	Neutralizing antibody responses 300 days after SARSâ€CoVâ€2 infection and induction of high antibody titers after vaccination. European Journal of Immunology, 2022, 52, 810-815.	1.6	9
1110	Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors. Biomedical Optics Express, 2022, 13, 2130.	1.5	10
1112	Optimizing COVID-19 vaccination programs during vaccine shortages. Infectious Disease Modelling, 2022, 7, 286-298.	1.2	26
1113	Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring. Microbiology Spectrum, 2022, 10, e0039622.	1.2	6
1114	Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatology, The, 2022, 4, e338-e350.	2.2	88
1115	Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab. Clinical and Experimental Medicine, 2023, 23, 371-379.	1.9	14
1116	Humoral immune response of BBIBP COVIDâ€19 vaccination before and after the booster immunization. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2404-2414.	2.7	34
1117	Immunogenic SARS-CoV-2 S and N Protein Peptide and Cytokine Combinations as Biomarkers for Early Prediction of Fatal COVID-19. Frontiers in Immunology, 2022, 13, 830715.	2.2	5
1118	Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 881-888.	0.5	33
1121	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. Science Immunology, 2022, 7, eabo0535.	5.6	17

#	Article	IF	Citations
1123	Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile. Clinical Infectious Diseases, 2022, 75, e594-e602.	2.9	27
1125	Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine, 2022, 77, 103904.	2.7	93
1126	Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients. Cell Reports Medicine, 2022, 3, 100600.	3.3	10
1127	Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Against SARS-CoV-2 After Natural Infection Is More Potent Than After Vaccination. Journal of Infectious Diseases, 2022, 225, 1688-1693.	1.9	17
1128	Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19. Kidney International, 2022, 101, 1077-1080.	2.6	9
1129	Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. Journal of Infection and Chemotherapy, 2022, 28, 1015-1017.	0.8	7
1130	Vaccination and immunotherapies in neuroimmunological diseases. Nature Reviews Neurology, 2022, 18, 289-306.	4.9	27
1131	Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: A preliminary observation. The Lancet Regional Health - Western Pacific, 2022, 21, 100440.	1.3	5
1132	Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile. Nature Microbiology, 2022, 7, 524-529.	5.9	22
1136	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, .	1.9	3
1137	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses. Journal of Virology, 2022, , e0003422.	1.5	7
1138	Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. Journal of the Formosan Medical Association, 2022, 121, 766-777.	0.8	22
1139	A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model. Vaccine, 2022, 40, 2848-2855.	1.7	7
1140	Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. Frontiers in Immunology, 2022, 13, 816389.	2.2	5
1141	Antiâ€“Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Antiâ€“SARS-CoV-2 Neutralizing Antibody. Archives of Pathology and Laboratory Medicine, 2022, 146, 814-821.	1.2	14
1142	Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. American Journal of Transplantation, 2022, 22, 1873-1883.	2.6	37
1144	Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer. Journal of Infection and Chemotherapy, 2022, 28, 516-520.	0.8	17
1145	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. Vaccine, 2022, 40, 2960-2969.	1.7	5

#	Article	IF	Citations
1146	Reinfection with SARSâ€CoVâ€2 in solidâ€organ transplant recipients: Incidence density and convalescent immunity prior to reinfection. Transplant Infectious Disease, 2022, 24, .	0.7	10
1147	Factors affecting the content of Ig G-antibodies to S-protein SARS-CoV-2 in the blood of reconvalescents after new coronaviral infection (COVID-19). Meditsinskiy Sovet, 2022, , 51-65.	0.1	5
1149	Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell, 2022, 185, 1875-1887.e8.	13.5	148
1151	First Detection of SARS-CoV-2 B.1.617.2 (Delta) Variant of Concern in a Symptomatic Cat in Spain. Frontiers in Veterinary Science, 2022, 9, 841430.	0.9	16
1153	Multi-scale modelling reveals that early super-spreader events are a likely contributor to novel variant predominance. Journal of the Royal Society Interface, 2022, 19, 20210811.	1.5	16
1154	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Immunity, 2022, 55, 998-1012.e8.	6.6	86
1157	An assessment of the potential impact of the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand. Infectious Disease Modelling, 2022, 7, 94-105.	1.2	12
1158	In search of protective antibody for coronavirus disease 2019: A retrospective study. Polish Annals of Medicine, 0, , 1-7.	0.3	0
1159	COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness. The Lancet Global Health, 2022, 10, e570-e573.	2.9	19
1160	Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cellâ€“cell fusion, and neutralization sensitivity. Emerging Microbes and Infections, 2022, 11, 1024-1036.	3.0	5
1161	The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-Î³ release by natural killer cells. Vaccine, 2022, 40, 2619-2625.	1.7	6
1162	Cellular Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination Schemes Authorized by the Chilean Ministry of Health in January 2022. Life, 2022, 12, 534.	1.1	3
1163	Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naÃ¯ve and previously infected individuals. EBioMedicine, 2022, 78, 103972.	2.7	31
1165	Development of flow cytometryâ€based assays to assess the ability of antibodies to bind to <scp>SARSâ€CoV</scp> â€2â€infected and spikeâ€transfected cells and mediate <scp>NK</scp> cell degranulation. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, , .	1.1	4
1166	Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination. Emerging Infectious Diseases, 2022, 28, 743-750.	2.0	18
1167	Monitoring of SARS-CoV-2 antibodies using dried blood spot for at-home collection. Scientific Reports, 2022, 12, 5812.	1.6	7
1168	Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS ONE, 2022, 17, e0266852.	1.1	49
1169	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 â€“ a review. Translational Research, 2022, 242, 1-19.	2.2	3

#	Article	IF	Citations
1171	Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2022, , .	1.3	4
1172	SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond. Expert Review of Respiratory Medicine, 2022, 16, 499-502.	1.0	10
1173	Cost-effectiveness of future lockdown policies against the COVID-19 pandemic. Health Services Management Research, 2023, 36, 51-62.	1.0	8
1174	Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers. Emerging Infectious Diseases, 2022, 28, 828-832.	2.0	20
1175	Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients. Scientific Reports, 2022, 12, 5876.	1.6	12
1176	Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study. Covid, 2022, 2, 485-491.	0.7	1
1177	Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2. JCI Insight, 2022, 7, .	2.3	13
1178	Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers. Vaccine: X, 2022, 10, 100153.	0.9	25
1179	Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months. EBioMedicine, 2022, 78, 103938.	2.7	47
1180	Two rapid SARS-CoV-2 disposable devices for semi-quantitative S-RBD antibody levels determination compared with CLIA and ELISA assays at different protective thresholds. Clinica Chimica Acta, 2022, 529, 104-108.	0.5	1
1181	Within-host models of SARS-CoV-2: What can it teach us on the biological factors driving virus pathogenesis and transmission?. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101055.	0.6	6
1182	Safety, tolerability, and antibody response after intradermal vaccination of PFE-BNT in adults who have completed two-doses of Verocell (inactivated vaccine). Vaccine: X, 2022, 10, 100148.	0.9	4
1183	The Beneficial Effect of the COVID-19 Vaccine Booster Dose among Healthcare Workers in an Infectious Diseases Center. Vaccines, 2022, 10, 552.	2.1	10
1185	Application of the SARS-CoV-2-S1 ACE-2 receptor interaction as the basis of the fully automated assay to detect neutralizing SARS-CoV-2-S1 antibodies in blood samples. Journal of Immunological Methods, 2022, 504, 113258.	0.6	2
1186	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. EBioMedicine, 2022, 79, 103986.	2.7	23
1187	Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. Metabolism Open, 2022, 14, 100180.	1.4	41
1190	COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision. Vaccines, 2021, 9, 1429.	2.1	4
1191	Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Clinical Chemistry and Laboratory Medicine, 2022, 60, 456-463.	1.4	32

#	Article	IF	Citations
1192	Protection against SARS-CoV-2 Variants with COVID-19 Vaccination in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 3-5.	2.2	1
1193	Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2022, 3, 39-43.	0.1	2
1194	Kinetics and persistence of antiâ€SARSâ€CoVâ€2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort. Immunity, Inflammation and Disease, 2022, 10, .	1.3	5
1199	Evaluation of Antibody Response to Heterologous Primeâ€“Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study. Vaccines, 2021, 9, 1478.	2.1	5
1201	Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies. Vaccines, 2021, 9, 1471.	2.1	17
1202	Short-time interruption of second-line mycophenolate treatment in a patient with renal sarcoidosis enabled a marked antibody response to SARS-CoV-2 messenger RNA vaccine. CKJ: Clinical Kidney Journal, 2022, 15, 584-586.	1.4	5
1203	Plasmonically Enhanced Ultrasensitive Epitope-Specific Serologic Assay for COVID-19. Analytical Chemistry, 2022, 94, 909-917.	3.2	6
1204	Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days. Frontiers in Immunology, 2021, 12, 786554.	2.2	32
1208	SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, 2022, 61, SI169-SI174.	0.9	9
1209	Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population. Vaccines, 2021, 9, 1435.	2.1	8
1214	HLA-Aâˆ—02:01 restricted TÂcell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. Cell Reports, 2021, 37, 110167.	2.9	18
1217	mRNA vaccines offer hope for HIV. Nature Medicine, 2021, 27, 2082-2084.	15.2	9
1218	In a search of a protective titer: Do we or do we not need to know?. Clinical and Translational Medicine, 2021, 11, e668.	1.7	0
1219	A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses. Vaccines, 2021, 9, 1492.	2.1	2
1221	Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Annals of Clinical Microbiology and Antimicrobials, 2021, 20, 85.	1.7	23
1224	A 1-minute blood test detects decreased immune function and increased clinical risk in COVID-19 patients. Scientific Reports, 2021, 11, 23491.	1.6	2
1226	Criteria for judging the immune markers of COVIDâ€19 disease vaccines. MedComm, 2022, 3, 1-12.	3.1	3
1227	Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer. Diagnostics, 2022, 12, 85.	1.3	1

#	Article	IF	Citations
1228	Adapting Serosurveys for the SARS-CoV-2 Vaccine Era. Open Forum Infectious Diseases, 2022, 9, ofab632.	0.4	30
1232	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. Wellcome Open Research, 0, 6, 358.	0.9	5
1235	Coronavirus Disease 2019 Outcomes Among Recipients of <scp>Antiâ€CD20</scp> Monoclonal Antibodies for <scp>Immuneâ€Mediated</scp> Diseases: A Comparative Cohort Study. ACR Open Rheumatology, 2022, 4, 238-246.	0.9	27
1236	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discovery, 2022, 12, 303-330.	7.7	24
1237	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Scientific Reports, 2021, 11, 23921.	1.6	44
1238	Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders. Frontiers in Immunology, 2021, 12, 808064.	2.2	13
1239	Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. PLoS Biology, 2021, 19, e3001384.	2.6	15
1240	Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up. Frontiers in Medicine, 2021, 8, 796676.	1.2	6
1242	Fatballs foster fabulous follicles. Immunity, 2021, 54, 2695-2697.	6.6	0
1243	T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants. Frontiers in Medicine, 2021, 8, 793102.	1.2	21
1245	Boosting Vaccine-Elicited Respiratory Mucosal and Systemic COVID-19 Immunity in Mice With the Oral Lactobacillus plantarum. Frontiers in Nutrition, 2021, 8, 789242.	1.6	23
1246	Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 98-106.	2.2	22
1248	Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2022, 75, e857-e864.	2.9	30
1250	Impact of SARSâ€CoVâ€2 infection on vaccineâ€induced immune responses over time. Clinical and Translational Immunology, 2022, 11, e1388.	1.7	20
1251	Evaluation of a Rapid Semiquantitative Lateral Flow Assay for the Prediction of Serum Neutralizing Activity Against SARS-CoV-2 Variants. SSRN Electronic Journal, 0, , .	0.4	0
1252	A Safe Pseudotyped Lentivirus-Based Assay to Titer SARS-CoV-2 Neutralizing Antibodies. SSRN Electronic Journal, 0, , .	0.4	0
1254	Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib. Frontiers in Medicine, 2022, 9, 826537.	1.2	5
1255	Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. , 2022, 19, 588-601.		27

#	Article	IF	Citations
1256	Humoral immunity in dually vaccinated SARS-CoV-2-naÃ¯ve individuals and in booster-vaccinated COVID-19-convalescent subjects. Infection, 2022, , 1.	2.3	11
1257	A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. Frontiers in Immunology, 2022, 13, 857440.	2.2	15
1258	Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands. Npj Digital Medicine, 2022, 5, 49.	5.7	24
1260	Antibody Profiling in COVID-19 Patients with Different Severities by Using Spike Variant Protein Microarrays. Analytical Chemistry, 2022, , .	3.2	7
1261	A third dose of inactivated SARS-CoV-2 vaccine induces robust antibody responses in people with inadequate response to two-dose vaccination. National Science Review, 2022, 9, .	4.6	9
1262	Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARSâ€CoVâ€2: A longitudinal study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2459-2467.	2.7	13
1263	Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray. Frontiers in Immunology, 2022, 13, 817345.	2.2	5
1264	BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19. Frontiers in Immunology, 2022, 13, 797918.	2.2	1
1265	The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic. Transplantation, 2022, 106, 1312-1329.	0.5	44
1267	SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study. Journal of Clinical Immunology, 2022, 42, 923-934.	2.0	37
1268	Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose. American Journal of Obstetrics and Gynecology, 2022, 227, 486.e1-486.e10.	0.7	7
1269	SARSâ€CoVâ€2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. Journal of Medical Virology, 2022, 94, 3768-3775.	2.5	13
1270	Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. , 2022, 1, .		5
1271	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. Communications Medicine, 2022, 2, .	1.9	32
1272	Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2022, 149, 1949-1957.	1.5	39
1273	Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Med, 2022, 3, 422-432.e3.	2.2	9
1274	Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine. Nature Communications, 2022, 13, 1971.	5.8	10
1275	Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques. PLoS Pathogens, 2022, 18, e1010155.	2.1	6

#	Article	IF	Citations
1277	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. Open Forum Infectious Diseases, 2022, 9, .	0.4	62
1278	Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. Communications Biology, 2022, 5, 342.	2.0	41
1282	Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. Frontiers in Cellular and Infection Microbiology, 2022, 12, 822599.	1.8	28
1283	Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination. Vaccines, 2022, 10, 636.	2.1	0
1284	Higher Antibody Concentrations in U.S. Health Care Workers Associated with Greater Reactogenicity Post-Vaccination. Vaccines, 2022, 10, 601.	2.1	7
1285	Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology. Journal of Molecular Cell Biology, 2022, 14, .	1.5	4
1286	Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection. JCI Insight, 2022, 7, .	2.3	15
1287	Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination. Scientific Reports, 2022, 12, 6496.	1.6	20
1288	Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands. EClinicalMedicine, 2022, 47, 101393.	3.2	15
1289	Dynamic changes of serum SARS-CoV-2 antibody levels in COVID-19 patients. Journal of Infection, 2022, 85, 90-122.	1.7	2
1290	The national COVID-19 vaccination campaign targeting the extremely vulnerable: the Florence Medical Oncology Unit experience in patients with cancer. European Journal of Cancer, 2022, 170, 149-157.	1.3	3
1291	Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron. Journal of Infectious Diseases, 2022, 226, 1551-1555.	1.9	4
1292	Covax-19/SpikogenÂ® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters. Vaccine, 2022, 40, 3182-3192.	1.7	25
1293	Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2. Journal of Clinical Virology, 2022, 150-151, 105161.	1.6	8
1294	Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects. Multiple Sclerosis and Related Disorders, 2022, 62, 103800.	0.9	4
1295	Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study. International Immunopharmacology, 2022, 108, 108774.	1.7	7
1296	Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant. JAMA Oncology, 2022, 8, 1053.	3.4	16
1297	Social cohesion and loneliness are associated with the antibody response to COVID-19 vaccination. Brain, Behavior, and Immunity, 2022, 103, 179-185.	2.0	13

#	Article	IF	Citations
1298	Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. EBioMedicine, 2022, 78, 103944.	2.7	119
1299	A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2. Npj Vaccines, 2022, 7, 47.	2.9	6
1300	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature, 2022, 607, 128-134.	13.7	197
1302	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open, 2022, 8, e002187.	1.8	34
1303	Investigation of the Neutralizing Antibody Response of Healthcare Workers at a Korean University Hospital Six Months After the Introduction of the COVID-19 Vaccine. Annals of Laboratory Medicine, 2022, 42, 612-615.	1.2	3
1304	Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Frontiers in Immunology, 2022, 13, 868915.	2.2	32
1305	BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients. Transplant International, 2022, 35, 10239.	0.8	17
1306	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. Science Translational Medicine, 2021, , eabj6824.	5.8	11
1307	Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210920.	1.5	5
1309	Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients. Frontiers in Immunology, 2022, 13, 878812.	2.2	3
1310	Would New SARS-CoV-2 Variants Change the War against COVID-19?. Epidemiologia, 2022, 3, 229-237.	1.1	3
1311	Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients. Viruses, 2022, 14, 882.	1.5	3
1313	Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host and Microbe, 2022, 30, 1093-1102.e3.	5.1	114
1314	A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. Vaccines, 2022, 10, 702.	2.1	18
1315	Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients. Vaccine, 2022, 40, 3313-3319.	1.7	8
1316	The Cytokine Storm in COVID-19: The Strongest Link to Morbidity and Mortality in the Current Epidemic. Covid, 2022, 2, 540-552.	0.7	12
1317	Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters. Npj Vaccines, 2022, 7, 49.	2.9	7
1318	Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series. Frontiers in Public Health, 2022, 10, 875558.	1.3	3

#	Article	IF	Citations
1319	Preparedness for further boosting coronavirus disease 2019 vaccines. Clinical and Translational Discovery, 2022, 2, e55.	0.2	1
1320	A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days. Frontiers in Immunology, 2022, 13, 876037.	2.2	25
1322	Comparison of Six Serological Immunoassays for the Detection of SARS-CoV-2 Neutralizing Antibody Levels in the Vaccinated Population. Viruses, 2022, 14, 946.	1.5	14
1323	COVID-19 Vaccine Efficacy and Immunogenicity in End-Stage Renal Disease Patients and Kidney Transplant Recipients. Current Transplantation Reports, 2022, 9, 174-184.	0.9	9
1324	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. Frontiers in Immunology, 2022, 13, 814365.	2.2	10
1325	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. Vaccines, 2022, 10, 712.	2.1	4
1326	Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. Nature Communications, 2022, 13, 2318.	5.8	33
1327	Effect of Heterologous Vaccination Strategy on Humoral Response against COVID-19 with CoronaVac plus BNT162b2: A Prospective Cohort Study. Vaccines, 2022, 10, 687.	2.1	6
1328	Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study. Tropical Medicine and Infectious Disease, 2022, 7, 66.	0.9	9
1329	Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil. Journal of Immunology, 2022, , ji2101199.	0.4	6
1330	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell, 2022, 185, 2265-2278.e14.	13.5	77
1331	Development of a smartphone-based quantum dot lateral flow immunoassay strip for ultrasensitive detection of anti-SARS-CoV-2 IgG and neutralizing antibodies. International Journal of Infectious Diseases, 2022, 121, 58-65.	1.5	19
1332	Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2. Vaccines, 2022, 10, 649.	2.1	6
1333	Probing the Immune System Dynamics of the COVID-19 Disease for Vaccine Designing and Drug Repurposing Using Bioinformatics Tools. Immuno, 2022, 2, 344-371.	0.6	2
1334	Evaluation of effectiveness of humoral immune response after vaccination with â€˜CoviVaÑâ€™. Medical Alphabet, 2022, 1, 18-24.	0.0	2
1335	Potential of Antibody-Dependent Cellular Cytotoxicity in Acute and Recovery Phases of SARS-CoV-2 Infection. Infectious Diseases & Immunity, 2022, 2, 74-82.	0.2	4
1336	Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection. Nature Communications, 2022, 13, 2263.	5.8	6
1337	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. Nature Reviews Immunology, 2022, 22, 387-397.	10.6	93

#	Article	IF	Citations
1341	Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era. PLoS ONE, 2022, 17, e0268050.	1.1	19
1342	Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study. Clinics and Practice, 2022, 12, 318-325.	0.6	1
1343	SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients â€“ A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. Frontiers in Immunology, 2022, 13, .	2.2	24
1344	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. PLoS Biology, 2022, 20, e3001609.	2.6	14
1345	Safety and Efficacy of the COVID-19 Vaccine in Kidney Transplant Recipients. Cureus, 2022, , .	0.2	3
1346	Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine. Nature Communications, 2022, 13, 2377.	5.8	23
1347	TNF-Î±+ CD4+ TÂcells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell Reports Medicine, 2022, 3, 100640.	3.3	15
1348	Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the â€œGreen Passâ€• Policy. Frontiers in Immunology, 2022, 13, .	2.2	5
1349	Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. Journal of Clinical Medicine, 2022, 11, 2565.	1.0	52
1350	Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naÃ¯ve and convalescent healthcare workers. Clinical and Experimental Immunology, 2022, 209, 90-98.	1.1	5
1351	Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. Nature Medicine, 2022, 28, 1476-1485.	15.2	24
1352	SARS-CoV-2 variants â€“ Evolution, spike protein, and vaccines. Biomedical Journal, 2022, 45, 573-579.	1.4	26
1353	Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetilâ€“containing Immunosuppressive Regimens. Transplantation, 2022, 106, 1615-1621.	0.5	20
1354	Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases. Current Opinion in Pharmacology, 2022, 65, 102243.	1.7	15
1355	Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France. Viruses, 2022, 14, 957.	1.5	5
1357	Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cases: Defining Immunological Mechanisms for Vaccine Waning and Vaccine-Variant Mismatch. Frontiers in Virology, 2022, 2, .	0.7	14
1358	Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma. Cancer Cell, 2022, 40, 587-589.	7.7	18
1359	Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects. Human Vaccines and Immunotherapeutics, 2022, 18, 1-5.	1.4	3

#	Article	IF	Citations
1360	Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. Journal of Infectious Diseases, 2022, 226, 1731-1742.	1.9	8
1361	Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months. Frontiers in Immunology, 2022, 13, 879036.	2.2	13
1362	SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. Eurosurveillance, 2022, 27, .	3.9	28
1363	Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients. Clinical and Molecular Hepatology, 2022, 28, 553-564.	4.5	9
1364	Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines. Antibodies, 2022, 11, 35.	1.2	3
1365	Predicting the efficacy of new coronavirus vaccines â€“ Are neutralising antibodies enough?. EBioMedicine, 2022, 79, 104034.	2.7	0
1366	Comparison of the Clinical and Laboratory Findings and Outcomes of Hospitalized COVID-19 Patients Who Were Either Fully Vaccinated with Coronavac or Not: An Analytical, Cross Sectional Study. Vaccines, 2022, 10, 733.	2.1	4
1368	Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2118312119.	3.3	86
1369	CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021â€“July 2021. Open Forum Infectious Diseases, 2022, 9, .	0.4	7
1371	The Reassessed Potential of SARS-CoV-2 Attenuation for COVID-19 Vaccine Developmentâ€”A Systematic Review. Viruses, 2022, 14, 991.	1.5	10
1373	Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Science Immunology, 2022, 7, eabp8328.	5.6	40
1374	Persistence of immune responses to the Sinopharm/BBIBPâ€CorV vaccine. Immunity, Inflammation and Disease, 2022, 10, .	1.3	20
1375	COVID-19 vaccines in pregnancy. Trends in Molecular Medicine, 2022, 28, 662-680.	3.5	16
1376	Assessment of Neonatal Cord Blood SARS-CoV-2 Antibodies after COVID-19 Vaccination in Pregnancy: A Prospective Cohort Study. Geburtshilfe Und Frauenheilkunde, 2022, 82, 510-516.	0.8	6
1377	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. Open Forum Infectious Diseases, 2022, 9, .	0.4	5
1378	Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. Immunity, 2022, 55, 945-964.	6.6	32
1379	Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature, 2022, 607, 356-359.	13.7	66
1380	Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies. Vaccines, 2022, 10, 763.	2.1	7

#	Article	IF	Citations
1381	Antiâ€spike <scp>IgG</scp> antibody kinetics following the second and third doses of <scp>BNT162b2</scp> vaccine in nursing home residents. Journal of the American Geriatrics Society, 2022, 70, 2552-2560.	1.3	11
1382	Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine) Tj ETQq1 1 0.784314 rgBT /Overloc	0.8	3
1384	Evaluation of S1RBD-Specific IgG Antibody Responses following COVID-19 Vaccination in Healthcare Professionals in Cyprus: A Comparative Look between the Vaccines of Pfizer-BioNTech and AstraZeneca. Microorganisms, 2022, 10, 967.	1.6	2
1385	Acute reactions after vaccination against COVID-19 and long-term antibody levels. Deutsches Ärzteblatt International, 0, , .	0.6	0
1386	Adults hospitalized with breakthrough COVIDâ€19 have lower mortality than matched unvaccinated adults. Journal of Internal Medicine, 2022, 292, 377-384.	2.7	8
1388	Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. The Lancet Global Health, 2022, 10, e798-e806.	2.9	141
1389	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals. Frontiers in Immunology, 2022, 13, 860215.	2.2	6
1390	Antibody-mediated neutralization of SARS-CoV-2. Immunity, 2022, 55, 925-944.	6.6	74
1391	Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nature Communications, 2022, 13, 2670.	5.8	108
1392	Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine, 2022, 40, 3621-3632.	1.7	15
1393	Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population. Npj Vaccines, 2022, 7, 52.	2.9	9
1394	Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizerâ€™s BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study. PLoS ONE, 2022, 17, e0268529.	1.1	2
1395	SARS-CoV-2 Omicron variant escapes neutralizing antibodies and TÂcell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Reports Medicine, 2022, 3, 100651.	3.3	24
1396	2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory InputsÂ(<u>Part 1A</u>â€“ Recommendations on Endogenous Compounds, Small Molecules,) Tj ETQq1 1 0.784314 rgBT	0.6	14
1397	Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals. Microbiology Spectrum, 2022, , e0270921.	1.2	2
1398	Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine. Science Bulletin, 2022, 67, 1326-1330.	4.3	3
1399	Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2. Vaccines, 2022, 10, 788.	2.1	2
1400	Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities. Frontiers in Cellular and Infection Microbiology, 2022, 12, .	1.8	6

#	Article	IF	Citations
1401	A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection. Cell Reports, 2022, 39, 110815.	2.9	0
1402	Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation PhaseÂ1 Study. Infectious Diseases and Therapy, 2022, , .	1.8	13
1403	Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics. International Journal of Antimicrobial Agents, 2022, 60, 106606.	1.1	13
1404	Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron. Frontiers in Immunology, 2022, 13, .	2.2	15
1405	Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients. JAMA Network Open, 2022, 5, e2211897.	2.8	15
1406	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Medicine, 2022, 19, e1003991.	3.9	75
1407	Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. The Lancet Regional Health - Western Pacific, 2022, 24, 100474.	1.3	13
1408	Demographic and Clinical Factors Associated With Antiâ€“SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses. JAMA Network Open, 2022, 5, e2212996.	2.8	9
1409	Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19. Virulence, 2022, 13, 890-902.	1.8	8
1410	Response to Third Dose of Vaccine Against SARS-CoV-2 in Adolescent and Young Adult Kidney Transplant Recipients. Transplantation, 2022, Publish Ahead of Print, .	0.5	5
1411	Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020. MSphere, 2022, 7, e0084121.	1.3	6
1412	SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol. BMJ Open, 2022, 12, e061345.	0.8	2
1413	Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2022, 71, 1426-1439.	6.1	20
1414	Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE). RMD Open, 2022, 8, e002301.	1.8	4
1415	Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1041-1050.	1.4	13
1416	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. Indian Journal of Medical Research, 2022, 155, 105.	0.4	2
1422	Understanding â€œHybrid Immunityâ€: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases, 2023, 76, e439-e449.	2.9	23
1425	Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges. Cancers, 2022, 14, 2494.	1.7	7

#	Article	IF	Citations
1426	Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. BMJ Open, 2022, 12, e059994.	0.8	17
1427	Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination. Diagnostics, 2022, 12, 1315.	1.3	18
1428	Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage. Molecular Biology Reports, 2022, 49, 10137-10140.	1.0	6
1429	Immune Response 5â€“7 Months after Vaccination against SARS-CoV-2 in Elderly Nursing Home Residents in the Czech Republic: Comparison of Three Vaccines. Viruses, 2022, 14, 1086.	1.5	3
1430	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. , 0, , .		1
1431	Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study. Vaccines, 2022, 10, 807.	2.1	3
1432	Trajectory patterns of SARS-CoV-2 neutralising antibody response in convalescent COVID-19 patients. Communications Medicine, 2022, 2, .	1.9	2
1434	A log-odds system for waning and boosting of COVID-19 vaccine effectiveness. Vaccine, 2022, , .	1.7	10
1436	Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine. Scientific Reports, 2022, 12, .	1.6	28
1437	Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. PLoS Medicine, 2022, 19, e1003953.	3.9	27
1438	Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine. Immunity and Ageing, 2022, 19, .	1.8	9
1439	Antibody Response to SARS-CoV-2 mRNA Vaccine Among Kidney Transplant Recipients: A Retrospective Cohort Study at a Single Transplant Institute in Japan. Experimental and Clinical Transplantation, 2022, 20, 463-471.	0.2	4
1440	Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy. Frontiers in Immunology, 2022, 13, .	2.2	7
1441	The challenge of evaluating of <scp>SARSâ€CoV</scp>â€2 antibody responses among vaccinated transplant patients. Pediatric Transplantation, 2022, 26, .	0.5	0
1442	ASSESSMENT OF THE HUMORAL IMMUNITY INDUCED BY SPUTNIK V COVID-19 VACCINE (GAM-COVID-VAC) IN HEALTHCARE WORKERS. Vacunas (English Edition), 2022, , .	0.3	0
1444	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern. Frontiers in Medicine, 2022, 9, .	1.2	43
1445	Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review. Infectious Diseases and Therapy, 2022, 11, 1391-1414.	1.8	8
1446	SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFi Impaired Immunogenicity?. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
1447	Post-Vaccination Seropositivity Against SARS-CoV-2 in Peruvian Health Workers Vaccinated with BBIBP-CorV (Sinopharm). SSRN Electronic Journal, 0, , .	0.4	0
1448	Omicron Infection Induces Low-Level, Narrow-Range SARS-CoV-2 Neutralizing Activity. SSRN Electronic Journal, 0, , .	0.4	1
1449	Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy. Journal of Korean Medical Science, 2022, 37, .	1.1	7
1450	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. Clinical Infectious Diseases, 2023, 76, e426-e438.	2.9	23
1451	Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population. Clinical Infectious Diseases, 2023, 76, e391-e399.	2.9	12
1452	The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. Immunity, 2022, 55, 1316-1326.e4.	6.6	38
1453	Immune Responses of a Novel Bi-Cistronic SARS-CoV-2 DNA Vaccine Following Intradermal Immunization With Suction Delivery. Frontiers in Virology, 0, 2, .	0.7	9
1454	LGL leukemia patients exhibit substantial protective humoral responses following SARSâ€CoVâ€2 vaccination. EJHaem, 0, , .	0.4	1
1456	Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study. Vaccines, 2022, 10, 862.	2.1	5
1457	Detection of SARS-CoV-2 Delta Variant of Concern AY.57 and Clinical Characteristics of Imported Cases on a Vietnamese Coal Carrier Vessel in East Kalimantan, Indonesia: A Case Report. Jurnal Respirasi, 2022, 8, 99-105.	0.1	0
1458	DiffÃ©rences dâ€™immunogÃ©nicitÃ© des vaccins anti-SRAS-CoV-2 mRNA-1273 (Moderna) et BNT162b2 (Pfizer-BioNTech) chez les patients dialysÃ©s. Cmaj, 2022, 194, E751-E760.	0.9	0
1459	Humoral and cellular immune memory to four COVID-19 vaccines. Cell, 2022, 185, 2434-2451.e17.	13.5	289
1460	Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice. Virology Journal, 2022, 19, .	1.4	3
1462	A Single Dose of the Deactivated Rabies-Virus Vectored COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model. Viruses, 2022, 14, 1126.	1.5	2
1463	Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. Scientific Reports, 2022, 12, .	1.6	8
1464	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. IScience, 2022, 25, 104457.	1.9	8
1465	The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine. Frontiers in Immunology, 2022, 13, .	2.2	10
1466	Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study. Vaccines, 2022, 10, 853.	2.1	11

#	Article	IF	Citations
1467	Patients with treated indolent lymphomas immunized with <scp>BNT162b2</scp> have reduced antiâ€spike neutralizing <scp>IgG</scp> to <scp>SARSâ€CoV</scp>â€2 variants, but preserved antigenâ€specific T cell responses. American Journal of Hematology, 2023, 98, 131-139.	2.0	9
1468	Protective neutralizing epitopes in SARSâ€CoVâ€2. Immunological Reviews, 2022, 310, 76-92.	2.8	23
1470	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. Wellcome Open Research, 0, 6, 358.	0.9	2
1471	Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine. Rheumatology, 2022, 62, 480-485.	0.9	11
1472	Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Frontiers in Immunology, 2022, 13, .	2.2	30
1473	Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore. Antibodies, 2022, 11, 38.	1.2	4
1475	Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination. Frontiers in Immunology, 0, 13, .	2.2	4
1476	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nature Microbiology, 2022, 7, 896-908.	5.9	32
1477	The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination. Vaccines, 2022, 10, 794.	2.1	5
1479	Coronavirus Disease 2019 Vaccine Booster Effects Are Seen in Human Milk Antibody Response. Frontiers in Nutrition, 2022, 9, .	1.6	10
1480	Comparison of Four Systems for SARS-CoV-2 Antibody at Three Time Points after SARS-CoV-2 Vaccination. Diagnostics, 2022, 12, 1349.	1.3	0
1481	COVID-19 outcomes in immunocompromised individuals: seroconversion and vaccine effectiveness. LymphoSign Journal, 0, , .	0.1	1
1484	Development and Evaluation about â€œ2nd-waveâ€•COVID-19 Vaccines. Yakugaku Zasshi, 2022, 142, 619-627.	0.0	1
1485	Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein. Journal of Virological Methods, 2022, , 114564.	1.0	7
1486	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. Cancers, 2022, 14, 2796.	1.7	9
1487	Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Science Immunology, 2022, 7, .	5.6	144
1488	COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis. Clinical and Molecular Hepatology, 2022, 28, 890-911.	4.5	29
1489	Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis. International Journal of Infectious Diseases, 2022, 122, 327-331.	1.5	1

#	Article	IF	Citations
1490	Laboratory Diagnosis for SARS-CoV-2 Infection. Infectious Disease Clinics of North America, 2022, 36, 327-347.	1.9	4
1491	Correlates of protection against <scp>SARS</scp>â€<scp>CoV</scp>â€2 infection and COVIDâ€19 disease. Immunological Reviews, 2022, 310, 6-26.	2.8	138
1492	Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	21
1493	COVID-19 vaccine design using reverse and structural vaccinology, ontology-based literature mining and machine learning. Briefings in Bioinformatics, 2022, 23, .	3.2	4
1494	The humoral immune response more than one year after SARS-CoV-2 infection: low detection rate of anti-nucleocapsid antibodies via Euroimmun ELISA. Infection, 2023, 51, 83-90.	2.3	7
1495	Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice. Virologica Sinica, 2022, , .	1.2	0
1496	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nature Immunology, 2022, 23, 960-970.	7.0	39
1498	Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees. Science Advances, 2022, 8, .	4.7	16
1499	Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials. Vaccine, 2022, 40, 4403-4411.	1.7	16
1501	Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials. Nature Communications, 2022, 13, .	5.8	19
1502	Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	15
1503	Long Term Vaccination Strategies to Mitigate the Global Impact of SARS-CoV-2 Transmission: A Modelling Study. SSRN Electronic Journal, 0, , .	0.4	2
1504	Rapid microfluidic platform for screening and enrichment of cells secreting virus neutralizing antibodies. Lab on A Chip, 2022, 22, 2578-2589.	3.1	4
1505	Natural and Hybrid Immunity Following Four COVID-19 Waves in a South African Cohort. SSRN Electronic Journal, 0, , .	0.4	0
1506	Immunogenicity and Safety of the Coronavac Inactivated SARS-CoV-2 Vaccine in People with Underlying Medical Conditions: A Retrospective Study. SSRN Electronic Journal, 0, , .	0.4	0
1507	Pivotal Immune-Bridging Study of the Inactivated Whole-Virus COVID-19 Vaccine VLA2001: A Phase 3, Randomized Controlled Clinical Trial in Adults Using Adenoviral Vector Vaccine AZD1222 as a Comparator. SSRN Electronic Journal, 0, , .	0.4	1
1508	Antibodies in healthcare personnel following severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) infection. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.2	1
1509	Antibody testing as the guide to our living with COVID-19. Japanese Journal of Thrombosis and Hemostasis, 2022, 33, 338-346.	0.1	0

#	Article	IF	Citations
1511	Antibody Level Predicts the Clinical Course of Breakthrough Infection of COVID-19 Caused by Delta and Omicron Variants: A Prospective Cross-Sectional Study. Open Forum Infectious Diseases, 2022, 9, .	0.4	22
1512	Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants. Vaccines, 2022, 10, 858.	2.1	2
1514	BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. Frontiers in Immunology, 0, 13, .	2.2	4
1515	Antibody- and T Cell-Dependent Responses Elicited by a SARS-CoV-2 Adenoviral-Based Vaccine in a Socially Vulnerable Cohort of Elderly Individuals. Vaccines, 2022, 10, 937.	2.1	1
1517	High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. Journal of Infectious Diseases, 2022, 226, 1401-1406.	1.9	18
1520	Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V. International Journal of Infectious Diseases, 2022, 122, 850-854.	1.5	6
1521	Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries. International Journal of Environmental Research and Public Health, 2022, 19, 7233.	1.2	5
1522	Understanding COVID-19 Vaccines Today: Are T-cells Key Players?. Vaccines, 2022, 10, 904.	2.1	7
1523	Is the fourth COVID-19 vaccine dose urgently needed? Revelation from a prospective cohort study. Journal of Infection, 2022, 85, e66-e68.	1.7	5
1524	Case Report: Assessing COVID-19 Transmission in Professional Volleyball in Germany, September to December 2020: An Epidemiological Study. Frontiers in Sports and Active Living, 0, 4, .	0.9	0
1525	The antiâ€“SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Science Translational Medicine, 2022, 14, .	5.8	19
1526	The past, current and future epidemiological dynamic of SARS-CoV-2. Oxford Open Immunology, 2022, 3, .	1.2	24
1527	Matched Versus Mixed COVID-19 Vaccinations in Korean Solid Organ Transplant Recipients: An Observational Study. Transplantation, 0, Publish Ahead of Print, .	0.5	4
1528	Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients. International Journal of General Medicine, 0, Volume 15, 5693-5700.	0.8	1
1529	Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19. Cell Reports, 2022, 39, 111020.	2.9	11
1530	Optimizing Spatio-Temporal Allocation of the COVID-19 Vaccine Under Different Epidemiological Landscapes. Frontiers in Public Health, 0, 10, .	1.3	2
1532	Observational Study of Receptor Binding Doman Spike Antibody Responses to Three SARS-CoV-2 Vaccinations in Non-Infected Subjects: Parallel Neutralizing Antibody and Cardiac Troponin I and T Observations. journal of applied laboratory medicine, The, 0, , .	0.6	0
1533	Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharmâ€™s COVID-19 Vaccines. Frontiers in Immunology, 0, 13, .	2.2	33

#	Article	IF	Citations
1534	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, 10, e004766.		11
1535	Predictors of the Third (Booster) Dose of COVID-19 Vaccine Intention among the Healthcare Workers in Saudi Arabia: An Online Cross-Sectional Survey. Vaccines, 2022, 10, 987.	2.1	13
1537	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nature Medicine, 2022, 28, 1715-1722.	15.2	29
1539	Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 986-994.	0.9	18
1540	Level and Duration of IgG and Neutralizing Antibodies to SARS-CoV-2 in Children with Symptomatic or Asymptomatic SARS-CoV-2 Infection. ImmunoHorizons, 2022, 6, 408-415.	0.8	4
1541	COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants. Vaccines, 2022, 10, 905.	2.1	5
1542	Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nature Communications, 2022, 13, .	5.8	40
1543	Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history. Genome Medicine, 2022, 14, .	3.6	15
1544	Serologic Tests for COVID-19 Infections and Vaccination. Pediatric Infectious Disease Journal, 2022, 41, e304-e305.	1.1	0
1545	Declining Course of Humoral Immune Response in Initially Responding Kidney Transplant Recipients after Repeated SARS-CoV-2 Vaccination. Journal of Clinical Medicine, 2022, 11, 3291.	1.0	1
1546	Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations. Current Opinion in Neurology, 2022, 35, 319-327.	1.8	12
1547	Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus. PLoS ONE, 2022, 17, e0269885.	1.1	2
1548	IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. Frontiers in Immunology, 0, 13, .	2.2	16
1549	Statistics of antibody binding to the spike protein explain the dependence of COVID 19 infection risk on antibody concentration and affinity. Scientific Reports, 2022, 12, .	1.6	4
1550	Potent human broadly SARS-CoV-2â€“neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. Journal of Experimental Medicine, 2022, 219, .	4.2	34
1551	Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update. Frontiers in Medicine, 0, 9, .	1.2	8
1553	Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. Emerging Microbes and Infections, 2022, 11, 1910-1919.	3.0	27
1555	Stochastic Modeling of Dynamics of the Spread of COVID-19 Infection Taking Into Account the Heterogeneity of Population According To Immunological, Clinical and Epidemiological Criteria. Mathematical Biology and Bioinformatics, 2022, 17, 43-81.	0.1	5

#	Article	IF	Citations
1556	Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine. PLoS ONE, 2022, 17, e0269917.	1.1	14
1557	Head-to-Head Comparison of 5 Anti-SARS-CoV-2 Assays Performance in One Hundred COVID-19 Vaccinees, over an 8-Month Course. Diagnostics, 2022, 12, 1426.	1.3	7
1558	Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021. Clinical Infectious Diseases, 2023, 76, e350-e359.	2.9	9
1560	SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies. Blood Reviews, 2022, 56, 100984.	2.8	6
1561	Vaccination of cats with Sad23L-nCoV-S vaccine candidate against major variants of SARS-CoV-2. Molecular Therapy - Methods and Clinical Development, 2022, 26, 181-190.	1.8	2
1562	Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong. Nature Communications, 2022, 13, .	5.8	45
1563	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. Nature Communications, 2022, 13, .	5.8	28
1565	Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy. International Journal of Infectious Diseases, 2022, 122, 420-426.	1.5	10
1566	Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies. Frontiers in Immunology, 0, 13, .	2.2	6
1567	Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants. Microbiology Spectrum, 2022, 10, .	1.2	3
1568	Predictors of Covid-19 Vaccination Response After In-Vivo T-Cellâ€“Depleted Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 618.e1-618.e10.	0.6	10
1569	Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. MBio, 2022, 13, .	1.8	9
1570	mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes. Cell Reports Medicine, 2022, 3, 100653.	3.3	10
1571	Machine Learning models for Customer Relationship Analysis to Improve Satisfaction Rate in Banking. , 2022, , .		1
1573	SARS-CoV-2 Specific Antibody Response and T Cell-Immunity in Immunocompromised Patients up to Six Months Post COVID: A Pilot Study. Journal of Clinical Medicine, 2022, 11, 3535.	1.0	2
1574	Presence of SARS-CoV-2 Antibodies among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine. Clinical Infectious Diseases, 0, , .	2.9	1
1575	Comprehensive Analysis of Disease Pathology in Immunocompetent and Immunocompromised Hosts following Pulmonary SARS-CoV-2 Infection. Biomedicines, 2022, 10, 1343.	1.4	11
1577	Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications. Journal of Clinical Practice, 2022, 13, 66-87.	0.2	1

#	Article	IF	Citations
1578	Expert review on global real-world vaccine effectiveness against SARS-CoV-2. Expert Review of Vaccines, 2022, 21, 1255-1268.	2.0	30
1579	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). Vaccine, 2022, 40, 5275-5293.	1.7	3
1581	Factors associated with COVID-19 breakthrough infections in large Midwestern healthcare system: implications for vulnerable healthcare personnel. Journal of Occupational and Environmental Medicine, 0, Publish Ahead of Print, .	0.9	2
1582	A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. Vaccines, 2022, 10, 914.	2.1	3
1583	SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity. Viruses, 2022, 14, 1237.	1.5	10
1585	Factors Associated With the Decay of Anti-SARS-CoV-2 S1 IgG Antibodies Among Recipients of an Adenoviral Vector-Based AZD1222 and a Whole-Virion Inactivated BBV152 Vaccine. Frontiers in Medicine, 0, 9, .	1.2	6
1586	Strength and durability of antibody responses to BNT162b2 and CoronaVac. Vaccine, 2022, 40, 4312-4317.	1.7	11
1587	Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy. Journal of Autoimmunity, 2022, 131, 102848.	3.0	10
1588	Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-inÂ®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. EClinicalMedicine, 2022, 50, 101526.	3.2	20
1589	Multi-Faceted Analysis of COVID-19 Epidemic in Korea Considering Omicron Variant: Mathematical Modeling-Based Study. Journal of Korean Medical Science, 2022, 37, .	1.1	9
1590	Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study. Journal of Korean Medical Science, 2022, 37, .	1.1	1
1591	SARS-CoV-2 Seroprevalence, Cumulative Infections, and Immunity to Symptomatic Infection â€“ A Multistage National Household Survey and Modeling Study, Dominican Republic, Juneâ€“October 2021. SSRN Electronic Journal, 0, , .	0.4	1
1592	Reinfection of SARS-CoV-2 in kidney transplant recipient. Indian Journal of Transplantation, 2022, 16, 234.	0.0	0
1594	Immunogenicity and Safety of the Booster BNT162b2 Vaccine in Patients with Axial Spondyloarthritis Treated with Biological Disease-Modifying Drugs. SSRN Electronic Journal, 0, , .	0.4	0
1595	A Visual Immunochromatographic Assay for Rapid Detection of SARS-CoV-2 Neutralizing Antibody. SSRN Electronic Journal, 0, , .	0.4	0
1596	Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nature Communications, 2022, 13, .	5.8	26
1597	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
1598	Landscape Determinants of Infectivity and Insights into Vaccine Development and Effectiveness - Novel Coronavirus. Letters in Drug Design and Discovery, 2023, 20, 119-143.	0.4	1

#	Article	IF	Citations
1599	Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study. Vaccines, 2022, 10, 1050.	2.1	3
1600	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	59
1601	Antibodyâ€“Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available Glucometers. Journal of the American Chemical Society, 2022, 144, 11226-11237.	6.6	13
1602	Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms. PLoS Pathogens, 2022, 18, e1010630.	2.1	14
1603	Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. Nature Communications, 2022, 13, .	5.8	42
1604	Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccinesâ€"Effectiveness in Delta Variant Breakthrough Infections. Viruses, 2022, 14, 1385.	1.5	1
1605	Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms. Nature Communications, 2022, 13, .	5.8	47
1606	Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respiratory Medicine,the, 2022, 10, 840-850.	5.2	52
1607	Assessment of the Humoral Immune Response Following COVID-19 Vaccination in Healthcare Workers: A One Year Longitudinal Study. Biomedicines, 2022, 10, 1526.	1.4	5
1608	SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes. Vaccines, 2022, 10, 1051.	2.1	2
1609	Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine. Clinical Infectious Diseases, 2023, 76, e299-e307.	2.9	16
1611	Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA). Life, 2022, 12, 966.	1.1	4
1613	Role of IgM Memory B Cells and Spleen Function in COVID-19. Frontiers in Immunology, 0, 13, .	2.2	6
1615	Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection. Clinical Microbiology and Infection, 2022, 28, 1629-1635.	2.8	12
1616	A Diagnostic Strategy for Gauging Individual Humoral Ex Vivo Immune Responsiveness Following COVID-19 Vaccination. Vaccines, 2022, 10, 1044.	2.1	3
1618	Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. ACS Nano, 2022, 16, 11769-11780.	7.3	108
1619	The humoral response and antibodies against SARS-CoV-2 infection. Nature Immunology, 2022, 23, 1008-1020.	7.0	84
1620	Tissue immunity to SARSâ€CoVâ€2: Role in protection and immunopathology*. Immunological Reviews, 2022, 309, 25-39.	2.8	11

#	Article	IF	Citations
1621	mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines. Vaccines, 2022, 10, 1057.	2.1	11
1622	Estimating decay curves of neutralizing antibodies to SARS-CoV-2 infection. Mathematical Medicine and Biology, 0, , .	0.8	3
1623	Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease. Vaccines, 2022, 10, 1036.	2.1	2
1626	Association between Recent Usage of Antibiotics and Immunogenicity within Six Months after COVID-19 Vaccination. Vaccines, 2022, 10, 1122.	2.1	12
1628	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. Emerging Microbes and Infections, 2022, 11, 1890-1899.	3.0	12
1630	One coronavirus infection wards off another â€" but only if itâ€™s a similar variant. Nature, 0, , .	13.7	5
1631	Three Separate Spike Antigen Exposures by COVID-19 Vaccination or SARS-CoV-2 Infection Elicit Strong Humoral Immune Responses in Healthcare Workers. Vaccines, 2022, 10, 1086.	2.1	3
1632	Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. Viruses, 2022, 14, 1491.	1.5	13
1635	An agent-based model to assess large-scale COVID-19 vaccination campaigns for the Italian territory: The case study of Lombardy region. Computer Methods and Programs in Biomedicine, 2022, 224, 107029.	2.6	5
1636	Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity, 2022, 55, 1732-1746.e5.	6.6	40
1637	Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	20
1638	Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. Scientific Reports, 2022, 12, .	1.6	23
1640	Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant. Microbiology Spectrum, 2022, 10, .	1.2	5
1641	COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy. Vaccines, 2022, 10, 1137.	2.1	6
1642	Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders. Communications Medicine, 2022, 2, .	1.9	9
1643	Use of Tumor Necrosis Factor-Î± Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease. Frontiers in Immunology, 0, 13, .	2.2	1
1644	Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3). Vaccines, 2022, 10, 1064.	2.1	6
1645	Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies. Nature Communications, 2022, 13, .	5.8	14

#	Article	IF	Citations
1647	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. ELife, 0, 11, .	2.8	7
1648	Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff. MSphere, 2022, 7, .	1.3	3
1649	Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients. Clinical Gastroenterology and Hepatology, 2022, 20, 2558-2566.e5.	2.4	28
1650	Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. Viruses, 2022, 14, 1560.	1.5	21
1651	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Cell Host and Microbe, 2022, 30, 1231-1241.e6.	5.1	55
1652	Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey. Vaccines, 2022, 10, 1140.	2.1	6
1654	Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Clinical Infectious Diseases, 2023, 76, e188-e199.	2.9	24
1655	Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nature Communications, 2022, 13, .	5.8	53
1657	Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study. Expert Review of Vaccines, 2022, 21, 1319-1329.	2.0	12
1658	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. Pharmaceutical Research, 2022, 39, 2119-2134.	1.7	10
1659	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 2022, 7, 1161-1179.	5.9	352
1660	From a recombinant key antigen to an accurate, affordable serological test: Lessons learnt from COVID-19 for future pandemics. Biochemical Engineering Journal, 2022, 186, 108537.	1.8	22
1663	Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine. Expert Review of Vaccines, 2022, 21, 1873-1881.	2.0	4
1664	Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19. Scientific Reports, 2022, 12, .	1.6	2
1665	Impact of Coronavirus Disease of 2019 Vaccine on Health and Physical Activities Among Physical Education Students in China. Frontiers in Public Health, 0, 10, .	1.3	2
1666	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. Journal of Experimental Medicine, 2022, 219, .	4.2	6
1667	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
1668	The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	47

#	Article	IF	Citations
1669	Guardians of the oral and nasopharyngeal galaxy: <scp>IgA</scp> and protection against <scp>SARSâ€CoV</scp>â€2 infection*. Immunological Reviews, 2022, 309, 75-85.	2.8	32
1670	Dengue and COVID-19: two sides of the same coin. Journal of Biomedical Science, 2022, 29, .	2.6	16
1671	Comparison of the immunogenicity of five COVIDâ€19 vaccines in Sri Lanka. Immunology, 2022, 167, 263-274.	2.0	12
1672	RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease. Pathogens, 2022, 11, 800.	1.2	3
1673	Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults. Vaccine, 2022, 40, 5050-5059.	1.7	9
1676	COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study. Scientific Reports, 2022, 12, .	1.6	5
1677	SARS-CoV-2 in companion animals: Do levels of SARS-CoV-2 seroconversion in pets correlate with those of petâ€™s owners and with protection against subsequent SARS-CoV-2 infection?. Virulence, 2022, 13, 1216-1220.	1.8	3
1678	Clinical characteristics and outcomes of critically ill patients with one, two and three doses of vaccination against COVIDâ€19 in Australia. Internal Medicine Journal, 2023, 53, 330-338.	0.5	8
1679	Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. BMJ Open Respiratory Research, 2022, 9, e001268.	1.2	7
1680	Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19â€”BNT162b2 mRNA Vaccination. Viruses, 2022, 14, 1470.	1.5	5
1681	Assessment of post-vaccination collective immunity against new coronavirus infection (COVID-19) among servicemen of the Armed Forces of the Russian Federation. Vestnik of Russian Military Medical Academy, 2022, 24, 267-276.	0.1	3
1682	Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and Î±-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine. Pharmaceutics, 2022, 14, 1455.	2.0	3
1683	Immunogenicity and safety of SpikoGenÂ®, an adjuvanted recombinant SARSâ€CoVâ€2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placeboâ€controlled trial. Immunology, 2022, 167, 340-353.	2.0	26
1685	Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections. Current Opinion in Infectious Diseases, 2022, 35, 280-287.	1.3	6
1686	A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1
1687	Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection. JAMA Network Open, 2022, 5, e2221616.	2.8	39
1688	Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. International Journal of Infectious Diseases, 2022, 122, 793-801.	1.5	17
1689	Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein. Antibody Therapeutics, 2022, 5, 177-191.	1.2	6

#	Article	IF	Citations
1690	Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector. Vaccines, 2022, 10, 1142.	2.1	7
1691	Translating a Thin-Film Rehydration Method to Microfluidics for the Preparation of a SARS-CoV-2 DNA Vaccine: When Manufacturing Method Matters. Pharmaceutics, 2022, 14, 1427.	2.0	4
1692	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. Vaccines, 2022, 10, 1103.	2.1	11
1693	A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Antiviral Research, 2022, 204, 105370.	1.9	16
1694	Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade. EBioMedicine, 2022, 82, 104153.	2.7	8
1695	Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. Lancet Regional Health - Europe, The, 2022, 20, 100452.	3.0	37
1696	Declining neutralizing antibody levels after SARS-CoV-2 mRNA vaccination: observational data from community point-of-care testing service in Brno, Czechia. Central European Journal of Public Health, 2022, 30, 111-118.	0.4	0
1698	Predicting a Positive Antibody Response After 2 SARS-CoV-2 mRNA Vaccines in Transplant Recipients: A Machine Learning Approach With External Validation. Transplantation, 2022, 106, e452-e460.	0.5	8
1699	Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity. Acta Pharmaceutica Sinica B, 2023, 13, 2219-2233.	5.7	9
1700	Making more COVID-19 vaccines available to address global needs: Considerations and a framework for their evaluation. Vaccine, 2022, , .	1.7	3
1701	Post-vaccination T cell immunity to omicron. Frontiers in Immunology, 0, 13, .	2.2	20
1702	Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. ELife, 0, 11, .	2.8	12
1703	Return to Flying Duties Following a COVID-19 Booster Dose. Aerospace Medicine and Human Performance, 2022, 93, 593-596.	0.2	0
1704	SARSâ€CoVâ€2 humoral responses following booster BNT162b2 vaccination in patients with Bâ€cell malignancies. American Journal of Hematology, 2022, 97, 1300-1308.	2.0	12
1706	SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection. Microbiology Spectrum, 2022, 10, .	1.2	8
1707	Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Science Immunology, 2022, 7, .	5.6	170
1708	Detection of neutralizing antibodies against multiple SARS-CoV-2 strains in dried blood spots using cell-free PCR. Nature Communications, 2022, 13, .	5.8	8
1709	Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science, 2022, 377, 890-894.	6.0	142

#	Article	IF	Citations
1710	Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2. Vaccine, 2022, 40, 5189-5196.	1.7	9
1711	SARS-CoV-2â€™s Variants of Concern: A Brief Characterization. Frontiers in Immunology, 0, 13, .	2.2	31
1713	Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan. Journal of Infection and Chemotherapy, 2022, 28, 1483-1488.	0.8	3
1714	Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. Cell Reports Medicine, 2022, 3, 100685.	3.3	11
1715	Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial. EBioMedicine, 2022, 82, 104138.	2.7	13
1716	The Effects of an mRNA Covid-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans. Medical Research Archives, 2022, 10, .	0.1	2
1717	Alternative Strategies to Increase the Immunogenicity of Covid-19 Vaccines in Kidney Transplant Recipients Not Responding to Two or Three Doses of an mRNA Vaccine. A Randomized Clinical Trial. SSRN Electronic Journal, 0, , .	0.4	4
1718	Seroprevalence Surgery of Anti-SARS-CoV-2 Antibodies Based on COVID-19 Vaccine Type in Academy Community, East Kalimantan, Indonesia. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 1169-1173.	0.1	0
1719	Heterologous adenovirusâ€vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients. Hepatology Communications, 2022, 6, 2850-2859.	2.0	9
1720	Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines. Infection and Drug Resistance, 0, Volume 15, 4127-4136.	1.1	8
1722	Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy. HemaSphere, 2022, 6, e764.	1.2	22
1724	Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study. Vaccines, 2022, 10, 1177.	2.1	2
1725	SARS-CoV-2 S2â€“targeted vaccination elicits broadly neutralizing antibodies. Science Translational Medicine, 2022, 14, .	5.8	57
1726	Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination. Diagnostics, 2022, 12, 1781.	1.3	11
1727	Assessing the Dynamic Outcomes of Containment Strategies against COVID-19 under Different Public Health Governance Structures: A Comparison between Pakistan and Bangladesh. International Journal of Environmental Research and Public Health, 2022, 19, 9239.	1.2	1
1728	Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa). Vaccines, 2022, 10, 1189.	2.1	10
1729	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. International Journal of Molecular Sciences, 2022, 23, 8485.	1.8	6
1730	High SARS-CoV-2 Seroprevalence and Rapid Neutralizing Antibody Decline among Agricultural Workers in Rural Guatemala, June 2020â€“March 2021. Vaccines, 2022, 10, 1160.	2.1	1

#	Article	IF	Citations
1731	Outcome after single dose of ChAdOx1 vaccine against SARS-CoV-2 infection at 16 weeks post-vaccination among healthy adults in Saudi Arabia. Annals of Saudi Medicine, 2022, 42, 223-228.	0.5	0
1732	Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S. Npj Vaccines, 2022, 7, .	2.9	13
1734	Elevenâ€month longitudinal study of antibodies in SARSâ€CoVâ€2 exposed and naÃ¯ve primary health care workers upon COVIDâ€19 vaccination. Immunology, 2022, 167, 528-543.	2.0	2
1735	High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020â€“2021. Frontiers in Medicine, 0, 9, .	1.2	6
1736	Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study. Annals of the Rheumatic Diseases, 2022, 81, 1594-1602.	0.5	22
1737	Mild reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant: First case report from Indonesia. Frontiers in Medicine, 0, 9, .	1.2	4
1738	Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines. Nature Communications, 2022, 13, .	5.8	28
1739	BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. Frontiers in Immunology, 0, 13, .	2.2	16
1740	Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis. Lupus Science and Medicine, 2022, 9, e000726.	1.1	14
1741	Assessing the dynamic impacts of non-pharmaceutical and pharmaceutical intervention measures on the containment results against COVID-19 in Ethiopia. PLoS ONE, 2022, 17, e0271231.	1.1	1
1742	SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. Annals of the Rheumatic Diseases, 2022, 81, 1585-1593.	0.5	12
1743	Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection. Vaccines, 2022, 10, 1210.	2.1	5
1745	Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study. Breast Cancer Research and Treatment, 2022, 195, 311-323.	1.1	7
1746	Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test. Diagnostics, 2022, 12, 1924.	1.3	6
1747	SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research. Oncologist, 0, , .	1.9	0
1750	Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection. Vaccine, 2022, 40, 5726-5731.	1.7	11
1752	Effectiveness of Naturally Acquired and Vaccine-Induced Immune Responses to SARS-CoV-2 Mu Variant. Emerging Infectious Diseases, 2022, 28, 1708-1712.	2.0	5
1753	SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients â€“ a comparative long term post-infection study. Frontiers in Immunology, 0, 13, .	2.2	4

#	Article	IF	Citations
1754	Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2. Biomedicines, 2022, 10, 1993.	1.4	8
1755	Function matters: Coronavirus cross-binding antibodies do not cross-neutralize. Frontiers in Medicine, 0, 9, .	1.2	1
1757	Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study. Journal of Infection, 2022, 85, e140-e144.	1.7	23
1758	Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination. Vaccines, 2022, 10, 1363.	2.1	5
1759	Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern. Biology Methods and Protocols, 2022, 7, .	1.0	1
1760	Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era. Nature Communications, 2022, 13, .	5.8	34
1761	Comparing parental distress and childrenâ€™s difficulties between parents of children with rheumatic diseases and parents of healthy children in families facing the COVID-19 pandemic. Current Psychology, 2023, 42, 20114-20123.	1.7	4
1762	Humoral responses after inactivated COVIDâ€19 vaccination in individuals with and without prior SARSâ€CoVâ€2 infection: A prospective cohort study. Journal of Medical Virology, 2022, 94, 5746-5757.	2.5	3
1763	Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management. Expert Review of Vaccines, 2022, 21, 1395-1403.	2.0	4
1764	The prospective screening for SARS-CoV-2 S1/S2 antibodies delineates the factual incidence of COVID-19 and shows a sustained serological response post COVID-19 in kidney transplant recipients. Acta Clinica Belgica, 2023, 78, 200-205.	0.5	0
1765	A Rapid and Sensitive Microfluidics-Based Tool for Seroprevalence Immunity Assessment of COVID-19 and Vaccination-Induced Humoral Antibody Response at the Point of Care. Biosensors, 2022, 12, 621.	2.3	7
1767	COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review. Clinical Immunology, 2022, 243, 109097.	1.4	23
1768	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. Frontiers in Immunology, 0, 13, .	2.2	4
1769	Vaccines against SARS-CoV-2 variants and future pandemics. Expert Review of Vaccines, 2022, 21, 1363-1376.	2.0	6
1770	A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern. MBio, 2022, 13, .	1.8	28
1771	Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022. Eurosurveillance, 2022, 27, .	3.9	11
1773	Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study. Vaccine, 2022, 40, 5701-5708.	1.7	0
1774	Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid. Frontiers in Medicine, 0, 9, .	1.2	10

#	Article	IF	Citations
1775	Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. The Cochrane Library, 2022, 2022, .	1.5	9
1776	Exploring the Willingness of the COVID-19 Vaccine Booster Shots in China Using the Health Belief Model: Web-Based Online Cross-Sectional Study. Vaccines, 2022, 10, 1336.	2.1	6
1778	Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response. Clinical Research in Cardiology, 2023, 112, 1506-1516.	1.5	2
1779	Effects of boosted mRNA and adenoviralâ€vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination. Journal of Medical Virology, 2022, 94, 5713-5722.	2.5	23
1780	Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses. Frontiers in Immunology, 0, 13, .	2.2	3
1781	Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. Nature Communications, 2022, 13, .	5.8	33
1782	Determining SARS-CoV-2 non-infectivity stateâ€“A brief overview. Frontiers in Public Health, 0, 10, .	1.3	0
1783	Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	11
1784	Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. Lancet Infectious Diseases, The, 2022, 22, 1577-1586.	4.6	32
1785	SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants. MBio, 2022, 13, .	1.8	6
1786	Antibody titers among healthcare workers for coronavirus disease 2019 at 6Âmonths after BNT162b2 vaccination. Vaccine, 2022, , .	1.7	1
1787	Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. Trends in Molecular Medicine, 2022, 28, 1082-1099.	3.5	11
1788	Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant. Journal of Infectious Diseases, 2023, 227, 211-220.	1.9	6
1789	Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study. Frontiers in Immunology, 0, 13, .	2.2	14
1791	The digital phenotype of vaccination. Nature Biotechnology, 2022, 40, 1174-1175.	9.4	1
1792	Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, The, 2022, 22, 1565-1576.	4.6	55
1793	Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings. Nature Communications, 2022, 13, .	5.8	14
1794	Indoxyl Sulfate Alters the Humoral Response of the ChAdOx1 COVID-19 Vaccine in Hemodialysis Patients. Vaccines, 2022, 10, 1378.	2.1	1

#	Article	IF	Citations
1796	Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer. Cell Reports Methods, 2022, 2, 100273.	1.4	5
1797	Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies. Frontiers in Immunology, 0, 13, .	2.2	14
1798	Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity. Scientific Reports, 2022, 12, .	1.6	3
1799	mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant. Communications Biology, 2022, 5, .	2.0	15
1800	Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques. Frontiers in Immunology, 0, 13, .	2.2	2
1801	Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273. Cell Reports Medicine, 2022, 3, 100706.	3.3	23
1805	Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study. BMJ Open, 2022, 12, e061584.	0.8	4
1806	Measurements of Anti-SARS-CoV-2 Antibody Levels after Vaccination Using a SH-SAW Biosensor. Biosensors, 2022, 12, 599.	2.3	6
1807	U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020â€“February 2022. PLOS Global Public Health, 2022, 2, e0000658.	0.5	0
1808	SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination. International Journal of Molecular Sciences, 2022, 23, 8982.	1.8	4
1809	Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	0
1810	COVID-19 forecasting using new viral variants and vaccination effectiveness models. Computers in Biology and Medicine, 2022, 149, 105986.	3.9	14
1811	Two Years into the COVID-19 Pandemic: Lessons Learned. ACS Infectious Diseases, 2022, 8, 1758-1814.	1.8	47
1813	Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nature Medicine, 2022, 28, 1924-1932.	15.2	42
1814	Protein-based vaccine as the booster dose for adults: evidence and beyond. Lancet Infectious Diseases, The, 2022, 22, 1515-1517.	4.6	3
1815	A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients. Viruses, 2022, 14, 1822.	1.5	25
1816	Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. Nature Communications, 2022, 13, .	5.8	18
1817	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nature Communications, 2022, 13, .	5.8	27

#	Article	IF	Citations
1818	Bridging Animal and Human Data in Pursuit of Vaccine Licensure. Vaccines, 2022, 10, 1384.	2.1	3
1819	Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6Âmonths after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan. Vaccine, 2022, 40, 5631-5640.	1.7	9
1821	Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring. Microbiology Spectrum, 2022, 10, .	1.2	2
1822	COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates. Frontiers in Oncology, 0, 12, .	1.3	1
1823	Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. Journal of Experimental Medicine, 2022, 219, .	4.2	12
1826	Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2ÂN and S proteins: mass screening. Applied Microbiology and Biotechnology, 0, , .	1.7	2
1827	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. Nature Communications, 2022, 13, .	5.8	12
1828	Two-years antibody responses following SARS-CoV-2 infection in humans: A study protocol. PLoS ONE, 2022, 17, e0272690.	1.1	0
1829	Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people. Cell Reports Medicine, 2022, 3, 100739.	3.3	5
1830	Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. Journal of Clinical Immunology, 2023, 43, 31-45.	2.0	4
1833	Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults. Med, 2022, 3, 760-773.e5.	2.2	13
1834	Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. Emerging Microbes and Infections, 2022, 11, 2229-2247.	3.0	8
1835	Statistical and agent-based modelling of the transmissibility of different SARS-CoV-2 variants in England and impact of different interventions. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2022, 380, .	1.6	11
1836	ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. Nature Communications, 2022, 13, .	5.8	23
1837	Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Nature Communications, 2022, 13, .	5.8	32
1838	Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents. Scientific Reports, 2022, 12, .	1.6	2
1839	Humoral and cellular response of COVIDâ€19 vaccine among solid organ transplant recipients: A systematic review and metaâ€analysis. Transplant Infectious Disease, 2022, 24, .	0.7	17
1840	Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients. Vaccines, 2022, 10, 1328.	2.1	13

#	Article	IF	Citations
1841	Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice. Gut, 2023, 72, 560-572.	6.1	5
1842	Pooled surveillance testing for asymptomatic SARS-CoV-2 infections at a Veterinary Teaching Hospital College, University of Minnesota, December 2020â€“April 2021. Frontiers in Public Health, 0, 10, .	1.3	0
1843	Durability of Immunity is low against SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 variants following second and third vaccination in children and young adults with Inflammatory Bowel Disease receiving biologics. Gastroenterology, 2022, , .	0.6	1
1844	Validity of Self-testing at Home With Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Detection by Lateral Flow Immunoassay. Clinical Infectious Diseases, 2023, 76, 658-666.	2.9	5
1846	SARS-CoV-2 immunity and vaccine strategies in people with HIV. Oxford Open Immunology, 2022, 3, .	1.2	12
1847	Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials. EBioMedicine, 2022, 83, 104217.	2.7	44
1848	Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study. EBioMedicine, 2022, 83, 104230.	2.7	11
1849	Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants. Journal of Clinical Virology, 2022, 155, 105268.	1.6	2
1850	Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study. Digestive Diseases and Sciences, 2023, 68, 676-684.	1.1	6
1851	Induction of robust humoral immunity against <scp>SARSâ€CoV</scp> â€2 after vaccine administration in previously infected haematological cancer patients. British Journal of Haematology, 0, , .	1.2	2
1854	Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines. Microbes and Infection, 2023, 25, 105044.	1.0	7
1855	SARS-CoV-2 mRNA-vaccine candidate; CORNAPCINÂ®, induces robust humoral and cellular immunity in mice and non-human primates. Npj Vaccines, 2022, 7, .	2.9	5
1856	COVID-19 diverse outcomes: Aggravated reinfection, type I interferons and antibodies. Medical Hypotheses, 2022, 167, 110943.	0.8	1
1857	Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach. EBioMedicine, 2022, 84, 104264.	2.7	4
1858	Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule.. Immunology Letters, 2022, 250, 1-6.	1.1	3
1859	Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection. Journal of Clinical Virology, 2022, 156, 105273.	1.6	19
1860	Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial. International Journal of Infectious Diseases, 2022, 124, 21-26.	1.5	4
1862	Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination. Journal of Immunological Methods, 2022, 510, 113345.	0.6	7

#	Article	IF	Citations
1863	Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa. EClinicalMedicine, 2022, 53, 101655.	3.2	21
1864	Omicron variant: Current insights and future directions. Microbiological Research, 2022, 265, 127204.	2.5	32
1865	SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays. Diagnostic Microbiology and Infectious Disease, 2022, 104, 115803.	0.8	8
1866	Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211193.	1.4	2
1867	Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	3
1868	Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review. Saudi Journal for Health Sciences, 2022, 11, 83.	0.1	1
1869	Plaque-Neutralizing Antibody to BA.2.12.1, BA.4 and BA.5 in Individuals with Three Doses of Biontech or Coronavac Vaccines, Natural Infection and Breakthrough Infection. SSRN Electronic Journal, 0, , .	0.4	0
1870	Antibody Response to SARS-CoV-2 Vaccination in COPD: A Cohort Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 0, , .	0.5	2
1871	SARS-CoV-2 Antibody Status after the BNT162b2 Vaccine in Healthcare Workers. Japanese Journal of Environmental Infections, 2022, 37, 10-17.	0.1	0
1872	A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala. Indian Journal of Medical Research, 2022, Publish Ahead of Print, .	0.4	3
1873	COVID-19 Vaccines Authorized byÂStringent Regulatory Authorities and Vaccine Candidates Expecting Approval in 2021. , 2022, , 575-594.		0
1874	Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults. Infection and Chemotherapy, 2022, 54, 504.	1.0	2
1875	Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. International Journal of Biological Sciences, 2022, 18, 4781-4791.	2.6	5
1876	Clinical Development of mRNA Vaccines: Challenges and Opportunities. Current Topics in Microbiology and Immunology, 2022, , 167-186.	0.7	2
1877	Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial. SSRN Electronic Journal, 0, , .	0.4	0
1878	Multiplexed COVID-19 Antibody Quantification from Human Sera Using Label-free Nanoplasmonic Biosensors. , 2022, , .		0
1879	Highâ€resolution analysis of individual spike peptideâ€specific <scp>CD4</scp>⁺ Tâ€cell responses in vaccine recipients and <scp>COVID</scp>â€19 patients. Clinical and Translational Immunology, 2022, 11, .	1.7	10
1880	Systematic Review of the SARS-CoV-2 Viral Vector Vaccine AstraZeneca (Azd1222). BioScientific Review, 2022, 4, 1-20.	0.0	0

#	Article	IF	Citations
1881	Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population. Scientific Reports, 2022, 12, .	1.6	3
1883	Viral vector and nucleic acid vaccines against COVID-19: A narrative review. Frontiers in Microbiology, 0, 13, .	1.5	14
1884	Effectiveness of the Inactivated SARS-CoV-2 (Vero Cell) Vaccine in Peruvian Health Workers. Life, 2022, 12, 1318.	1.1	3
1886	Leveraging lessons learned from the COVID-19 pandemic for HIV. Communications Medicine, 2022, 2, .	1.9	2
1887	Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan. PLoS ONE, 2022, 17, e0273712.	1.1	4
1888	Enhanced Enzymatically Amplified Metallization on Nanostructured Surfaces for Multiplexed Pointâ€ofâ€Care Electrical Detection of COVIDâ€19 Biomarkers. Small, 2022, 18, .	5.2	4
1890	Glucocorticoidsâ€™ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients. Scientific Reports, 2022, 12, .	1.6	8
1892	Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples. BMJ Open, 2022, 12, e062567.	0.8	1
1893	Predicting SARS-CoV-2 Variant Spread in a Completely Seropositive Population Using Semi-Quantitative Antibody Measurements in Blood Donors. Vaccines, 2022, 10, 1437.	2.1	5
1894	Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis. Autoimmunity, 2022, 55, 620-631.	1.2	5
1895	Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants. Frontiers in Public Health, 0, 10, .	1.3	7
1896	Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection. Nature Communications, 2022, 13, .	5.8	8
1897	Technology-assisted adaptive recruitment strategy for a large nation-wide COVID-19 vaccine immunogenicity study in Brunei. Frontiers in Public Health, 0, 10, .	1.3	3
1898	Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)â€”rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients. Trials, 2022, 23, .	0.7	4
1899	Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein ExpressedÂin Escherichia coli for the Development of Neutralizing Antibody Assay. Molecular Biotechnology, 0, , .	1.3	2
1900	Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine. Vaccines, 2022, 10, 1512.	2.1	3
1901	Microfluidic affinity selection of active SARS-CoV-2 virus particles. Science Advances, 2022, 8, .	4.7	10
1902	Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland. Nature Communications, 2022, 13, .	5.8	3

#	Article	IF	Citations
1903	False positive serology of prepandemic chagasic samples with <scp>SARSâ€CoV</scp> â€2 antigen. Tropical Medicine and International Health, 0, , .	1.0	1
1904	Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies. Blood Cancer Discovery, 2022, 3, 481-489.	2.6	14
1905	New insights into human immune memory from <scp>SARSâ€CoV</scp> â€2 infection and vaccination. Allergy: European Journal of Allergy and Clinical Immunology, 0, , .	2.7	5
1906	Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea. Frontiers in Immunology, 0, 13, .	2.2	7
1907	Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination. IScience, 2022, 25, 105209.	1.9	2
1908	Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infectious Diseases, The, 2022, 22, 1716-1727.	4.6	25
1909	T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine. Vaccines, 2022, 10, 1494.	2.1	6
1910	Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth. Nature Communications, 2022, 13, .	5.8	16
1912	Salivary IgAs and Their Role in Mucosal Neutralization of SARS-CoV-2 Variants of Concern. Journal of Clinical Microbiology, 2022, 60, .	1.8	7
1913	Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients. Frontiers in Immunology, 0, 13, .	2.2	8
1914	Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls. Annals of the Rheumatic Diseases, 2023, 82, 292-300.	0.5	16
1916	New Omicron-specific vaccines offer similar protection to existing boosters. Nature, 2022, 609, 232-233.	13.7	18
1918	Longitudinal Comparison of Neutralizing Antibody Responses to COVID-19 mRNA Vaccines after Second and Third Doses. Vaccines, 2022, 10, 1459.	2.1	3
1921	Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up. BMJ Open, 2022, 12, e065897.	0.8	5
1923	Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. Emerging Microbes and Infections, 2022, 11, 2412-2422.	3.0	10
1924	Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination. Infection, 2023, 51, 531-534.	2.3	6
1925	Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2. Viruses, 2022, 14, 2061.	1.5	15
1927	Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating NaÃ¯ve CD4+ T Cell Counts Correspond with Delayed Viral Clearance. Cells, 2022, 11, 2743.	1.8	9

#	Article	IF	Citations
1928	Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. Clinical Infectious Diseases, 2023, 76, 271-280.	2.9	3
1930	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	4
1932	Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study. Vaccines, 2022, 10, 1497.	2.1	7
1933	Comparative Effectiveness of BNT162b2 and mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Registries in Japan. Clinical Infectious Diseases, 2023, 76, 18-24.	2.9	18
1934	Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Microbiology Spectrum, 2022, 10, .	1.2	19
1935	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. Medicine (United States), 2022, 101, e30609.	0.4	4
1936	Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis. Joint Bone Spine, 2023, 90, 105464.	0.8	7
1937	Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination. Frontiers in Immunology, 0, 13, .	2.2	8
1938	COVIDâ€19 immunopathology: From acute diseases to chronic sequelae. Journal of Medical Virology, 2023, 95, .	2.5	24
1939	A global epidemiological analysis of COVID-19 vaccine types and clinical outcomes. International Journal of Infectious Diseases, 2022, 124, 206-211.	1.5	4
1940	Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	5
1941	Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. Frontiers in Immunology, 0, 13, .	2.2	20
1942	Pathogen evolution during vaccination campaigns. PLoS Biology, 2022, 20, e3001804.	2.6	11
1943	OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines. Frontiers in Immunology, 0, 13, .	2.2	1
1944	Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers. Biomedicines, 2022, 10, 2402.	1.4	2
1945	Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants. Microbiology Spectrum, 2022, 10, .	1.2	3
1946	Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults. Frontiers in Pharmacology, 0, 13, .	1.6	6
1947	Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouseHG mice through rapid hybridoma screening and high-throughput single-cell V(D)J sequencing. Frontiers in Immunology, 0, 13, .	2.2	6

#	Article	IF	Citations
1948	Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs. Frontiers in Immunology, 0, 13, .	2.2	0
1949	Building a Resilient Scientific Network for COVID-19 and Beyond. MBio, 0, , .	1.8	1
1950	An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results. Vaccines, 2022, 10, 1546.	2.1	1
1951	Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay. Frontiers in Immunology, 0, 13, .	2.2	4
1953	Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	8
1954	Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population. Vaccines, 2022, 10, 1498.	2.1	4
1955	Assessment of Predictors for SARS-CoV-2 Antibodies Decline Rate in Health Care Workers after BNT162b2 Vaccinationâ€"Results from a Serological Survey. Vaccines, 2022, 10, 1443.	2.1	1
1956	Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region. PLoS ONE, 2022, 17, e0273694.	1.1	1
1957	Time of Day of Vaccination Does Not Associate With SARSâ€"CoVâ€"2 Antibody Titer Following First Dose of mRNA COVIDâ€"19 Vaccine. Journal of Biological Rhythms, 2022, 37, 700-706.	1.4	8
1960	Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study. Journal of Infection, 2022, 85, 545-556.	1.7	20
1962	Evaluating the efficacy and safety of SpikoGenÂ®, an Advax-CpG55.2â€"adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial. Clinical Microbiology and Infection, 2023, 29, 215-220.	2.8	25
1963	Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer. Cell Reports Medicine, 2022, 3, 100781.	3.3	15
1964	Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2. Vaccine, 2022, 40, 5868-5872.	1.7	3
1965	SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged â‰¥60 years: One year of surveillance. Frontiers in Immunology, 0, 13, .	2.2	5
1966	HLA alleles, disease severity, and age associate with T-cell responses following infection with SARS-CoV-2. Communications Biology, 2022, 5, .	2.0	4
1967	Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection. Vaccines, 2022, 10, 1548.	2.1	25
1968	COVID-19 Exposure Assessment Tool (CEAT): Exposure quantification based on ventilation, infection prevalence, group characteristics, and behavior. Science Advances, 2022, 8, .	4.7	7
1969	SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil. PLoS Neglected Tropical Diseases, 2022, 16, e0010337.	1.3	9

#	Article	IF	Citations
1970	Neutralizing Antibody Responses Among Residents and Staff of Long-Term Care Facilities in the State of New Jersey During the First Wave of the COVID-19 Pandemic. Journal of Community Health, 0, , .	1.9	0
1971	Humoral and Cellular Immune Responses After a 3-dose Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort Study. Transplantation Direct, 2022, 8, e1389.	0.8	4
1972	Vaccineâ€induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. Journal of Medical Virology, 2023, 95, .	2.5	19
1973	Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines. Frontiers in Medicine, 0, 9, .	1.2	17
1975	BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. Cell Reports, 2022, 41, 111544.	2.9	17
1976	Delta Variant. , 2022, 57, 7-34.		0
1977	Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution. Journal of Infectious Diseases, 2022, 226, 1913-1923.	1.9	19
1978	Nanovaccines to combat virusâ€related diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023, 15, .	3.3	3
1980	A Bivalent Omicron-Containing Booster Vaccine against Covid-19. New England Journal of Medicine, 2022, 387, 1279-1291.	13.9	401
1982	Development and validation of multivariable prediction models of serological response to SARS-CoV-2 vaccination in kidney transplant recipients. Frontiers in Immunology, 0, 13, .	2.2	6
1983	Protective efficacy of COVAXINÂ® against Delta and Omicron variants in hamster model. IScience, 2022, 25, 105178.	1.9	4
1984	The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controlsâ€"a prospective cohort study. BMC Medicine, 2022, 20, .	2.3	8
1985	The Relationship Between Anti-Spike SARS-CoV-2 Antibody Levels and Risk of Breakthrough COVID-19 Among Fully Vaccinated Adults. Journal of Infectious Diseases, 2023, 227, 339-343.	1.9	9
1986	The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States. Journal of Medical Economics, 2022, 25, 1127-1139.	1.0	7
1987	Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity. Frontiers in Immunology, 0, 13, .	2.2	4
1988	A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. Molecular Therapy - Methods and Clinical Development, 2022, 27, 309-323.	1.8	14
1989	Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients. Transplantation Direct, 2022, 8, e1397.	0.8	5
1990	A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination. Journal of Theoretical Biology, 2023, 556, 111280.	0.8	4

#	Article	IF	Citations
1991	Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. Nature Communications, 2022, 13, .	5.8	15
1992	Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients. Nature Communications, 2022, 13, .	5.8	3
1994	SARS-CoV-2 spike IgG titres up to 137â€‰days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021. Eurosurveillance, 2022, 27, .	3.9	1
1995	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. EBioMedicine, 2022, 85, 104294.	2.7	11
1996	Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. EClinicalMedicine, 2022, 54, 101680.	3.2	22
1997	Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nature Medicine, 2022, 28, 2388-2397.	15.2	89
1998	Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study. Frontiers in Immunology, 0, 13, .	2.2	15
1999	Heterologous <scp>SARSâ€CoV</scp>â€2 <scp>IgA</scp> neutralising antibody responses in convalescent plasma. Clinical and Translational Immunology, 2022, 11, .	1.7	5
2000	Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project. Frontiers in Immunology, 0, 13, .	2.2	4
2001	Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina. Frontiers in Immunology, 0, 13, .	2.2	2
2002	Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study. Viruses, 2022, 14, 2361.	1.5	3
2003	No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers. Journal of Infection, 2022, 85, e177-e180.	1.7	6
2004	Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. RMD Open, 2022, 8, e002575.	1.8	3
2006	Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review. British Journal of Cancer, 2022, 127, 1827-1836.	2.9	18
2007	Estimation of mRNA COVID-19 Vaccination Effectiveness in Tokyo for Omicron Variants BA.2 and BA.5: Effect of Social Behavior. Vaccines, 2022, 10, 1820.	2.1	1
2008	A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept. Scientific Reports, 2022, 12, .	1.6	10
2009	Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in TÃ¼rkiye: A randomized trial. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	5
2010	Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nature Medicine, 2023, 29, 147-157.	15.2	32

#	Article	IF	Citations
2011	Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota. Nature Immunology, 2022, 23, 1564-1576.	7.0	33
2012	Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. Frontiers in Immunology, 0, 13, .	2.2	5
2013	Observational study of antibody levels after second and third <scp>SARSâ€CoV</scp> â€2 vaccinations in medical workers. Journal of Clinical Laboratory Analysis, 0, , .	0.9	1
2014	Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding Domain. Microbiology Spectrum, 2022, 10, .	1.2	3
2015	Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia and Lymphoma, 2023, 64, 662-670.	0.6	3
2016	Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study. PLoS Medicine, 2022, 19, e1003979.	3.9	24
2018	Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Frontiers in Immunology, 0, 13, .	2.2	8
2019	Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response. Vaccines, 2022, 10, 1839.	2.1	5
2020	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. Journal of Biomedical Science, 2022, 29, .	2.6	77
2023	Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses. Nature Communications, 2022, 13, .	5.8	7
2024	COVID-19 vaccine hesitancy and GAD: The role of risk perception and vaccination status. Frontiers in Public Health, 0, 10, .	1.3	6
2025	Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2. Journal of Infectious Diseases, 2023, 227, 353-363.	1.9	2
2026	Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1bâ€“2a trial. Lancet Infectious Diseases, The, 2023, 23, 295-306.	4.6	14
2027	Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling. Vaccine, 2022, 40, 7032-7041.	1.7	4
2028	Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. PLoS ONE, 2022, 17, e0263861.	1.1	12
2029	Humoral and cellular immune response after severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccination in heart transplant recipients: An observational study in France. Frontiers in Medicine, 0, 9, .	1.2	2
2030	A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults â‰¥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network. Trials, 2022, 23, .	0.7	2
2031	Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection. PLoS ONE, 2022, 17, e0274845.	1.1	3

#	Article	IF	Citations
2032	Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study. Vaccines, 2022, 10, 1677.	2.1	0
2033	<scp>COVID</scp>â€19 vaccinations in pregnancy: Save mother and baby from <scp>COVID</scp>â€19 pandemic. International Journal of Gynecology and Obstetrics, 2023, 160, 864-873.	1.0	4
2035	SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. Nature Communications, 2022, 13, .	5.8	14
2037	Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants. Vaccines, 2022, 10, 1807.	2.1	9
2038	Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine. Current Medical Research and Opinion, 2022, 38, 2069-2075.	0.9	1
2039	Characterizing Longitudinal Antibody Responses in Recovered Individuals Following COVID-19 Infection and Single-Dose Vaccination: A Prospective Cohort Study. Viruses, 2022, 14, 2416.	1.5	3
2040	Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study. Hormones, 0, , .	0.9	3
2041	The Comparative Superiority of SARS-CoV-2 Antibody Response in Different Immunization Scenarios. Journal of Personalized Medicine, 2022, 12, 1756.	1.1	2
2042	Key lessons from the COVID-19 public health response in Australia. The Lancet Regional Health - Western Pacific, 2023, 30, 100616.	1.3	22
2043	Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection. PLoS ONE, 2022, 17, e0276241.	1.1	5
2044	Detection of SARS-CoV-2 Neutralizing Antibodies in Vaccinated Pregnant Women and Neonates by Using a Lateral Flow Immunoassay Coupled with a Spectrum-Based Reader. Biosensors, 2022, 12, 891.	2.3	3
2045	SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nature Reviews Microbiology, 2023, 21, 112-124.	13.6	128
2047	Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nature Communications, 2022, 13, .	5.8	51
2048	Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial. Lancet Infectious Diseases, The, 2023, 23, 307-319.	4.6	31
2049	A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2. Emerging Microbes and Infections, 2022, 11, 2724-2734.	3.0	21
2050	Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222. Vaccines, 2022, 10, 1701.	2.1	3
2051	Safety, tolerability and immunogenicity of Biological Eâ€™s CORBEVAXâ„¢ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study. Vaccine, 2022, 40, 7130-7140.	1.7	17
2052	Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults. Nature Aging, 2022, 2, 896-905.	5.3	20

#	Article	IF	Citations
2053	Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population: a population-based study. BMC Neurology, 2022, 22, .	0.8	4
2054	Outliers Matterâ€"Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies. Microorganisms, 2022, 10, 2067.	1.6	2
2056	Waning immunity to SARS-CoV-2 following vaccination or infection. Frontiers in Medicine, 0, 9, .	1.2	13
2057	Monoclonal antibodies for the treatment of COVID-19 infection in children. Expert Review of Anti-Infective Therapy, 2022, 20, 1529-1535.	2.0	1
2058	Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines. Vaccines, 2022, 10, 1649.	2.1	3
2059	Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques. Emerging Microbes and Infections, 2023, 12, .	3.0	4
2060	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nature Medicine, 2023, 29, 247-257.	15.2	98
2061	Post-Vaccination Neutralization Responses to Omicron Sub-Variants. Vaccines, 2022, 10, 1757.	2.1	13
2063	Increased Levels of Autoantibodies against ROS-Modified Proteins in Depressed Individuals with Decrease in Antibodies against SARS-CoV-2 Antigen (S1-RBD). Current Issues in Molecular Biology, 2022, 44, 5260-5276.	1.0	2
2064	The secret to longevity, plasma cell style. Nature Immunology, 2022, 23, 1507-1508.	7.0	4
2065	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. Frontiers in Immunology, 0, 13, .	2.2	5
2066	Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Dosesâ€™ Vaccinated Solid Organ Transplant Recipients. Viruses, 2022, 14, 2299.	1.5	7
2067	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. BMC Medicine, 2022, 20, .	2.3	3
2068	In-silico evaluation of adenoviral COVID-19 vaccination protocols: Assessment of immunological memory up to 6 months after the third dose. Frontiers in Immunology, 0, 13, .	2.2	9
2070	On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy. Viruses, 2022, 14, 2378.	1.5	0
2071	Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. Frontiers in Immunology, 0, 13, .	2.2	15
2073	Cross neutralization of SARSâ€CoVâ€2 omicron subvariants after repeated doses of COVIDâ€19 mRNA vaccines. Journal of Medical Virology, 2023, 95, .	2.5	6
2074	SARS-CoV-2 infected children form early immune memory responses dominated by nucleocapsid-specific CD8+ T cells and antibodies. Frontiers in Immunology, 0, 13, .	2.2	3

#	Article	IF	Citations
2075	Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection. MSphere, 2022, 7, .	1.3	3
2076	Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy. RMD Open, 2022, 8, e002417.	1.8	12
2078	A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. Npj Vaccines, 2022, 7, .	2.9	24
2079	Immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population. Expert Review of Vaccines, 2022, 21, 1883-1893.	2.0	2
2080	The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: An observational study. Frontiers in Immunology, 0, 13, .	2.2	6
2081	Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Science Immunology, 2022, 7, .	5.6	39
2082	Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis. International Journal of Infectious Diseases, 2022, 124, 212-223.	1.5	21
2083	Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies. Lancet Microbe, The, 2023, 4, e58-e59.	3.4	7
2084	MULTI-PARAMETRIC PREDICTION MODELS FOR COVID-19 VACCINE SELECTION: RESULTS OF A COMPARATIVE POPULATION-BASED COHORT STUDY. Clinical Infectious Diseases, 0, , .	2.9	0
2085	Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity. Vaccine, 2022, 40, 6864-6872.	1.7	1
2086	Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination. IScience, 2022, 25, 105379.	1.9	4
2087	Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies. Immunology Letters, 2022, 251-252, 20-28.	1.1	5
2088	NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens. Journal of Clinical Virology, 2022, 157, 105321.	1.6	17
2089	Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19. Infectious Diseases and Therapy, 2023, 12, 177-191.	1.8	2
2090	Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nature Microbiology, 2022, 7, 1996-2010.	5.9	39
2091	Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Medicine, 2022, 19, e1004107.	3.9	107
2092	Neutralization of B.1.617.2 variant through antibodies elicited by ChAdOx1â€S, BBIBPâ€CorV, and Gamâ€COVIDâ€Vac in an Argentinean cohort. Journal of Medical Virology, 2023, 95, .	2.5	0
2094	Effectiveness of SARSâ€CoVâ€2â€inactivated vaccine and the correlation to neutralizing antibodies: A testâ€negative caseâ€“control study. Journal of Medical Virology, 2023, 95, .	2.5	3

#	Article	IF	Citations
2096	Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study. Human Vaccines and Immunotherapeutics, 0, , .	1.4	3
2097	Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial. Nature Microbiology, 2022, 7, 1987-1995.	5.9	6
2098	Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	4
2099	SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. Science Immunology, 2022, 7, .	5.6	42
2101	Reactogenicity and immunogenicity of the intradermal administration of BNT162b2 mRNA vaccine in healthy adults who were primed with an inactivated SARS-CoV-2 vaccine. Vaccine: X, 2022, 12, 100242.	0.9	3
2102	Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey. Scientific Reports, 2022, 12, .	1.6	4
2103	Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters. Nature Communications, 2022, 13, .	5.8	11
2104	Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-NaÃ¯ve and Convalescent BNT162b2 Recipients. Vaccines, 2022, 10, 1904.	2.1	6
2105	SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection. Microbes and Infection, 2022, , 105077.	1.0	2
2106	Success of nano-vaccines against COVID-19: a transformation in nanomedicine. Expert Review of Vaccines, 2022, 21, 1739-1761.	2.0	2
2107	Pilot genome-wide association study of antibody response to inactivated SARS-CoV-2 vaccines. Frontiers in Immunology, 0, 13, .	2.2	3
2108	Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan. Frontiers in Immunology, 0, 13, .	2.2	3
2109	BNT162b2 mRNA Vaccineâ€“Induced Immune Response in Oral Fluids and Serum. International Dental Journal, 2023, 73, 435-442.	1.0	3
2110	Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19. Nature Communications, 2022, 13, .	5.8	6
2112	Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection. Journal of Travel Medicine, 2022, 29, .	1.4	4
2114	Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. Infectious Disease Clinics of North America, 2023, 37, 27-45.	1.9	6
2115	Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection. Medical Microbiology and Immunology, 2023, 212, 25-34.	2.6	4
2116	Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 306-314.e2.	2.0	7

#	Article	IF	Citations
2117	Automated detection of neutralizing SARS-CoV-2 antibodies in minutes using a competitive chemiluminescence immunoassay. Analytical and Bioanalytical Chemistry, 0, , .	1.9	2
2118	Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe, The, 2022, 3, e944-e955.	3.4	34
2119	Development and evaluation of low-volume tests to detect and characterize antibodies to SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	3
2120	IgA quantification as a good predictor of the neutralizing antibodies levels after vaccination against SARS-CoV-2. Journal of Clinical Virology Plus, 2022, 2, 100121.	0.4	4
2121	Discriminating endogenous vaccineâ€elicited antiâ€Spike antibody responses from exogenous antiâ€Spike monoclonal antibodies: The case of Evusheld. Journal of Medical Virology, 2023, 95, .	2.5	2
2122	Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination. Cell Reports Medicine, 2022, 3, 100845.	3.3	6
2123	Influencing factors of antiâ€SARSâ€CoVâ€2â€spikeâ€IgG antibody titers in healthcare workers: A crossâ€section study. Journal of Medical Virology, 2023, 95, .	2.5	7
2124	Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study. Lancet Rheumatology, The, 2023, 5, e36-e46.	2.2	10
2125	Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster. Antibodies, 2022, 11, 70.	1.2	4
2126	Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice. Nature Communications, 2022, 13, .	5.8	8
2127	Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster. Cancers, 2022, 14, 5537.	1.7	1
2128	Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice. Frontiers in Immunology, 0, 13, .	2.2	3
2129	The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases, 2023, 76, 1315-1317.	2.9	8
2130	Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. ELife, 0, 11, .	2.8	53
2131	Infection, immunity, and surveillance of COVID-19. PLoS Medicine, 2022, 19, e1004132.	3.9	0
2132	Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. Npj Vaccines, 2022, 7, .	2.9	10
2133	SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection â€“ A multistage national household survey and modelling study, Dominican Republic, Juneâ€“October 2021. The Lancet Regional Health Americas, 2022, 16, 100390.	1.5	2
2134	Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis. Molecular Immunology, 2022, 152, 172-182.	1.0	10

#	Article	IF	Citations
2135	Determining the SARS-CoV-2 Anti-Spike Cutoff Level Denoting Neutralizing Activity Using Two Commercial Kits. Vaccines, 2022, 10, 1952.	2.1	3
2136	Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection. Heliyon, 2022, 8, e11676.	1.4	4
2137	Humoral and Cellular Response of Transplant Recipients to a Third Dose of mRNA SARS-CoV-2 Vaccine: A Systematic Review and Meta-analysis. Transplantation, 2023, 107, 204-215.	0.5	10
2138	Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 1948.	2.1	3
2139	Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children. International Journal of Infectious Diseases, 2023, 126, 164-173.	1.5	10
2140	Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination. Journal of Infectious Diseases, 2023, 227, 651-662.	1.9	7
2141	Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. IScience, 2023, 26, 105726.	1.9	9
2142	Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose. Clinics, 2023, 78, 100150.	0.6	1
2143	CD4 and IL-2 mediated NK cell responses after COVID-19 infection and mRNA vaccination in adults. Immunobiology, 2023, 228, 152304.	0.8	2
2144	The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination. Multiple Sclerosis and Related Disorders, 2023, 69, 104425.	0.9	7
2145	Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. IScience, 2023, 26, 105753.	1.9	4
2146	Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination. Journal of Theoretical Biology, 2023, 559, 111384.	0.8	7
2147	Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro. International Journal of Infectious Diseases, 2023, 127, 11-16.	1.5	4
2148	Post-vaccination seropositivity against SARS-CoV-2 in peruvian health workers vaccinated with BBIBP-CorV (Sinopharm). Travel Medicine and Infectious Disease, 2023, 52, 102514.	1.5	3
2149	Evaluation and follow-up of antibody formation after CoronaVac vaccine. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2022, 68, 1769-1773.	0.3	1
2150	Vaccination Rates of Hospitalized Patients at High Risk of Severe COVID-19: A Single-Center Cross-Sectional Study. Infection and Chemotherapy, 0, 54, .	1.0	1
2151	Protection against SARS-CoV-2 BA.4 and BA.5 subvariants via vaccination and natural infection: A modeling study. Mathematical Biosciences and Engineering, 2022, 20, 2530-2543.	1.0	1
2152	Mucosal immunization with a delta-inulin adjuvanted recombinant spike vaccine elicits lung-resident immune memory and protects mice against SARS-CoV-2. Mucosal Immunology, 2022, 15, 1405-1415.	2.7	7

#	Article	IF	Citations
2153	COVID-19 clinical outcomes and risk factors in fully vaccinated hemodialysis patients: A single-center prospective cohort study. Ukrainian Journal of Nephrology and Dialysis, 2022, , 43-50.	0.0	0
2154	Assessing the Pre-Vaccination Anti-SARS-CoV-2 IgG Seroprevalence among Residents and Staff in Nursing Home in Niigata, Japan, November 2020. Viruses, 2022, 14, 2581.	1.5	2
2155	A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity. Frontiers in Immunology, 0, 13, .	2.2	0
2156	T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy. Multiple Sclerosis Journal, 2023, 29, 648-656.	1.4	6
2159	COVID-19 in kidney transplantation-implications for immunosuppression and vaccination. Frontiers in Medicine, 0, 9, .	1.2	2
2160	Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65Âyears. Scientific Reports, 2022, 12, .	1.6	5
2161	Endemicity Is Not a Victory: The Unmitigated Downside Risks of Widespread SARS-CoV-2 Transmission. Covid, 2022, 2, 1689-1709.	0.7	3
2162	Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay. Frontiers in Immunology, 0, 13, .	2.2	3
2163	COVID-19 Vaccines: An Updated Overview of Different Platforms. Bioengineering, 2022, 9, 714.	1.6	11
2165	Clinical Chemistry and Laboratory Medicine celebrates 60 yearsÂâ€“ narrative review devoted to the contribution of the journal to the diagnosis of SARS-CoV-2. Clinical Chemistry and Laboratory Medicine, 2023, 61, 811-821.	1.4	7
2167	High Anti-CoV2S Antibody Levels at Hospitalization Are Associated with Improved Survival in Patients with COVID-19 Vaccine Breakthrough Infection. International Journal of Environmental Research and Public Health, 2022, 19, 15581.	1.2	1
2168	Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose. International Journal of Molecular Sciences, 2022, 23, 14341.	1.8	4
2169	A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants. Frontiers in Immunology, 0, 13, .	2.2	3
2172	Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease. Pediatric Nephrology, 2023, 38, 1935-1948.	0.9	4
2173	Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	6
2174	Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19. Journal of the Formosan Medical Association, 2023, 122, 714-722.	0.8	4
2175	Early-stage antibody kinetics after the third dose of BNT162b2 mRNA COVID-19 vaccination measured by a point-of-care fingertip whole blood testing. Scientific Reports, 2022, 12, .	1.6	3
2177	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3

#	Article	IF	Citations
2178	Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile. Clinical Microbiology and Infection, 2023, 29, 541.e1-541.e7.	2.8	2
2179	Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions. Communications Medicine, 2022, 2, .	1.9	5
2180	Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients. Scientific Reports, 2022, 12, .	1.6	6
2181	Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study. BMJ Open, 2022, 12, e067020.	0.8	1
2182	SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, Mayâ€“June, 2021. BMC Public Health, 2022, 22, .	1.2	7
2183	Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Science Immunology, 2023, 8, .	5.6	89
2184	An Evaluation of Serological Tests to Determine Postvaccinal Immunity to SARS-CoV-2 by mRNA Vaccines. Journal of Clinical Medicine, 2022, 11, 7534.	1.0	0
2185	Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice. Vaccines, 2023, 11, 30.	2.1	3
2186	Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma. Nature Cancer, 0, , .	5.7	6
2189	Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination. European Respiratory Journal, 2023, 61, 2201390.	3.1	8
2190	Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases. Journal of Autoimmunity, 2023, 135, 102981.	3.0	5
2191	SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis. American Journal of Kidney Diseases, 2023, 81, 406-415.	2.1	11
2192	Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses. Viral Immunology, 2022, 35, 663-672.	0.6	2
2193	Anti-SARS-CoV-2 Antibody Status at the Time of Hospital Admission and the Prognosis of Patients with COVID-19: A Prospective Observational Study. Infectious Disease Reports, 2022, 14, 1004-1016.	1.5	2
2194	Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later. Science Translational Medicine, 2023, 15, .	5.8	10
2195	Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin â€“ study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients. BMJ Open, 2022, 12, e062747.	0.8	3
2196	One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine. Vaccine, 2022, , .	1.7	4
2198	Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	7

#	Article	IF	Citations
2199	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. Journal of Taibah University Medical Sciences, 2023, 18, 600-638.	0.5	1
2200	Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity. Journal of Infectious Diseases, 2023, 227, 780-787.	1.9	10
2202	Prevalence of Anti-SARS-CoV-2 Antibodies in HIV-Positive Patients in Wroclaw, Polandâ€"Unexpected Difference between First and Second Wave. Covid, 2022, 2, 1748-1757.	0.7	0
2203	Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. PLOS Global Public Health, 2022, 2, e0001308.	0.5	2
2204	Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. International Immunology, 2023, 35, 213-220.	1.8	6
2205	Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis. Blood Cancer Journal, 2022, 12, .	2.8	11
2206	Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Reports, 2022, 41, 111845.	2.9	46
2207	Coronary bypass surgery on the background of Covid-19. A clinical case. Hirurg, 2022, , 31-44.	0.0	0
2208	Risk of waning humoral responses after inactivated or subunit recombinant SARSâ€CoVâ€2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China. Journal of Medical Virology, 2023, 95, .	2.5	5
2209	Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults. Vaccine, 2023, 41, 1834-1847.	1.7	0
2210	Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression. Vaccines, 2022, 10, 2180.	2.1	16
2212	Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children. Pediatric Nephrology, 0, , .	0.9	1
2213	High Heterogeneity of Virus-Neutralizing and RBD-Binding Activities of COVID-19 Convalescent Sera. Molecular Biology, 2022, 56, 1028-1035.	0.4	1
2215	SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments. Vaccines, 2022, 10, 2145.	2.1	4
2216	Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum. Pathogens, 2022, 11, 1531.	1.2	2
2217	Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood Cancer Discovery, 2023, 4, 106-117.	2.6	14
2218	Immune Responses against the Omicron Variant of SARS-CoV-2 after a Third Dose of COVID-19 Vaccine in Patients Living with Human Immunodeficiency Virus (PLWH): Comparison with Healthcare Workers. Vaccines, 2022, 10, 2129.	2.1	5
2220	A performance comparison of two (electro) chemiluminescence immunoassays for detection and quantitation of serum antiâ€spike antibodies according to SARSâ€CoVâ€2 vaccination and infections status. Journal of Medical Virology, 2023, 95, .	2.5	5

#	Article	IF	Citations
2221	Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant. Cell Reports Medicine, 2023, 4, 100910.	3.3	5
2222	Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study. Lancet Regional Health - Europe, The, 2023, 24, 100547.	3.0	18
2224	Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial. Journal of Infection, 2023, 86, 154-225.	1.7	7
2225	High titre neutralizing antibodies in response to SARSâ€“CoVâ€“2 infection require RBDâ€“specific CD4 T cells that include proliferative memory cells. Frontiers in Immunology, 0, 13, .	2.2	5
2226	Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to <scp>SARSâ€CoV</scp>â€2 <scp>mRNA</scp>â€1237 vaccine in patients with solid tumors. Molecular Oncology, 2023, 17, 686-694.	2.1	1
2227	Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand. Epidemics, 2022, 41, 100657.	1.5	10
2228	Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. Scientific Reports, 2022, 12, .	1.6	20
2229	SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test. Life, 2022, 12, 2064.	1.1	0
2230	Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nature Reviews Immunology, 2023, 23, 381-396.	10.6	61
2232	Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial. Npj Vaccines, 2022, 7, .	2.9	6
2233	SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients. Microbiology Spectrum, 2022, 10, .	1.2	3
2234	Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease. RMD Open, 2022, 8, e002650.	1.8	10
2235	Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. IScience, 2022, 25, 105649.	1.9	7
2236	Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients. Transplantation Direct, 2023, 9, e1401.	0.8	8
2237	Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. Emerging Microbes and Infections, 2023, 12, .	3.0	16
2239	Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes. Vaccines, 2022, 10, 2063.	2.1	1
2240	Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers. Clinical Microbiology and Infection, 2023, 29, 635-641.	2.8	10
2241	Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations. Journal of the Formosan Medical Association, 2023, 122, 384-392.	0.8	7

#	Article	IF	Citations
2244	Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT). Scientific Reports, 2023, 13, .	1.6	5
2245	Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients. American Journal of Transplantation, 2023, 23, 278-283.	2.6	2
2247	Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies. Blood Advances, 2023, 7, 2459-2462.	2.5	8
2248	Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study. Frontiers in Medicine, 0, 9, .	1.2	5
2249	Current and Emerging Knowledge in COVID-19. Radiology, 2023, 306, .	3.6	30
2250	PD-1highCXCR5â€“CD4+ peripheral helper TÂcells promote CXCR3+ plasmablasts in human acute viral infection. Cell Reports, 2023, 42, 111895.	2.9	9
2251	Impacts of delta and omicron variants on inactivated SARSâ€CoVâ€2 vaccineâ€induced T cell responses in patients with autoimmune diseases and healthy controls. Clinical and Translational Medicine, 2023, 13, .	1.7	2
2252	Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection. Frontiers in Immunology, 0, 13, .	2.2	6
2253	Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. Frontiers in Immunology, 0, 13, .	2.2	2
2254	COVID-19 vaccines and a perspective on Africa. Trends in Immunology, 2023, 44, 172-187.	2.9	4
2255	Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) outbreaks in nursing homes involving residents who had completed a primary coronavirus disease 2019 (COVID-19) vaccine seriesâ€”13 US jurisdictions, Julyâ€“November 2021. Infection Control and Hospital Epidemiology, 0, , 1-5.	1.0	1
2256	Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients. Viruses, 2023, 15, 253.	1.5	2
2257	Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nature Communications, 2023, 14, .	5.8	54
2258	Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. Viruses, 2023, 15, 175.	1.5	33
2259	Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults. Immunity and Ageing, 2023, 20, .	1.8	10
2260	COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5â€“11 Years Oldâ€“Non-Randomized Clinical Trial. Vaccines, 2023, 11, 195.	2.1	3
2261	Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management. Vaccines, 2023, 11, 160.	2.1	10
2262	Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference. Microbiology Spectrum, 2023, 11, .	1.2	16

#	Article	IF	Citations
2263	BNT162b2 COVID-19 vaccination elicited protective robust immune responses in pediatric patients with inborn errors of metabolism. Frontiers in Immunology, 0, 13, .	2.2	0
2264	Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	12
2265	Ribosome biogenesis in disease: new players and therapeutic targets. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	41
2266	Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination. Nature Aging, 2023, 3, 82-92.	5.3	23
2268	Flight Training Subject Identification Method Based on Multivariate Subsequence Search With Double Windows. IEEE Access, 2023, 11, 3221-3231.	2.6	1
2270	Vaccination against SARS-CoV-2 in adults with aÂdiagnosis of cancer: aÂshort review. Memo - Magazine of European Medical Oncology, 0, , .	0.3	0
2271	Boosting maternal and neonatal antiâ€“SARS-CoV-2 humoral immunity using a third mRNA vaccine dose. JCI Insight, 2023, 8, .	2.3	0
2272	Experience of the United Arab Emirates in the use of monoclonal antibody drug sotrovimab in high-risk vaccinated and unvaccinated patients with COVID-19: an observational cohort study. BMJ Open, 2023, 13, e066095.	0.8	0
2273	Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated. Frontiers in Immunology, 0, 13, .	2.2	1
2274	Persistent humoral and CD4+ TH cell immunity after mild SARS-COV-2 infectionâ€”The CoNAN long-term study. Frontiers in Immunology, 0, 13, .	2.2	0
2275	Detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination. Journal of Perinatology, 2023, 43, 775-781.	0.9	11
2276	Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	0
2277	Humoral immunity for durable control of SARS-CoV-2 and its variants. Inflammation and Regeneration, 2023, 43, .	1.5	6
2278	COVID-19 infection during blinatumomab therapy: Is safety a dilemma?. SAGE Open Medical Case Reports, 2023, 11, 2050313X2211485.	0.2	1
2279	An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. IScience, 2023, 26, 105949.	1.9	1
2280	Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. Infectious Diseases and Therapy, 2023, 12, 367-387.	1.8	22
2281	Anti-SARS-CoV-2 IgM Secondary Response Was Suppressed by Preexisting Immunity in Vaccinees: A Prospective, Longitudinal Cohort Study over 456 Days. Vaccines, 2023, 11, 188.	2.1	2
2283	Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nature Medicine, 2023, 29, 348-357.	15.2	74

#	Article	IF	Citations
2284	D614G SARS-CoV-2 Pseudovirus Infectivity and Binding of Spike Protein to the ACE2 Receptor Inversely Correlates with Serum SARS-CoV-2-Specific IgG Levels. Viral Immunology, 2023, 36, 63-70.	0.6	0
2285	Waning of humoral immunity depending on the types of COVID-19 vaccine. Infectious Diseases, 2023, 55, 216-220.	1.4	5
2286	Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. Journal of Clinical Investigation, 2023, 133, .	3.9	32
2287	Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study. Vaccines, 2023, 11, 120.	2.1	4
2288	COVID-19 Vaccinesâ€"All You Want to Know. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 143-172.	0.8	4
2291	Evaluation of a point of care lateral flow assay for antibody detection following SARS CoV-2 mRNA vaccine series. Journal of Immunological Methods, 2023, 513, 113410.	0.6	1
2292	Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy. Multiple Sclerosis and Related Disorders, 2023, 70, 104486.	0.9	6
2293	Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non-to low-responders and B cell deficient rheumatic disease patients. Journal of Autoimmunity, 2023, 135, 102996.	3.0	2
2294	Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies. Journal of Clinical Virology Plus, 2023, 3, 100137.	0.4	1
2295	Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study. International Journal of Infectious Diseases, 2023, 128, 166-175.	1.5	6
2296	Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device. International Journal of Infectious Diseases, 2023, 128, 112-120.	1.5	6
2297	Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine: X, 2023, 13, 100262.	0.9	9
2298	Preference and Willingness to Pay for the Regular COVID-19 Booster Shot in the Vietnamese Population: Theory-Driven Discrete Choice Experiment. JMIR Public Health and Surveillance, 0, 9, e43055.	1.2	7
2299	Other Facets of SARS-CoV-2 Immunity, the Risk of Immune Tolerance and T Cell Exhaustion. , 2023, , 325-363.		0
2300	Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. Npj Vaccines, 2022, 7, .	2.9	19
2301	Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. Genome Medicine, 2022, 14, .	3.6	12
2302	RNA Interference Approach Is a Good Strategy against SARS-CoV-2. Viruses, 2023, 15, 100.	1.5	2
2303	Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. Vaccines, 2023, 11, 42.	2.1	5

#	Article	IF	Citations
2304	Ginger supplement significantly reduced length of hospital stay in individuals with COVID-19. Nutrition and Metabolism, 2022, 19, .	1.3	3
2305	The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages. Journal of Clinical Medicine, 2023, 12, 146.	1.0	5
2306	Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naÃ¯ve adult Nigerians. PLoS ONE, 2023, 18, e0280276.	1.1	2
2307	Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	9
2308	COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study. Lancet Microbe, The, 2023, 4, e149-e158.	3.4	5
2309	Association of Lower Antispike Antibody Levels with Mortality in ICU Patients with COVID-19 Disease. Critical Care Research and Practice, 2023, 2023, 1-8.	0.4	0
2310	Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies. ELife, 0, 12, .	2.8	8
2311	High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients. Virology Journal, 2023, 20, .	1.4	3
2312	Bellâ€™s Palsy and COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Vaccines, 2023, 11, 236.	2.1	3
2313	Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy. Microbes and Infection, 2023, 25, 105103.	1.0	1
2314	COVID-19 vaccination improved outcomes in the treatment of geriatric hip fractures between December 2020 and January 2022. HIP International, 2023, 33, 1133-1139.	0.9	3
2315	Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases. Inflammation and Regeneration, 2023, 43, .	1.5	3
2316	Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Frontiers in Immunology, 0, 14, .	2.2	14
2317	Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2. Nature Communications, 2023, 14, .	5.8	8
2318	Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi. Vaccines, 2023, 11, 299.	2.1	5
2321	COVID-19 vaccinations for children and adolescents. , 2023, , 141-174.		0
2324	SARS-CoV-2 epidemiology, antibody dynamics, and neutralisation capacity in Irish healthcare workers in the era of booster COVID-19 vaccinations. Frontiers in Medicine, 0, 10, .	1.2	3
2326	Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 2023, 14, .	2.7	4

#	Article	IF	Citations
2327	Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination. Frontiers in Public Health, 0, 10, .	1.3	2
2330	Mathematical modelling of the waning of anti-RBD IgG SARS-CoV-2 antibody titers after a two-dose BNT162b2 mRNA vaccination. Frontiers in Immunology, 0, 14, .	2.2	0
2331	First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. Lancet Microbe, The, 2023, 4, e140-e148.	3.4	7
2332	Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers. Vaccines, 2023, 11, 283.	2.1	3
2333	The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration. Vaccines, 2023, 11, 278.	2.1	0
2334	Recent updates on correlates of vaccine-induced protection. Frontiers in Immunology, 0, 13, .	2.2	11
2335	Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose. Frontiers in Immunology, 0, 14, .	2.2	6
2336	Fear and Empathy with COVID-19 Patients Among Medical Students. Shiraz E Medical Journal, 2023, 24, .	0.1	0
2337	Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice. Vaccines, 2023, 11, 314.	2.1	7
2338	Severe SARS-Cov2 pneumonia in vaccinated patients: a multicenter cohort study. Scientific Reports, 2023, 13, .	1.6	5
2339	Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants. International Journal of Infectious Diseases, 2023, 129, 19-31.	1.5	6
2340	Impact of antibody-level on viral shedding in B.1.617.2 (Delta) variant-infected patients analyzed using a joint model of longitudinal and time-to-event data. Mathematical Biosciences and Engineering, 2023, 20, 8875-8891.	1.0	0
2341	Determining the Longitudinal Serologic Response to COVID-19 Vaccination in the Chronic Kidney Disease Population: A Clinical Research Protocol. Canadian Journal of Kidney Health and Disease, 2023, 10, 205435812311605.	0.6	2
2342	Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study. PLoS ONE, 2023, 18, e0281673.	1.1	2
2343	Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. Viruses, 2023, 15, 448.	1.5	0
2344	Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models. Nature Communications, 2023, 14, .	5.8	10
2345	PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application. Npj Vaccines, 2023, 8, .	2.9	0
2346	STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2. Nano Letters, 2023, 23, 2593-2600.	4.5	15

#	Article	IF	Citations
2348	Mycophenolic Acid Exposure Determines Antibody Formation Following <scp>SARSâ€CoV</scp>â€2 Vaccination in Kidney Transplant Recipients: A Nested Cohort Study. Clinical Pharmacology and Therapeutics, 2023, 114, 118-126.	2.3	4
2349	SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers. Viruses, 2023, 15, 751.	1.5	3
2350	Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters. Frontiers in Immunology, 0, 14, .	2.2	0
2351	Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2). Open Forum Infectious Diseases, 2023, 10, .	0.4	6
2352	Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants. Journal of Molecular Modeling, 2023, 29, .	0.8	4
2353	Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy. Vaccines, 2023, 11, 806.	2.1	1
2354	Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: a long-term, longitudinal prospective study. IJID Regions, 2023, , .	0.5	0
2355	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine. Vaccine, 2023, 41, 2615-2629.	1.7	2
2356	Effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5â€“17. Nature Communications, 2023, 14, .	5.8	3
2357	Impaired Humoral Immunity Identified in Inactivated SARS-CoV-2 Vaccine Recipients without Anti-Spike RBD Antibodies. Microbiology Spectrum, 2023, 11, .	1.2	0
2358	Better Anti-Spike IgG Antibody Response to SARS-CoV-2 Vaccine in Patients on Haemodiafiltration than on Haemodialysis. Blood Purification, 2023, 52, 600-608.	0.9	3
2359	COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma. MBio, 0, , .	1.8	1
2361	SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo. Microorganisms, 2023, 11, 1015.	1.6	8
2362	Efficacy of SARS-CoV-2 vaccines and the doseâ€“response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. Lancet Microbe, The, 2023, 4, e236-e246.	3.4	46
2363	Syrian hamster convalescence from prototype SARS-CoV-2 confers measurable protection against the attenuated disease caused by the Omicron variant. PLoS Pathogens, 2023, 19, e1011293.	2.1	7
2364	Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. Frontiers in Immunology, 0, 14, .	2.2	1
2365	Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models. Antiviral Research, 2023, , 105605.	1.9	0
2366	Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021â€“August 2022. Emerging Infectious Diseases, 2023, 29, 723-733.	2.0	1

#	Article	IF	Citations
2367	SARS-CoV-2 vaccination in liver transplant recipients: We still haven't found what we are looking for. Annals of Hepatology, 2023, 28, 101081.	0.6	2
2368	Novel pro-and eukaryotic expression plasmid expressing omicron antigens delivered via Salmonella elicited MHC class I and II based protective immunity. Journal of Controlled Release, 2023, 357, 404-416.	4.8	3
2369	Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2â€“ seropositive individuals. , 2023, 2, 100083.		2
2370	Sensitive SARS-CoV-2 salivary antibody assays for clinical saline gargle samples using smartphone-based competitive particle immunoassay platforms. Biosensors and Bioelectronics, 2023, 229, 115221.	5.3	4
2371	Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents. International Immunopharmacology, 2023, 119, 110151.	1.7	2
2372	Susceptibility to reinfection with SARS-CoV-2 virus relative to existing antibody concentrations and T cell response. International Journal of Infectious Diseases, 2023, 131, 100-110.	1.5	3
2373	Antiviral neutralizing antibodies: from in vitro to in vivo activity. Nature Reviews Immunology, 2023, 23, 720-734.	10.6	8
2374	COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS). Vaccine, 2023, 41, 3317-3327.	1.7	2
2375	Longitudinal analysis of anti-SARS-CoV-2 neutralizing antibody (NAb) titers in vaccinees using a novel giant magnetoresistive (GMR) assay. Sensors and Actuators B: Chemical, 2023, 387, 133773.	4.0	1
2376	Lessons learned: A look back at the performance of nine COVID-19 serologic assays and their proposed utility. Clinical Biochemistry, 2023, 117, 60-68.	0.8	0
2378	Comparative assessment of efficacy and immunogenicity of Gam-COVID-Vac and CoviVac vaccines against SARS-CoV-2. Profilakticheskaya Meditsina, 2022, 25, 82.	0.2	1
2379	Human leukocyte antigen association with anti-SARS-CoV-2 spike protein antibody seroconversion in renal allograft recipients - An observational study. Indian Journal of Transplantation, 2022, 16, 397.	0.0	1
2380	Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera. Biochemical and Biophysical Research Communications, 2023, 646, 8-18.	1.0	0
2381	A Brief Questionnaire on Healthcare Workersâ€™ Awareness Toward the COVID-19 Vaccine and Antibody Tests. Journal of Disaster Research, 2023, 18, 21-26.	0.4	0
2382	Epidemiologic and economic modelling of optimal COVID-19 policy: public health and social measures, masks and vaccines in Victoria, Australia. The Lancet Regional Health - Western Pacific, 2023, 32, 100675.	1.3	5
2383	Antibody titer levels and the effect on subsequent SARS-CoV-2 infection in a large US-based cohort. Heliyon, 2023, 9, e13103.	1.4	4
2384	Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings. Diagnostic Microbiology and Infectious Disease, 2023, 105, 115903.	0.8	5
2385	Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study. EBioMedicine, 2023, 88, 104446.	2.7	8

#	Article	IF	Citations
2386	Viral T-cell epitopes â€“ Identification, characterization and clinical application. Seminars in Immunology, 2023, 66, 101725.	2.7	5
2387	Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerging Infectious Diseases, 2023, 29, 381-388.	2.0	42
2388	Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 485-490.	2.2	16
2389	Modelling the impact of the Omicron BA.5 subvariant in New Zealand. Journal of the Royal Society Interface, 2023, 20, .	1.5	9
2390	Treatment with integrase inhibitors alters SARSâ€CoVâ€2 neutralization levels measured with HIVâ€based pseudotypes in people living with HIV. Journal of Medical Virology, 2023, 95, .	2.5	1
2392	Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency. Annals of Allergy, Asthma and Immunology, 2023, , .	0.5	0
2393	Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study. Frontiers in Immunology, 0, 14, .	2.2	0
2394	Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 â€” China, 2020â€“2021. China CDC Weekly, 2023, 5, 103-107.	1.0	0
2395	Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. IScience, 2023, 26, 106124.	1.9	4
2397	Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study. Frontiers in Immunology, 0, 14, .	2.2	2
2398	One-Year Post-Vaccination Longitudinal Follow-Up of Quantitative SARS-CoV-2 Anti-Spike Total Antibodies in Health Care Professionals and Evaluation of Correlation with Surrogate Neutralization Test. Vaccines, 2023, 11, 355.	2.1	5
2399	A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen. Vaccine, 2023, 41, 1694-1702.	1.7	5
2400	SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection. Nature Communications, 2023, 14, .	5.8	25
2401	Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice. Viruses, 2023, 15, 432.	1.5	2
2404	Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafurâ€“uracil as postoperative adjuvant chemotherapy. Surgery Today, 0, , .	0.7	0
2406	Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization. Vaccine, 2023, 41, 2329-2338.	1.7	14
2407	Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach. Frontiers in Immunology, 0, 14, .	2.2	1
2408	Fourth dose of BNT162b2 vaccine for patients with autoimmune rheumatic diseases in a nationwide setting. Rheumatology, 2023, 62, 3332-3338.	0.9	2

#	Article	IF	Citations
2409	The impacts of SARS-CoV-2 vaccine dose separation and targeting on the COVID-19 epidemic in England. Nature Communications, 2023, 14, .	5.8	8
2410	Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study. Biomedicines, 2023, 11, 511.	1.4	3
2411	Weighted gene co-expression network-based identification of genetic effect of mRNA vaccination and previous infection on SARS-CoV-2 infection. Cellular Immunology, 2023, 385, 104689.	1.4	1
2412	Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients. American Journal of Transplantation, 2023, 23, 649-658.	2.6	12
2413	<scp>IgG</scp> antispike persistence and immunophenotype in children infected by <scp>SARSâ€CoV</scp>â€2. Acta Paediatrica, International Journal of Paediatrics, 2023, 112, 805-812.	0.7	0
2414	Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19. Npj Vaccines, 2023, 8, .	2.9	2
2415	Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. Open Forum Infectious Diseases, 2023, 10, .	0.4	4
2416	Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard. Frontiers in Immunology, 0, 14, .	2.2	0
2419	Engineered Ferritin Nanoparticle Vaccines Enable Rapid Screening of Antibody Functionalization to Boost Immune Responses. Advanced Healthcare Materials, 2023, 12, .	3.9	0
2420	High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020. MBio, 2023, 14, .	1.8	4
2421	Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine. Frontiers in Oncology, 0, 13, .	1.3	5
2423	Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose. Science Translational Medicine, 2023, 15, .	5.8	9
2424	SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy. Aids, 2023, 37, F11-F18.	1.0	5
2425	An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. Science Translational Medicine, 2023, 15, .	5.8	2
2426	Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron. Viruses, 2023, 15, 530.	1.5	1
2427	Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru. Vaccines, 2023, 11, 447.	2.1	2
2428	Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. Med, 2023, 4, 191-215.e9.	2.2	16
2429	Factors Influencing Antibody Response to SARS-CoV-2 Vaccination. Vaccines, 2023, 11, 451.	2.1	4

#	Article	IF	Citations
2430	Liveâ€virus neutralization of the omicron variant in children and adults 14 months after SARSâ€CoVâ€2 wildâ€type infection. Journal of Medical Virology, 2023, 95, .	2.5	2
2431	Factors associated with the humoral response after three doses of COVID-19 vaccination in kidney transplant recipients. Frontiers in Immunology, 0, 14, .	2.2	1
2432	COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates. Journal of Epidemiology and Global Health, 2023, 13, 67-90.	1.1	3
2433	Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19. Mathematical Biosciences, 2023, 360, 108981.	0.9	5
2434	Immunological Findings in a Group of Individuals Who Were Poor or Non-Responders to Standard Two-Dose SARS-CoV-2 Vaccines. Vaccines, 2023, 11, 461.	2.1	2
2435	Coronavirus disease - 19 immunity in inflammatory bowelÂdisease patients: The progressive discovery from ignorance. Indian Journal of Gastroenterology, 2023, 42, 11-13.	0.7	0
2436	Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3â€“17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. The Lancet Child and Adolescent Health, 2023, 7, 269-279.	2.7	6
2439	SARS-CoV-2 S Glycoprotein Stabilization Strategies. Viruses, 2023, 15, 558.	1.5	1
2440	Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone. Current Issues in Molecular Biology, 2023, 45, 1741-1761.	1.0	2
2441	Effectiveness and Safety of COVID-19 Vaccination in Patients with Malignant Disease. Vaccines, 2023, 11, 486.	2.1	0
2442	Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients. Journal of Translational Medicine, 2023, 21, .	1.8	2
2443	Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis. Microbiology Spectrum, 2023, 11, .	1.2	3
2444	Comparison of immune response to SARS-COV-2 vaccine in COVID-recovered versus non-infected Individuals. Clinical and Experimental Medicine, 0, , .	1.9	2
2445	Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar. Vaccines, 2023, 11, 496.	2.1	2
2446	The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection. Annals of Medicine, 2023, 55, 722-732.	1.5	0
2447	A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452. Vaccine, 2023, 41, 2184-2197.	1.7	7
2448	Method for the Rapid Detection of SARS-CoV-2-Neutralizing Antibodies Using a Nanogel-Based Surface Plasmon Resonance Biosensor. ACS Applied Polymer Materials, 2023, 5, 2195-2202.	2.0	5
2449	Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques. Npj Vaccines, 2023, 8, .	2.9	4

#	Article	IF	Citations
2452	Acute Myocarditis and Pericarditis After mRNA COVID-19 Vaccinationsâ€"A Single-Centre Retrospective Analysis. Heart Lung and Circulation, 2023, 32, 467-479.	0.2	4
2453	Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay. Diagnostics, 2023, 13, 889.	1.3	1
2454	Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents. Viruses, 2023, 15, 633.	1.5	3
2455	Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits. Vaccine, 2023, 41, 2261-2269.	1.7	4
2457	Kinetics of dried blood spot-measured anti-SARS-CoV2 Spike IgG in mRNA-vaccinated healthcare workers. Frontiers in Microbiology, 0, 14, .	1.5	1
2458	Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations. Vaccines, 2023, 11, 564.	2.1	1
2459	The comparison ofÂSARS-CoV-2 antibody levels in medical personnel induced by different types ofÂvaccines compared to theÂnatural infection. Central-European Journal of Immunology, 0, , .	0.4	1
2460	Predicting the efficacy of variant-modified COVID-19 vaccine boosters. Nature Medicine, 2023, 29, 574-578.	15.2	24
2461	Durability of Immune Response after Application of a Third Dose of SARS-CoV-2 Vaccination in Liver Transplant Recipients. Vaccines, 2023, 11, 572.	2.1	3
2462	Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination. EBioMedicine, 2023, 89, 104475.	2.7	4
2463	Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents. Frontiers in Immunology, 0, 14, .	2.2	6
2464	Higher plasma levels of thymosin-Î±1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home. Immunity and Ageing, 2023, 20, .	1.8	1
2465	Variants of SARS-CoV-2: Influences on the Vaccinesâ€™ Effectiveness and Possible Strategies to Overcome Their Consequences. Medicina (Lithuania), 2023, 59, 507.	0.8	5
2466	Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose. Frontiers in Immunology, 0, 14, .	2.2	5
2467	Multi-omics of NET formation and correlations with CNDP1, PSPB, and L-cystine levels in severe and mild COVID-19 infections. Heliyon, 2023, 9, e13795.	1.4	3
2468	Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection. Frontiers in Immunology, 0, 14, .	2.2	4
2469	Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19. JCI Insight, 2023, 8, .	2.3	1
2471	Preâ€existing immunity to SARSâ€CoVâ€2 associates with strong T cell responses induced by inactivated COVIDâ€19 vaccines. Journal of Medical Virology, 2023, 95, .	2.5	3

#	Article	IF	Citations
2472	An update on SARS-CoV-2 immunization and future directions. Frontiers in Pharmacology, 0, 14, .	1.6	2
2473	5. Clinical Practice of Respiratory Infectious Diseases in the "with/after COVID-19 Era". The Journal of the Japanese Society of Internal Medicine, 2022, 111, 578-584.	0.0	0
2474	T Cell Responses Correlate with Self-Reported Disease Severity and Neutralizing Antibody Responses Predict Protection against SARS-CoV-2 Breakthrough Infection. Viruses, 2023, 15, 709.	1.5	3
2475	A Multiparametric and High-Throughput Platform for Hostâ€“Virus Binding Screens. Nano Letters, 0, , .	4.5	0
2476	Antibody response to different COVID-19 vaccines among the migrant workers of Bangladesh. Frontiers in Immunology, 0, 14, .	2.2	0
2477	Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates. Nature Communications, 2023, 14, .	5.8	7
2478	Projection of COVID-19 Positive Cases Considering Hybrid Immunity: Case Study in Tokyo. Vaccines, 2023, 11, 633.	2.1	2
2479	The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study. Frontiers in Immunology, 0, 14, .	2.2	5
2480	The changing health impact of vaccines in the COVID-19 pandemic: A modeling study. Cell Reports, 2023, 42, 112308.	2.9	1
2481	Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	0
2482	Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults. Communications Medicine, 2023, 3, .	1.9	3
2483	Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients. Frontiers in Immunology, 0, 14, .	2.2	3
2485	Does Physical Exercise Enhance the Immune Response after Vaccination? A Systematic Review for Clinical Indications of COVID-19 Vaccine. International Journal of Environmental Research and Public Health, 2023, 20, 5183.	1.2	1
2486	COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study. Frontiers in Immunology, 0, 14, .	2.2	3
2487	Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China. ELife, 0, 12, .	2.8	5
2488	Longer intervals between SARSâ€CoVâ€2 infection and mRNAâ€1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology, 2023, 95, .	2.5	1
2489	Longitudinal neutralizing antibody responses after SARS-CoV-2 infection: A convalescent cohort study in Taiwan. Journal of Microbiology, Immunology and Infection, 2023, 56, 506-515.	1.5	1
2491	Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study. Vaccines, 2023, 11, 676.	2.1	0

#	Article	IF	Citations
2492	Humoral and T-cellâ€“mediated immunity to SARS-CoV-2 vaccination in patients with liver disease and transplant recipients. Hepatology Communications, 2023, 7, .	2.0	2
2494	Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. Lancet Microbe, The, 2023, 4, e309-e318.	3.4	26
2495	Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization. IScience, 2023, 26, 106457.	1.9	3
2496	Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Science Translational Medicine, 2023, 15, .	5.8	12
2497	SARS-CoV-2 breakthrough infection induces rapid memory and de novo TÂcell responses. Immunity, 2023, 56, 879-892.e4.	6.6	40
2498	SARS-CoV-2 specific T-cell humoral response assessment after COVID-19 vaccination using a rapid direct real-time PCR amplification. Clinical Chemistry and Laboratory Medicine, 2023, 61, 1652-1660.	1.4	3
2499	Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nature Communications, 2023, 14, .	5.8	31
2500	Response and duration of serum antiâ€SARSâ€CoVâ€2 antibodies induced by the third dose of an inactivated vaccine: A prospective longitudinal cohort study at 21 serial time points over 641 days. Journal of Medical Virology, 2023, 95, .	2.5	0
2501	Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2. Npj Vaccines, 2023, 8, .	2.9	1
2502	SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies. Npj Vaccines, 2023, 8, .	2.9	3
2503	Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO). Trials, 2023, 24, .	0.7	0
2504	Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. Nature Communications, 2023, 14, .	5.8	8
2505	Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. Nature Communications, 2023, 14, .	5.8	6
2506	Robust SARS-CoV-2 TÂcell responses with common TCRÎ±Î² motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. Cell Reports Medicine, 2023, 4, 101017.	3.3	7
2507	Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia. Viruses, 2023, 15, 844.	1.5	3
2508	Performance evaluation of newly developed surrogate virus neutralization tests for detecting neutralizing antibodies against SARS-CoV-2. Scientific Reports, 2023, 13, .	1.6	2
2509	Determinants of COVID-19 vaccine fatigue. Nature Medicine, 2023, 29, 1164-1171.	15.2	19
2510	Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens. Vaccines, 2023, 11, 744.	2.1	1

#	Article	IF	Citations
2511	Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial. ELife, 0, 12, .	2.8	6
2512	COVID-19 vaccine antibody responses in community-dwelling adults to 48Âweeks post primary vaccine series. IScience, 2023, 26, 106506.	1.9	4
2513	The origins of new SARS-COV-2 variants in immunocompromised individuals. Current Opinion in HIV and AIDS, 2023, 18, 148-156.	1.5	3
2514	Omicron BA.4/5 Neutralization and T-Cell Responses in Organ Transplant Recipients After Booster Messenger RNA Vaccine: A Multicenter Cohort Study. Clinical Infectious Diseases, 2023, 77, 229-236.	2.9	5
2515	Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination. Open Forum Infectious Diseases, 2023, 10, .	0.4	0
2516	Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern. Frontiers in Microbiology, 0, 14, .	1.5	0
2518	Similar Time Course of Humoral Response to SARS-CoV-2 mRNA Vaccines in People With and Without Type 1 Diabetes. Diabetes Technology and Therapeutics, 2023, 25, 492-496.	2.4	1
2520	Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes. Vaccine, 2023, 41, 3003-3010.	1.7	1
2521	A new multiplex SARS-CoV-2 antigen microarray showed correlation of IgG, IgA, and IgM antibodies from patients with COVID-19 disease severity and maintenance of relative IgA and IgM antigen binding over time. PLoS ONE, 2023, 18, e0283537.	1.1	3
2522	A new setâ€up of vanishing antibodies: A biennial followâ€up of five different clients' humoral responses against SARSâ€CoVâ€2 after systemic vaccination in an oncology hospital in Poland. Health Science Reports, 2023, 6, .	0.6	0
2523	A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB. Vaccines, 2023, 11, 778.	2.1	1
2524	Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients. Frontiers in Immunology, 0, 14, .	2.2	2
2525	Humoral Response to Two Doses of the mRNA-1273 Vaccine in Taiwanese Liver Transplant Recipients Unaffected by Antimetabolites: A Single Institute Experience. Formosan Journal of Surgery, 0, Publish Ahead of Print, .	0.1	0
2526	HLA Variation and SARS-CoV-2 Specific Antibody Response. Viruses, 2023, 15, 906.	1.5	4
2528	Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing. Clinical Chemistry and Laboratory Medicine, 2023, 61, 1670-1675.	1.4	3
2529	Fc-Î³R-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2. Nature Microbiology, 2023, 8, 569-580.	5.9	33
2530	Neutralization of Wild-Type and Alpha SARS-CoV-2 Variant by CoronaVacÂ® Vaccine and Natural Infection- Induced Antibodies. Current Microbiology, 2023, 80, .	1.0	1
2531	Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity. Vaccines, 2023, 11, 784.	2.1	0

#	Article	IF	Citations
2532	Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study. CMAJ Open, 2023, 11, E305-E313.	1.1	0
2534	Immunology of COVID-19. , 2024, , 52-71.		0
2535	Prevention and Treatment of Infectious Complications in Pediatric Renal Transplant Recipients. , 2023, , 1919-1936.		0
2536	Selective SARS-CoV2 BA.2 escape of antibody Fc/Fc-receptor interactions. IScience, 2023, 26, 106582.	1.9	2
2537	Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	0
2538	Humoral and Cellular Immune Response Elicited by Two Doses of mRNA BNT162b2 Vaccine Against SARS-CoV-2 in People Living with HIV. AIDS Research and Human Retroviruses, 2023, 39, 495-499.	0.5	1
2539	Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. Vaccines, 2023, 11, 819.	2.1	0
2540	Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster vaccination. , 2023, 12, 100198.		1
2541	Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients. Blood Cancer Journal, 2023, 13, .	2.8	2
2542	Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	15
2543	DNA immunization with in silico predicted T-cell epitopes protects against lethal SARS-CoV-2 infection in K18-hACE2 mice. Frontiers in Immunology, 0, 14, .	2.2	3
2544	Immunological Facet and Inception after Post-COVID-19 Vaccination. Infectious Disorders - Drug Targets, 2023, 23, .	0.4	0
2545	Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants. Emerging Microbes and Infections, 2023, 12, .	3.0	3
2546	Waning anti-SARS-CoV-2 receptor-binding domain total antibody in CoronaVac-vaccinated individuals in Indonesia. F1000Research, 0, 11, 300.	0.8	1
2547	Evaluation of humoral immune response after <scp>ChAdOx1 nCoV</scp>â€19 vaccination among health care workers. Scandinavian Journal of Immunology, 2023, 98, .	1.3	0
2548	Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial. Vaccine, 2023, 41, 3497-3505.	1.7	3
2549	Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations. International Journal of Molecular Sciences, 2023, 24, 7292.	1.8	2
2550	An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies. AIMS Microbiology, 2023, 9, 375-401.	1.0	4

#	Article	IF	Citations
2551	Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. Lancet Regional Health - Europe, The, 2023, 28, 100613.	3.0	6
2552	Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	1
2553	Does the SARS-CoV-2 spike really have an Achilles heel?. Journal of Clinical Investigation, 2023, 133, .	3.9	0
2554	COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint. Lancet Respiratory Medicine,the, 2023, 11, 395-396.	5.2	2
2555	Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nature Communications, 2023, 14, .	5.8	12
2556	A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nature Communications, 2023, 14, .	5.8	21
2557	Boosting in the age of Omicron. ELife, 0, 12, .	2.8	0
2558	A machine learning model for predicting serum neutralizing activity against Omicron SARSâ€CoVâ€2 BA.2 and BA.4/5 sublineages in the general population. Journal of Medical Virology, 2023, 95, .	2.5	2
2559	Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV. Aids, 2023, 37, 1345-1360.	1.0	7
2560	Serologic response to COVID-19 infection or vaccination in pediatric kidney transplant recipients compared to healthy children. Transplant Immunology, 2023, 78, 101839.	0.6	2
2561	Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. Science Translational Medicine, 2023, 15, .	5.8	14
2562	Levels and durability of neutralizing antibodies against SARS-CoV-2 Omicron and other variants after ChAdOx-1 or BNT162b2 booster in CoronaVac-primed elderly individuals. Heliyon, 2023, 9, e15653.	1.4	1
2564	Antibody titer after administration of <scp>mRNA</scp> â€based vaccine against severe acute respiratory syndrome coronavirus 2 in liver transplant recipients. Annals of Gastroenterological Surgery, 0, , .	1.2	2
2565	Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses. PLoS Pathogens, 2023, 19, e1010870.	2.1	11
2566	Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection. Journal of Korean Medical Science, 2023, 38, .	1.1	3
2567	Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration. Clinical Chemistry and Laboratory Medicine, 2023, 61, 1875-1885.	1.4	3
2568	Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt. Egyptian Journal of Bronchology, 2023, 17, .	0.3	2
2569	Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections. IScience, 2023, 26, 106716.	1.9	1

#	Article	IF	Citations
2588	An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaques. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5
2590	What has vaccination against COVID-19 in CKD patients taught us?. Journal of Nephrology, 2023, 36, 1257-1266.	0.9	1
2591	Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia, 2023, 37, 1175-1185.	3.3	16
2703	Knifeâ€™s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines. Experimental and Molecular Medicine, 2023, 55, 1305-1313.	3.2	11
2706	The role of vaccines in the COVID-19 pandemic: what have we learned?. Seminars in Immunopathology, 0, , .	2.8	13
2724	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
2816	Antibody titers of individuals vaccinated forÂCOVID-19: A systematic review. Journal of Biosciences, 2023, 48, .	0.5	0
2818	Key advances in vaccine development for tuberculosisâ€”success and challenges. Npj Vaccines, 2023, 8, .	2.9	3
2887	Rapid COVID-19 immunity screening by machine learning aided multiplexed nanoplasmonic biosensor. , 2023, , .		0
2920	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
2923	SARS-CoV-2 and innate immunity: the good, the bad, and the â€œgoldilocksâ€• , 2024, 21, 171-183.		4
3015	Editorial: COVID-19 booster vaccination: increasing immunity against life-threatening infection. Frontiers in Public Health, 0, 11, .	1.3	0